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ABSTRACT
Fractures are a global health concern, leading to morbidity and mortality.
Individuals with reduced kidney function experience bone mineral metabolism changes
which can increase fracture risk. Yet, there is little consensus on the fundamentals:
prediction, incidence, risk factors, and screening of fractures in kidney disease patients.
This thesis addressed these critical areas helping decrease the health burden of fracture in
this unique population.
This research used data from the Canadian Multicentre Osteoporosis Study
(CaMos) to examine individuals with chronic kidney disease (CKD) (n=320). CaMos is a
national longitudinal study designed to collect information on fractures. To examine
kidney transplant recipients data from Ontario administrative healthcare databases was
used (n=4821). The predictive ability of the Fracture Risk Assessment Tool (FRAX) in
individuals with CKD was evaluated using area under the receiver operator characteristic
curves and survival analyses. The incidence and risk factors for fracture in kidney
transplant recipients were assessed using incidence rates and Cox hazard regression
analysis.
The first manuscript systematically summarized the incidence and risk factors for
fracture in kidney transplant recipients; fracture incidence and risk factors were variable
across studies.
The second manuscript examined the predictive value of FRAX in individuals
with CKD compared to individuals with normal kidney function. The discriminative
ability of FRAX for fracture prediction was comparable in both groups.
The third manuscript examined the incidence of fracture in kidney transplant
recipients. The cumulative incidence of fracture was low with approximately 2%
sustaining a hip fracture over 10-years.
The fourth manuscript examined risk factors for fracture in kidney transplant
recipients. Transplant-specific risk factors (i.e., diabetes or cystic kidney disease as the
cause of end-stage renal disease and donor age) and general risk factors (i.e., older
recipient age and female sex) were significantly associated with fractures.
The fifth manuscript examined the frequency and variability in bone mineral
density (BMD) testing across Ontario transplant centres. Over half of kidney transplant
ii

recipients received at least one BMD and the ordering of BMD tests varied widely by
centre – from 15% to 92%.
Results can be used to improve prognostication, advance clinical guidelines,
clarify fracture incidence, and guide informed consent.

Keywords: fracture, kidney disease, chronic kidney disease, kidney transplant recipient,
epidemiology, bone
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GLOSSARY
Bisphosphonate: A drug given to help prevent fracture.
Bone Mineral Density (BMD): The quantity of minerals present in a specific volume of
the bone (1). In the general population as BMD decreases fracture risk has been shown to
increase (2, 3).
Bone Mineral Density Test: A tool used to measure bone mineral density which
provides information on bone mass.
Chronic Kidney Disease (CKD): Estimated glomerular filtration rate (eGFR) (measure
of kidney function) less than 60 ml/min/1.73 m2 for at least 3 months or the presence of
kidney damage (4). In this thesis CKD was defined by evidence of one eGFR
measurement <60 mL/min/1.73 m2 (Chapter 3) or using diagnostic codes for CKD
(Chapter 4).
Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): A disorder caused
by chronic kidney disease that affects bone and mineral metabolism and is characterized
by at least one of the following:
-

Abnormal metabolism of calcium, phosphorous, parathyroid hormone, or
vitamin D

-

Abnormal bone mineralization, bone volume, bone turnover, bone strength,
or bone growth

-

Calcification of the soft tissue or calcification of vasculature (5).

Dialysis: A process that removes wastes and excess water from the body when an
individual has kidney failure (eGFR <15 mL/min/1.73 m2) (6).
End Stage Renal Disease: A loss in kidney function so severe that the kidneys cannot
function at a level required in day to day life and at which point dialysis is required (7).
Generally this occurs with an eGFR <15 mL/min/1.73 m2.
Estimated glomerular filtration rate: A measure of kidney function quantified by the
amount of blood that travels through the glomeruli per minute (8).
Fracture Risk Assessment Tool (FRAX): A tool developed and validated in the general
population that predicts the ten-year probability of hip or major osteoporotic fracture
(hip, proximal humerus, forearm, or clinical vertebral) through the use of the following
variables: age, sex, clinical risk factors, and with or without bone mineral density (9).
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Kidney Disease: A range of diseases that adversely affect the kidney (8). In this thesis
kidney disease refers to chronic kidney disease without transplantation and chronic
kidney disease with kidney transplantation.
Non-vertebral Fracture: For the purposes of this thesis includes: forearm (radius and
ulna), proximal humerus, and hip fractures.
Osteoporosis: A bone disease that increases an individual’s susceptibility to fracture
(10).
Osteoporotic Fracture: Fractures that occur due to a bone disease (osteoporosis) that
causes reduced bone mass and a weakening of the bone microarchitecture, resulting in
diminished bone strength (10). Hip, forearm, vertebral, and humerus fractures are
considered major osteoporotic fracture locations.
T-score: Bone density compared to white females aged 20-29 years and is expressed in
the number of standard deviations above normal (normal defined as ≥ -1) (11, 12).
United States Renal Data System (USRDS): An American national dataset that
contains information on end-stage renal disease patients (13).
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CHAPTER 1: Introduction

2
1.1 Background and Overview
The number of individuals in Canada living with kidney disease is increasing with
a 40% increase in the number of Canadians living with kidney failure from 2003-2012
(1). The reasons for this increase are multifactorial, including an aging population and an
increase in type II diabetes and hypertension (two of the most common causes of kidney
disease) (1). There is a desire for the 3 million Canadians living with chronic kidney
disease and over 17,000 living with a kidney transplant to live long and healthy lives (2,
3). One often overlooked complication of kidney disease is fracture. When kidney
function declines changes in bone mineral metabolism occur which adversely affects the
skeleton and increases fracture risk (4). Specifically, many individuals with kidney
disease have a complex bone disorder called chronic kidney disease-mineral and bone
disorder which is characterized by increased phosphate levels, decreased vitamin D and
calcium levels, and secondary hyperparathyroidism (4). Although kidney transplantation
improves kidney function many recipients continue to have chronic kidney diseasemineral and bone disorder post-transplant (4). Therefore, fracture risk is thought to be
high, relative to the non-kidney disease general population, across the spectrum of kidney
disease (mild kidney dysfunction to kidney failure to kidney transplantation) (5-8).
Fractures are a concern as they are associated with mortality, morbidity, and economic
costs (9-11). Yet, there is little consensus on the fundamentals: prediction, incidence, risk
factors, and frequency of preventative screening for fractures in kidney disease patients
(defined in this thesis as chronic kidney disease without kidney transplantation and
kidney transplantation). This thesis will address this critical area, and will inform future
interventional strategies to reduce the health burden of fracture in the kidney disease
population.

1.2 Overall Aim
The overall aim of this thesis is to better understand the epidemiology of fracture
in adults with kidney disease and to use this information in the care of this unique patient
population. Despite the health and economic impact of fractures, there is currently a gap
in knowledge about the epidemiology of fracture in patients with kidney disease.
Addressing the objectives outlined in this thesis will inform future strategies to reduce the

3
incidence of fracture in this growing patient population. This thesis is part of a larger
body of research I developed throughout my PhD studying bone health in individuals
with kidney disease. The five objectives described below will address this overall
objective.

1.3 Study Objectives
Objective 1: To efficiently and systematically summarize the incidence and risk factors
for fracture in kidney transplant recipients.

Objective 2a: To determine if kidney function modifies the predictive model
performance of the Fracture Risk Assessment tool (FRAX). This will be done by
assessing the discrimination and calibration of FRAX in individuals who have reduced
kidney function compared to individuals with normal kidney function.
Objective 2b: To assess the discrimination and calibration of FRAX (without bone
mineral density) after the addition of chronic kidney disease as a variable in the model.
Objective 2c: To assess the ability of the following variables to predict fracture in
individuals with normal kidney function and reduced kidney function: age, T-score, and
T-score with a history of fall.

Objective 3a: To estimate the age- and sex- specific three-year incidence of nonvertebral fractures (proximal humerus, forearm, hip) in kidney transplant recipients.
Secondary Objectives
i)

To estimate the age- and sex-specific three-year incidence of fracture
(including all fracture locations) in kidney transplant recipients.

ii)

To estimate the age- and sex-specific five-year incidence of non-vertebral
fractures in kidney transplant recipients.

iii)

To estimate the age- and sex-specific ten-year incidence of non-vertebral
fractures in kidney transplant recipients.

iv)

To estimate the age- and sex-specific three-year incidence of non-vertebral
fractures in kidney transplant recipients who received a transplant in more
recent years (2002-2009).
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v)

To estimate the age- and sex-specific three-year incidence of falls with
hospitalization among kidney transplant recipients.

Objective 3b: To assess whether kidney transplant recipients have a higher incidence of
non-vertebral fractures compared to the following age-, sex-, and cohort entry date
matched reference groups: healthy segment of the general population with no bone
disease and no kidney disease, healthy segment of the general population with no
evidence of kidney disease and a history of a non-vertebral fracture, individuals with
chronic kidney disease (excluding individuals on dialysis), and individuals with
rheumatoid arthritis.
Objective 3c: To assess whether kidney transplant recipients have a higher incidence of
non-vertebral fractures compared to patients receiving dialysis controlling for age, sex,
cohort entry date, and comorbidities in the analysis.

Objective 4: To determine the transplant specific (e.g. type of donor [living vs.
deceased]) and general risk factors (e.g. age) for major fractures (proximal humerus,
forearm, hip, and clinical vertebral) and other fractures (excluding major fractures, and
those of the skull, fingers, and toes) in kidney transplant recipients.

Objective 5a: To determine the frequency, total cost, and the variability in bone mineral
density testing across the six Ontario transplant centres in the first three years after
kidney transplantation.
Objective 5b: To compare the frequency of bone mineral density testing in kidney
transplant recipients to two non-transplant reference groups matching on age-, sex-, and
cohort entry date (individuals with no evidence of kidney disease and with no prior nonvertebral fracture; individuals with no evidence of kidney disease and a history of a nonvertebral fracture).

1.4 Structure of the Thesis Document
An integrated manuscript style will be used to present the work of this thesis in a
series of five manuscripts. A brief description of each manuscript is provided below. An
in-depth description of the methods and additional results are provided in several
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appendices (Appendix A for Chapter 2, Appendix C for Chapter 3, Appendix D for
Chapter 4, and Appendix E for Chapter 5). Appendix B contains information on the
ethics approval, consent form, and questionnaire for Chapter 3. Appendix F provides
documentation for the privacy impact assessment approval for Chapters 4, 5, and 6.
Appendix G provides copyright information.
The second chapter of this thesis contains the literature review, conceptual model,
and a version of the first manuscript entitled “Fracture Risk in Kidney Transplant
Recipients: A Systematic Review” which was published in Transplantation. This
manuscript addresses objective 1 of this thesis and systematically summarizes the
incidence and risk factors for fracture in kidney transplant recipients.
The second manuscript entitled “Comparison of fracture risk prediction among
individuals with reduced and normal kidney function” was published in the Clinical
Journal of the American Society of Nephrology and represents a version of Chapter 3.
This manuscript addresses objective 2 of this thesis and assesses the prognostic value of
the Fracture Risk Assessment Tool (FRAX) in adults with reduced and normal kidney
function.
The third manuscript entitled “Fracture incidence in adult kidney transplant
recipients” was published in Transplantation and represents a version of Chapter 4. This
manuscript addresses objective 3 of this thesis and provides a comprehensive
examination of the incidence of fracture in adult kidney transplant recipients.
The fourth manuscript entitled “Risk factors for fracture in adult kidney transplant
recipients” is being prepared for submission to the Canadian Journal of Kidney Health
and Disease. This manuscript addresses objective 4 of this thesis and provides
information on risk factors for fracture in adult kidney transplant recipients.
The fifth manuscript entitled “Frequency of bone mineral density testing in adult
kidney transplant recipients” has been submitted to the Canadian Journal of Kidney
Health and Disease. This manuscript addresses objective 5 of this thesis and examines
the frequency, total cost, and the variability in bone mineral density testing in kidney
transplant recipients across the six Ontario transplant centres. This manuscript was
initially a secondary objective in Chapter 4; however, given the importance of the
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findings and the additional analyses that were performed, a chapter dedicated to these
findings was warranted.
The last chapter of this thesis is the Discussion (Chapter 7). This chapter
summarizes the major findings of this thesis and links all chapters of the thesis together.
Information on implications for clinical practice, strengths and limitations, future
directions, and conclusions are also discussed.

7
Reference List
1. Canadian Institute for Health Information. Canadian Organ Replacement Register
Annual Report: Treatment of End-Stage Organ Failure in Canada, 2003 to 2012.
Ottawa, ON: CIHI; 2013.
2. Canadian Institute for Health Information. Canadian Organ Replacement Register
Annual Report: Treatment of End-Stage Organ Failure in Canada, 2002 to 2011.
Ottawa, ON: CIHI; 2012.
3. Arora P, Vasa P, Brenner D, Iglar K, McFarlane P, Morrison H, et al. Prevalence
estimates of chronic kidney disease in Canada: results of a nationally
representative survey. CMAJ 2013;185:E417-423.
4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work
Group, KDIGO clinical practice guidelines for the prevention, diagnosis,
evaluation, and treatment of chronic kidney disease-mineral and bone disorder
(CKD-MBD). Kidney Int 2009; 113: S1- S1-S130.
5. Naylor KL, McArthur E, Leslie WD, Fraser LA, Jamal SA, Cadarette SM, et al.
The three-year incidence of fracture in chronic kidney disease. Kidney Int 2014;
86:810-818.
6. Ramsey-Goldman R, Dunn JE, Dunlop DD, Stuart FP, Abecassis MM, Kaufman
DB, et al. Increased risk of fracture in patients receiving solid organ transplants. J
Bone Miner Res 1999;14:456-63.
7. Abbott KC, Oglesby RJ, Hypolite IO, Kirk AD, Ko CW, Welch PG, et al.
Hospitalizations for fractures after renal transplantation in the United States. Ann
Epidemiol 2001;11:450-457.
8. Dukas L, Schacht E, Stahelin HB. In elderly men and women treated for
osteoporosis a low creatinine clearance of <65 ml/min is a risk factor for falls and
fractures. Osteoporos Int 2005;16:1683-1690.
9. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after
all major types of osteoporotic fracture in men and women: an observational
study. Lancet 1999;35:878-882.
10. Wiktorowicz ME, Goeree R, Papaioannou A, Adachi JD, Papadimitropoulos E.
Economic implications of hip fracture: health service use, institutional care and
cost in Canada. Osteoporos Int 2001;12:271-278.
11. Adachi JD, Ioannidis G, Pickard L, Berger C, Prior JC, Joseph L, et al. The
association between osteoporotic fractures and health-related quality of life as

8
measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis
Study (CaMos). Osteoporos Int 2003;14:895-904.

9

CHAPTER 2: Literature Reviewa

a

A version of this chapter, in particular Sections 2.5 and 2.6, was published elsewhere as,
Naylor KL, Li AH, Lam NN, Hodsman BA, Jamal SA and Garg AX. Fracture Risk in
Kidney Transplant Recipients: A Systematic Review. Transplantation 2013; 95:14611470. Wolters Kluwer Health Lippincott Williams & Wilkins© No modifications will be
permitted.
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An extensive literature review was performed through searching PubMed,
Embase, Medline, and Google Scholar for all objectives. For objectives 3 and 4 there was
a large amount of literature assessing the incidence and risk factors for fracture in kidney
transplant recipients, therefore, a systematic review was performed and is highlighted in
part of this chapter.

2.1 Osteoporotic Fracture
Osteoporotic fractures are fractures that occur due to a bone disease
(osteoporosis) that causes reduced bone mass and a weakening of the bone
microarchitecture, resulting in diminished bone strength (1). The most common
osteoporotic fracture sites include hip, vertebrae, forearm, and proximal humerus (2).
These fractures are a global health concern for several reasons (3-7). First, these fractures
are associated with morbidity (7, 8). For example, hip fractures have been found to be
associated with chronic pain and loss of mobility (9). Second, these fractures can
adversely impact quality of life (10, 11), with Adachi et al., finding women with a prior
hip fracture had a significantly lower health-related quality of life score with particularly
low scores in self-care (4). Last, these fractures increase mortality (12, 13). For example,
compared to women and men without a major osteoporotic fracture individuals with a
fracture had a significantly higher age-standardized mortality ratio (proximal femur: 2.18,
95% [confidence interval] CI 2.03-2.32; vertebral 1.66, 95% CI 1.51-1.80) (6). The
adverse effects of these fracture are troublesome as from 1985-2005 there were over
570,000 hip fractures in Canada, with more than 145,000 hip fractures from 2001 to 2005
(14). The monetary cost of these fractures can also place a large economic burden on the
healthcare system. The direct healthcare costs of osteoporotic fractures in Canada
currently exceed $2 billion each year with the cost of hip fracture alone estimated to
reach $2.4 billion / year in the next three decades (3, 15).

2.2 Kidney Disease
The kidneys are important organs in our body that are needed to remove waste
and filter blood (16). When the kidneys are not functioning properly an individual can
develop kidney disease which is a broad term used to describe a range of diseases that
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adversely affect the kidney (16). A permanent and meaningful decrement in kidney
function is called chronic kidney disease (CKD) (16). Chronic kidney disease can
progress to kidney failure (end-stage renal disease) at which point an individual requires
either dialysis or a kidney transplant to survive (16). An in-depth description of CKD and
kidney transplantation, which are the exposures of interest in this thesis, is provided
below.
2.2.1 Chronic Kidney Disease
The Kidney Disease Improving Global Outcomes (KDIGO) guidelines define
CKD as an estimated glomerular filtration rate [eGFR] <60mL/min/1.73 m2 (lower eGFR
indicative of worse kidney function) for at least three months or a higher eGFR with the
presence of kidney damage (17). The KDIGO guidelines further categorize CKD into 5
stages (Table 2.1) (17). The number of Canadians with CKD is increasing with
approximately 3 million adult Canadians living with CKD (18, 19). This increase is
partially attributable to the aging population and an increase in the number of Canadians
with type II diabetes and hypertension (20, 21). CKD can advance to kidney failure, at
which point an individual would require dialysis or a kidney transplant to sustain life.
From 2003 to 2012, there has been an approximate 40% increase in the number of
Canadians living with kidney failure (n=40,000) (20). The large number of Canadians
with CKD is concerning given the large number of comorbidities, increased mortality,
and high economic costs (dialysis costs over $1 billion per year in Canada) associated
with the disease (22-25).

Table 2. 1. Description of the stages of chronic kidney disease (17)
Stage

Estimated Glomerular Filtration Rate (eGFR) and Description

Stage 1:

Estimated glomerular filtration rate (eGFR) is normal (≥ 90 mL/min/1.73m2) or
increased with evidence of kidney damage

Stage 2:

Mild decrease in kidney function (eGFR 60-80 mL/min/1.73m2) with evidence
of kidney damage

Stage 3a:

Moderate decrease in kidney function (eGFR 45-59 mL/min/1.73m2 )

Stage 3b:

Moderate to severe declines in kidney function (eGFR 30-44mL/min /1.73m2)
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Stage 4:

Severe decline in kidney function (eGFR 15-29 mL/min/1.73m2)

Stage 5:

Kidney failure (eGFR <15 ml/min/1.73m2)

2.2.2 Kidney Transplantation
While dialysis can be used to maintain life, kidney transplantation is considered
the best treatment for kidney failure as it improves survival and decreases costs to the
healthcare system (26, 27). The number of kidney transplants performed in Canada, as in
most countries, has increased over the last decade (with 1,193 kidney transplants
performed in 2003 and 1,358 in 2012) (20, 28). As of 2012, over 17,000 Canadians were
living with a functioning kidney transplant (20). With over 90% of kidney transplant
recipients surviving one-year post-transplant and over 80% of kidney transplant
recipients surviving five-years post-transplant, the focus is now on maximizing long-term
recipient health (27).

2.3 Changes in Bone Mineral Metabolism in Kidney Disease
It is well established that individuals with CKD are at an increased fracture risk
(29-38). For example, Naylor et al., found women aged 40-65 years with an eGFR of 1529 mL/min/1.73 m2 had approximately a two-time higher fracture risk compared to
similarly aged women with normal kidney function (rate ratio 2.4, 95% CI 1.5-4.0) (29).
Conversely, in kidney transplant recipients the risk of fracture has not been well
quantified but many studies suggest that the fracture risk is higher than the non-kidney
disease population (39-41). For example, Ramsey-Goldman et al. reported that the risk
of fracture in female kidney transplant recipients aged 45-64 years was 34 times higher
than their counterparts in the general population (41). Similar to the non-kidney disease
population, these fractures are concerning in individuals with kidney disease as they are
associated with mortality and morbidity (32, 39, 42). Nitsch et al., reported that compared
to individuals with an eGFR ≥ 60 mL/min/1.73 m2 (normal kidney function) individuals
with an eGFR < 45 mL/min/1.73 m2 had almost a two-fold higher age- and sex-adjusted
hazard ratio of death related to hip fracture (hazard ratio 1.98, 95% CI 1.12-3.50) (43).
Abbott et al., found that the 1-year mortality for kidney transplant recipients after hip
fracture was 14% compared to 7% in recipients who did not fracture (P <0.01) (39).
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The reasons for the higher fracture risk amongst individuals with kidney disease
are not fully understood but are likely multifactorial. Figure 2.1 provides a schematic on
the pathways that lead to fracture. As kidney function declines individuals may develop a
complex disorder of bone and mineral metabolism called chronic kidney disease-mineral
and bone disorder (CKD-MBD). CKD-MBD is characterized by at least one of the
following 1) abnormal metabolism of calcium, phosphorous, parathyroid hormone or
vitamin D; 2) abnormal bone mineralization, bone volume, bone turnover, bone strength
or bone growth; and 3) calcification of the soft tissue or calcification of vasculature (44).
In summary, changes in bone mineral metabolism occur when kidney function declines
and often continues after kidney transplantation. Specifically, these changes include
declining levels of serum calcium and calcitriol (active form of vitamin D), and
increasing levels of serum phosphate, and fibroblast growth factor 23 (44-46). Many
individuals on dialysis develop secondary hyperparathyroidism which increases bone
turnover, thereby weakening the bone (47). Post-transplant, after some of the kidney
function has been restored, serum calcium levels and phosphate levels may normalize
(48, 49); however, secondary hyperparathyroidism often persists (47, 50-52). Drugs
administered to kidney transplant recipients may also play a role in fracture. Specifically,
corticosteroids used to prevent transplant rejection have been found to promote bone loss
(apoptosis of osteoblasts; decrease in gonadal function; decrease in intestinal calcium
absorption) (53, 54). The role of cyclosporine (an immunosuppressant) in bone loss is
controversial with in vivo studies finding cyclosporine increases bone resorption and in
vitro studies finding it impedes bone resorption (55-61). In summary, individuals with
kidney disease experience numerous bone mineral metabolism changes that are
detrimental to the skeletal system raising a concern about fracture risk.
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Figure 2. 1. Mechanisms for increased fracture risk in individuals with kidney disease
2.4 Fracture Risk Prediction in Chronic Kidney Disease
As previously discussed, it is well established that individuals with chronic kidney
disease (CKD) have a higher risk of fracture compared to individuals with normal kidney
function (29-38). Even individuals with a more moderate decline in kidney function
experience a high fracture risk with risk increasing in a graded manner as kidney function
declines (P for trend <0.0001; Figure 2.2) (29). For example, Naylor et al., found women
aged > 65 years with an estimated glomerular filtration rate (eGFR) 45-59 mL/min/1.73
m2 had a significantly higher fracture rate (proximal humerus, forearm, hip, and pelvis)
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compared to individuals with normal kidney function (defined as an eGFR ≥ 60
mL/min/1.73 m2 ) (rate ratio 1.4, 95% CI 1.3-1.5) (29). However, the best technique to
identify individuals with CKD who are at a high fracture risk is not known. This is
concerning as to decrease the economic costs, morbidity, and mortality associated with
fractures we must identify those at high risk and target treatments to these individuals.
Moreover, early therapeutic intervention is particularly important in individuals with
reduced kidney function as there is a concern about the safety and efficacy of
bisphosphonates (fracture prevention therapy) in individuals with an eGFR <
30ml/min/1.73 m2 (17, 62).

Cumulative Incidence (%)

10
8
6
4
2
0

age >65
age 40-65

Estimated Glomerular Filtration Rate
(mL/min/1.73 m2)

Figure 2. 2. Three-year cumulative incidence of fracture in women (29)
Source: Naylor KL, McArthur E, Leslie WD, Fraser LA, Jamal SA et al. The three-year incidence of fracture in chronic
kidney disease. Kidney International 2014;86 :810-818.

2.4.1 Fracture Risk Assessment Tool (FRAX)
The fracture risk assessment tool (FRAX) is widely used in clinical practice to
predict fracture and to help guide treatment decisions in individuals with normal kidney
function (63). FRAX was developed by the World Health Organization and can be
described as a computer-based algorithm which can be easily used by physicians to
predict a patient’s fracture risk (Figure 2.3) (63, 64). It has been validated in the general
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population using eleven validation cohorts and has been found to be accurate (average
area under the receiver operating characteristic curve >0.6) (65). Specifically, FRAX
predicts the 10-year probability of major osteoporotic fracture (hip, humerus, forearm or
clinical spine) or hip fracture alone through the use of the following variables: age, sex,
and clinical risk factors (with or without bone mineral density [BMD]) (66).These
clinical risk factors were identified through meta-analyses assessing risk factors for
fracture and include: high alcohol intake (defined as ≥3 units per day), previous fracture,
current smoking, parental hip fracture, secondary osteoporosis, rheumatoid arthritis, low
body mass index (defined as <19 kg/m2), and extended glucocorticoid use (defined as
exposure for ≥3 months at a dose of 5mg/day) (63, 64, 67-69) (Table 2.2). However,
given the complex pathophysiology of bone disease in CKD this patient population may
have unique risk factors for fracture. For example, Nickolas et al., found low BMD, older
age, and female sex, common risk factors in the non-kidney disease population, were not
associated with an increased hip fracture risk in individuals with CKD (36).

Figure 2. 3. Screen shot of the Canadian FRAX input page and the results (67)
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Table 2. 2. FRAX variables (67, 69)
Variables
Age
Sex
Body mass index (kg/m2)
Previous fracture
Parental hip fracture
Current smoking
Prolonged use of glucocorticoids
Rheumatoid arthritis
Secondary osteoporosis (chronic liver disease, type I diabetes, hyperthyroidism,
hypogonadism, premature menopause (<45 years), chronic malnutrition/malabsorption
and osteogenesis imperfect)
Alcohol use ≥3 units/day
Femoral neck BMD (g/cm2 or T-score) is optional

2.4.2 Fracture Risk Assessment Tool (FRAX) in Chronic Kidney Disease
One previous study has assessed the ability of FRAX to predict fracture in
individuals with CKD, finding that FRAX was able to discriminate between individuals
with and without a clinical non-spine fracture (area under the receiver operating
characteristic curve 0.72, 95% CI 0.65-0.78) (70). However, this study had limitations.
First, the study was cross-sectional preventing the calibration (comparison between the
observed and FRAX predicted fracture risk) of the tool to be assessed. Second, CKD was
defined as an eGFR <90 mL/min/1.73 m2. The KDIGO guidelines define CKD as an
eGFR < 60 mL/min/1.73 m2 and an eGFR ≥ 60 mL/min/1.73 m2 requires other evidence
of kidney disease (e.g. proteinuria) (17). Third, there was no comparison group of
individuals with normal kidney function to determine how the tool’s performance in
individuals with CKD compares (70). Fourth, the study did not assess several other
potential predictors of fracture in addition to FRAX. For example, T-score and previous
falls may be accurate predictors of fracture in the CKD population; in the general
population a lower T-score and a previous fall have been found to increase fracture risk
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(71-73). Fifth, all the FRAX variables were not able to be included in the FRAX model;
information on previous fracture was not available (70). Last, the study included both
Canadian and American CKD patients (70); this is problematic as FRAX needs to be
calibrated for each country given the variability in fracture rates across countries (74).
Therefore, the best way to identify individuals with CKD who are at a high fracture risk
is unknown.

2.5 Kidney Transplantation and Fracture Risk
2.5.1 Fracture Incidence
As previously discussed, literature suggests that fracture risk remains high in
kidney transplant recipients relative to the non-kidney disease population despite
improvements in kidney function after transplantation (39-41). However, there remains
poor consensus on the incidence of fracture in kidney transplant recipients with values
varying widely in the literature.
Ten studies published between 1996 and 2012 reported on the incidence of
fracture in kidney transplant recipients (39, 41, 75-82). The incidence rate of fractures
across studies varied from 3.3 to 99.6 fractures per 1000 person-years (Tables 2.3 and
2.4). Similarly, the cumulative incidence was highly variable. There are several
potential reasons for this variation. First, recipient characteristics varied across studies.
For example, Kalker et al. only included diabetic recipients which likely resulted in a
high cumulative incidence of fracture (diabetes has been found to increase fracture risk
(83)) (79). Specifically, Kalker et al. found that the 5-year cumulative incidence of ankle
fracture was 27% (79). In contrast, other studies that included both diabetic and nondiabetic recipients found that the 5-year cumulative incidence of fracture ranged from 5%
to 22% (76, 80). Second, studies included different fracture sites. Ball et al. only included
hip fractures and found an incidence rate of 3.3 fractures per 1000 person-years (77). In
contrast, Conley et al., included multiple fracture locations and found a fracture incidence
rate of 99.6 fractures per 1000 person-years (78). Last, previous studies had variable
methodological quality, with study methods’ quality scores ranging from 8 to 13 (with
higher quality studies receiving a higher score, range 0 to 17) (Table 2.4); methodological
quality was assessed using a modified version of the Downs and Black checklist for
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nonrandomized studies which assesses the completeness and clarity of reporting, bias,
and external validity (84) (Appendix A).
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Table 2. 3. Study characteristics of kidney transplant recipients
Study, First Author,
Country
Prospective Cohort
de Sévaux et al.,
(2003)
Netherlands
Rizzari et al.,
(2012)
United States

Number of patients

Age, years
(mean ± SD)

Women,
percent

Time zero

Year
transplanted

Mean follow-up,
years (mean ± SD)

Diabetic,
percent

61

42.0 ± 13.0

37.7%

Transplant date

1995-1996

2.0 €

3.3%

Living Donor: 791

NR

38%

Transplant date

1999-2010

5.3*

Type 1 Diabetes 27% ,
Type 2 Diabetes 11%

Deceased Donor: 450

NR

41%

Transplant date

1999-2010

3.0*

Type 1 Diabetes 22%,
Type 2 Diabetes 20%

47.7 ± 14.0

48.5%

Transplant date

1994- 1997

1.7 ± 1.1

49.9%†

42.8 ± 14.6

39.7%

Transplant date

1994- 1997

1.7 ± 1.1

26.4%†

59 944

NR

39.2%

Transplant date

1990-1999

NR

26.1%‡

No Bisphosphonate:
239

46.9 ± 0.2

46%

1.2 ± 0.05 years
after transplant

1998-2006

2.5 ± 0.05

Type 1 Diabetes 17%,
Type 2 Diabetes 12%;

Bisphosphonate: 315

45.9 ± 0.7

40%

1.2 ± 0.05 years
after transplant

1998-2006

2.5 ± 0.05

Type 1 Diabetes 32%,
Type 2 Diabetes 9%

214

39ß

38%

6 months after
transplant

1985-1992

3.8

100%

No Fracture: 53 344

43.3

38%

Transplant date

1988-1998

5€

22.9%†

Fracture: 15 470

44.2

45.5%

Transplant date

1988-1998

5€

36%†

Retrospective Cohort
Abbott et al.,
Fracture: 379
(2001)
United States
No Fracture: 33 100
Ball et al.,
(2002)
United States
Conley et al.,
(2008)
United States

Kalker et al.,
(1996)
United States
Nikkel et al.,
(2009)
United States
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Table 2.3. Study characteristics of kidney transplant recipients (continued)
Study, First
Author, Country

Number of patients

Age, years
(mean ±
SD)

Women,
percent

Time zero

Year
transplanted

Mean follow-up,
years (mean ±
SD)

Diabetic,
percent

Early Corticosteroid
Withdrawal : 11 164

49.9 ± 13.4

38%

Transplant date

2000 to 2006

4.1

26%†

Corticosteroid-base
immunosuppression:
66 266
20 509

48.9 ± 13.4

40%

Transplant date

2000 to 2006

2.5*

24.1%†

47.9 ± 13.0

38.4%

1 year after
transplant

1995 to 2008

5€

8.6%‡

432

41.3 ± 12.3

40%

30 days after
transplant

1992 to 1996

2.1 ± 1.5

40% ¥

Retrospective Cohort
Nikkel et al.,
(2012)
United States

Opelz et al.,
(2011)
Multinational
Ramsey-Goldman
et al.,
(1999)
United States

NR - not reported
ß
reported as an average
€
reported as total time since transplant
*
reported as median
†
type 1 and type 2 diabetes are combined
‡
reported as diabetic neuropathy
¥
combined diabetes and hypertension
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Table 2.4. Fracture incidence in kidney transplant recipients
Study

Incidence/Cumulative incidence

Most common
fracture location

Time to fracture

Quality
score

Males: 6.90 fractures per 1000 person-years
Females: 9.93 fractures per 1000 person-years
3.3 fractures per 1000 person-years

Femur (34.8%)

13

Conley et al.

No bisphosphonate 36.7 fracture per 1000 patient years;
Bisphosphonate 99.6 fractures per 1000 patient years

Nikkel et al.

Early corticosteroid withdrawal :5.8 fractures per 1000
patient years; Corticosteroid-based
immunosuppression:8.0 fractures per 1000 patient years
39 fractures per 1000 person-years

Fractures other
than vertebral and
femoral neck
(91.7%)
Femur (29%)

Linear increase in cumulative hazard of fracture after
transplant.
Shortly after transplant hip fracture risk was higher in
transplant recipients compared to dialysis patients on the
transplant wait list (RR 1.34 , 95% CI 1.12-1.61); 630 days
after transplant, patients who were on dialysis had a similar
fracture risk as recipients (RR 1.00, 95% CI 0.87-1.15)
Fracture free survival was over 90% at 2 years and
decreased to approximately 40% at 6 years

Fracture incidence was significantly less than those with
early corticosteroid withdrawal compared to corticosteroidbased immunosuppression 24 months after fracture
Mean time to first fracture after transplant was 1.64±1.18
years

13

Incidence

Abbott et al.
Ball et al.

Ramsey-Goldman
et al.

Hip† (100%)

Foot (42.4%)

12

12

8

34 fractures per 1000 person-years

Hip (50%)

NR

10

Foot¶ (100%)

Incidence increased from 0- 2 years post-transplant,
plateaued from 2-3 years and increased up until 5 years
Mean time to first fracture 2.5 years

8

Nikkel et al.

~10% at 2 years
~27% at 5 years
22.5% in 5 years

Opelz et al.

0.85% over 5 years

Cumulative rate of fracture increases over 5 years

12

NR

11

de Sévaux et al.
Cumulative Incidence

Kalker et al.

Living Donor: Recipients w/ Diabetes: 4% 1 year; 16%
5 years; 33% 10 years
w/o Diabetes:1% 1 year; 5% years; 10% 10 years
Deceased Donor: Recipients w/ Diabetes: 6%1 year;
15% 5 years; 23% 10 years
w/o Diabetes:3% 1 year; 7% 5 years; 9% 10 years
NR-not reported; RR, relative risk; CI, confidence interval.
†
hip only location assessed;¶ foot only region assessed

Rizzari et al.

Foot/ankle(28.2%
)
Hip† (100%)
NR

12
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The aforementioned studies have several limitations worth noting. First, none of
the studies included Canadian kidney transplant recipients and therefore may not
accurately reflect Canadian recipients’ fracture rate. In the general population fracture
rates have been found to vary as much as 15-fold across countries (74). For example,
Leslie et al. found that proximal femoral fracture rates were significantly lower in
Canadian women compared to women from the U.S. with Canadian women having a
30% lower fracture rate (85). Additionally, differences in transplant outcomes and
transplant characteristics exist across countries (86). For example, there are differences in
mortality in recipients from the United States and Canada (e.g. 29.8 deaths per 1000
person-years, Canada: 40.9 deaths per 1000 person-years, United States) and differences
in recipient characteristics (e.g. Canadians have more male kidney transplant recipients
[63.8% versus 60.0%]) (86). Previous work supports that Canadian kidney transplant
recipients may have a different fracture rate compared to recipients from other countries.
For example, in a study which included kidney transplant recipients (n=458) from
Manitoba, Canada, Naylor et al. found the 10-year observed major osteoporotic fracture
risk was only 6.3% (defined as a composite of hip, forearm, proximal humeurs, and
clinical vertebral fractures) (87); clinical guidelines define high fracture risk as a 10-year
major osteoporotic risk ≥ 20% and low fracture risk < 10% (2, 88, 89). However, the low
observed fracture risk in the Naylor et al. study may not accurately reflect the fracture
rate of Canadian recipients as recipients were approximately 5 years younger (mean age
45 years) than the average age of a Canadian recipient (87). Moreover, cohort entry was
an average of 1-year post-transplant (87); recipients may have a rapid loss in bone
mineral density and a higher fracture risk in the first year post-transplant, consequently
fracture events may have been missed (77, 90-93). Second, previous studies did not have
long-term follow-up. The largest studies to assess fracture risk in kidney transplant
recipients have all used the United States Renal Data System (USRDS) (19, 41-43); a
major limitation of this data source is that after 3 years all data is censored for recipients
less than 65 years of age, preventing long-term follow-up. Specifically, the average
follow-up of previous studies was less than 6 years, limiting discussion on long term
fracture risk. With over 80% of recipients surviving 5 years post-transplant long-term
follow-up is crucial (27). Third, close to half of studies included only one fracture
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location (e.g. foot fractures) preventing a precise estimate of fracture incidence (63).
Fourth, studies may not be representative of the current recipient population. Only four
out of ten studies included recipients of kidney transplants after the year 2000 (63); the
characteristics of recipients (e.g. comorbidities) and clinical practice patterns have
changed in the last 10 years, potentially impacting fracture rates (20, 94). Specifically,
the age of Canadian recipients has increased with approximately 27% over the age of 60
years in 2003 and 35% in 2012 (increasing age is a risk factor for fracture (68, 73, 95))
(20); there has also been a trend towards decreasing corticosteroid dose (81, 96). This
hypothesis is supported by a study which found hip fracture rates in kidney transplant
recipients from the United States have decreased from 1997 to 2010 (P<0.001); they
hypothesized that potential reasons for this decrease were decreased corticosteroid dose,
decrease in acute rejection episodes, increase in tacrolimus (may decrease bone loss
compared to cyclosporine) (97), and lifestyle changes (e.g. physical activity) (93). Last,
only one study reported on loss to follow-up and reasons for losses (63). This is a serious
concern that threatens the validity of most prior studies, particularly if there were
differential losses to follow-up (80). Therefore, the true incidence of fracture in kidney
transplant recipients is unknown.
2.5.2 Fracture Risk in Kidney Transplant Recipients Compared to Several
Referent Groups
Previous studies have compared fracture rates in kidney transplant recipients to
the non-kidney disease population and to the dialysis population (39, 77, 87, 98).
However, no previous studies have compared fracture rates in kidney transplant
recipients to other referent groups. The use of referent groups is crucial to help quantify
fracture risk among kidney transplant recipients. One group that is defined by
Osteoporosis Canada as low fracture risk and four groups that are defined as having an
increased fracture risk are described in detail below (99).
2.5.2a Healthy Segment of the General Population with No Kidney
Disease and No Previous Non-vertebral Fracture (Low fracture risk)
Three previous studies have compared fracture risk in kidney transplant recipients
to the general population (39-41). However, no previous studies have compared fracture
rates in kidney transplant recipients to individuals without kidney disease excluding
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individuals who have had a prior non-vertebral fracture and/or an osteoporosis diagnosis.
The benefit of the aforementioned exclusion criteria is it helps ensure this is truly a low
risk referent group. Studies that have compared kidney transplant recipients to individuals
from the general population have suggested that kidney transplant recipients are at an
increased risk of fracture, with Abbott et al. describing an incidence ratio of 4.59 (95%
CI 3.29-6.31) (39). Similarly, Ramsey-Goldman et al. found that male kidney transplant
recipients ages 25-44 and 45-64 years had a five-time higher fracture risk compared to
the general male population of a similar age (41). Particularly concerning is the
potentially high hip fracture rate in kidney transplant recipients compared to the general
population (39, 81). Ball et al. found an incidence rate of 3.3 hip fractures per 1000
person-years (approximately 80% of the sample was ≤ 54 years) (77). In contrast, hip
fracture rates in the general Canadian population (age <54 years) are less than 0.1
fractures per 1000 person-years (14).
2.5.2b Healthy Segment of the General Population with No Kidney
Disease and a History of Non-vertebral Fracture (Increased fracture risk)
No previous studies have compared fracture rates in kidney transplant recipients
to individuals without kidney disease who have previously sustained a non-vertebral
fracture. In the non-transplant population, one of the strongest risk factors for a future
fracture is sustaining a previous osteoporotic fracture (100). A meta-analysis conducted
in the non-transplant population found that individuals who had sustained a previous
fracture had an 86% relative increase in fracture compared to individuals who had not
sustained a previous fracture (relative risk [RR] 1.86, 95% CI 1.75-1.98) (100).
2.5.2c Non-dialysis Chronic Kidney Disease (CKD) (Increased fracture
risk)
No previous studies have compared fracture rates in kidney transplant recipients
to individuals with CKD (excluding patients on dialysis). As described in section 2.4,
previous literature has found that individuals with CKD are at an increased risk of
fracture compared to individuals with normal kidney function (35-37). For example,
Dooley et al. found that there was a 439% relative increase in hip fracture risk in
individuals with stage 4 CKD compared to individuals with normal kidney function (RR
5.39, 95% CI 2.86 to 10.15) (37).
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2.5.2d Rheumatoid Arthritis (Increased fracture risk)
No previous studies have compared fracture rates in kidney transplant recipients
to individuals with rheumatoid arthritis. Rheumatoid arthritis is a well-established risk
factor for fracture due to the use of steroids and the disease itself (101, 102). Van Staa et
al. found that individuals with rheumatoid arthritis have a 100% relative increase in hip
fracture (RR 2.0, 95% CI 1.8-2.3) compared to age- and sex-matched individuals without
rheumatoid arthritis (102).
2.5.2e Dialysis (Increased fracture risk)
It is well established that dialysis patients have a high fracture risk with 1 in 10
(9.6%) women aged ≥ 65 years sustaining a fracture (defined as proximal humerus,
forearm, hip, or pelvis) in the first 3 years of end-stage renal disease (29). Two previous
studies have compared fracture risk in kidney transplant recipients to the dialysis
population (77, 87). Ball et al. found that shortly after transplant hip fracture risk was
higher in recipients compared to the dialysis population on the transplant waitlist (RR
1.34, 95% CI 1.12-1.61). However, this study only assessed hip fracture and included
recipients who received a transplant over 10 years ago; as previously discussed changes
in recipient characteristics and practice patterns may have affected fracture rates (7, 77).
In contrast, Stehman-Breen et al. found that kidney transplant recipients and the
hemodialysis population had a comparable hip fracture risk with kidney transplant
recipients having a slightly higher risk, but this did not reach statistical significance (RR
1.1, 95% CI 0.4-2.9) (87). However, this study included all end-stage renal disease
patients instead of restricting to individuals on the transplant waitlist; to make health
status comparable previous literature recommends comparing recipients to individuals on
the transplant waitlist (77, 103).

2.6 Risk Factors for Fracture in Kidney Transplant Recipients
Six previous studies reported on risk factors for fracture in kidney transplant
recipients and their associated effect measures (39, 77, 78, 80-82) (Table 2.5). Risk
factors for fracture in kidney transplant recipients were variable across studies. The most
common factors found to be associated with an increased risk of fracture included: older
age, female sex, diabetes, and dialysis prior to transplant. Other risk factors associated
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with fracture in recipients included previous history of fracture, the induction regimen
used to immunosuppress the recipient, type of donor (living versus deceased), and year of
transplant. Potential reasons for the variation in risk factors across studies include
inclusion of different recipient populations, inclusion of different fracture locations, and
the use of different statistical models (i.e., backward elimination versus forward
selection) with different p-values to determine which variables should be included in the
multivariable model (104).
Unlike the transplant population, risk factors for fracture in the general population
are well-established and include: older age, female sex, low body mass index (BMI),
history of fracture, family history of a parent fracturing a hip, glucocorticoid use,
rheumatoid arthritis, smoking, low bone mineral density (BMD [g/cm2]), secondary
osteoporosis (e.g. type 1 diabetes), previous fall and drinking ≥ 3 units of alcohol a day
(2). Kidney transplant recipients may have different risk factors for fracture given the
unique pathophysiology that underlies their bone disease (105). For example, many of the
common risk factors for fracture in the general population (e.g. age, sex, BMI) are not
consistently associated with fracture in kidney transplant recipients (Table 2.5). In a
study conducted by Naylor et al. it was found that the only common risk factor for major
osteoporotic fracture in the general population that reached statistical significance in
kidney transplant recipients was high alcohol use (87). However, this study had a small
sample size (n=326) and therefore may have had inadequate statistical power (87).
Moreover, a recent study found that a parathyroid hormone level >130 ng/L was a unique
and independent risk factor for fracture (adjusted hazard ratio 7.5, 95% CI 2.2 -25.5) in
kidney transplant recipients while age, sex, and BMI did not reach statistical significance;
however, this may have been due to limited power (106).
The aforementioned studies had a few limitations. Previous studies failed to
assess potentially relevant risk factors of fracture. In the kidney transplant population no
previous studies have assessed fall in the year prior to transplant as a risk factor for
fracture. Falls have been found to be associated with an increased fracture risk in the
general population (72, 107). Previous studies have also failed to assess risk factors
specific to different fracture locations; in the general population different fractures sites
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have been found to have unique risk factors (108, 109). For example, increasing age may
not be associated with an increased risk of ankle fracture (110).
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Table 2. 5. Fracture risk factors in kidney transplant recipients
Number of studies
with significance
3
1
1
2

Author, Effect measures*
(95% Confidence Interval)

Older age
45-65
50-65
>65 years

Number of studies that
assessed risk factor
4
1
1
2

Continuous (per year)
Female sex

2
4

1
3

Combined age gender interaction
Female aged 40 to 59
Female recipients ≥ 60 years of age
Male recipients ≥ 60 years of age

1
1
1
1

1
1
1
1

Abbott, OR 1.02 (1.03-1.04)
Nikkel (2012), HR 1.36 (1.32-1.40) Reference male
Nikkel (2009), HR 1.42 (1.31-1.55) Reference male
Abbott, OR 1.29 (1.02-1.64) Reference male
Opelz
HR 2.26 (1.09-4.68)
HR 5.14 (2.43-10.9)
HR 2.39 (1.10-5.20)

Diabetes
Diabetes (Type 1 and Type2)

5

4
3

Risk factor

Type 1 diabetes
Pre-transplant dialysis
Per year of dialysis prior to transplantation

6

Dialysis treatment 3 to 12 months before
transplantation
Administration of pre-transplant dialysis
Prior Fracture
Hospitalization for fracture prior to
transplant
Fracture between ESRD and transplant
Donor type
Deceased

2

4

Nikkel (2012), HR 1.14 (1.10-1.18) Reference (<45 years)
Nikkel (2009), HR 1.76 (1.59-1.94) Reference 18-50
Nikkel (2009), HR 3.27 (2.91-3.67) Reference 18-50
Nikkel (2012), HR 1.69 (1.58-1.81) Reference (<45 years)

Abbott, OR 1.97 (1.46-2.66) Reference no diabetes
Nikkel (2009), HR 1.39 (1.18-1.64) Reference hypertension
Nikkel (2012), HR 1.41 (1.25-1.59) Reference no diabetes

1
4
2

Conley, HR 2.02 (1.18-3.48) Reference no diabetes

1

Ball, RR 1.67 (1.22- 2.29 ) Reference recipients on dialysis for less than
3 months

1
2
1

Nikkel (2012), HR 1.08 (1.04-1.13) Reference no pre-transplant dialysis

1
2
2

Nikkel (2009), HR 2.82 (2.33-3.43) Reference no prior fracture

Abbott, OR 1.74 (1.02-2.96)
Nikkel (2009), HR 1.04 (1.03–1.06)

Abbott, OR 2.82 (1.06-5.14) Reference no prior fracture

Nikkel (2012), HR 1.30 (1.19-1.42) Reference living donor
Nikkel (2009), HR 1.36 (1.24-1.49) Reference living donor
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Table 2.5. Fracture risk factors in kidney transplant recipients (continued)
Number of studies
with significance

Author, Effect measures*
(95% Confidence Interval)

Race
White

Number of studies
that assessed risk
factor
5
1

3
1

Abbott, OR 1.66 (1.24-2.24) Reference black

Asian

1

1

Nikkel (2012), HR 0.34 (0.26-0.47) Reference white

Black

2

2

Nikkel (2009), HR 0.81 (0.78-0.85) Reference white
Nikkel (2012), HR 0.63 (0.56- 0.7) Reference white

Other
Donor Age
Donor age ≥ 60 years of age
Body Mass Index (Kg/m2)
<18
25-30
>30
Weight
< 48.6 kg
48.6–72.3 kg
72.4–95.9 kg
Glomerulonephritis (as cause of kidney failure)

2
1

Nikkel (2009), HR 0.54 other (0.48-0 .61) Reference white

4

1
1
1
1
1
1
1
1
1
1
1
2

Hypertension (as cause of kidney failure)
Femoral neck T-score at baseline† (lower T-score
indicative of greater risk) (continuous: SD)
Interleukin-2 receptor blockade

3
1

1
1

1

1

y-GT, gamma-glutamyltransferase (continuous:
units/litre)
urine protein to creatinine ratio (continuous:
gram/gram)
Human leukocyte antigen mismatches
1 HLA-DR mismatch

1

1

Conley, HR 0.40 (0.25-0.66) Reference no Interleukin-2
receptor blockade
Conley, HR 1.005 (1.0034-1.0076)

1

1

Conley, HR 1.23 (1.05-1.45)

3

1
1

Opelz, HR 1.85 (1.18 -2.89) Reference zero HLA-DR mismatch

1

Opelz, HR 2.24 (1.25-4.02) Reference zero HLA-DR mismatch

Risk factor

2 HLA-DR mismatch

5

1

Opelz, HR 1.75 (1.15 -2.66) reference donors < 60 years of age
Nikkel (2012)
OR 1.39 (1.08-1.78) Reference BMI 18-25
OR 0.87 (0.78-0.96) Reference BMI 18-25
OR 0.83 (0.75-0.93) Reference BMI 18-25
Abbott
OR 2.01 (1.38-2.94) Reference Weight >95.9 kg
OR 1.86 (1.32-2.63) Reference Weight >95.9 kg
OR 1.77 (1.26-2.49) Reference Weight >95.9 kg
Abbott, OR 0.51 (0.32-0.82) Reference no glomerulonephritis
Nikkel (2009), HR 0.53 (0.51-0.56) Reference diabetes
Nikkel (2009), HR 0.56 (0.53-0.59) Reference diabetes
Conley, HR 0.69 (0.57 -0.86)
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Table 2.5. Fracture risk factors in kidney transplant recipients (continued)
Risk factor
Induction regimen
Early steroid withdrawal
Dual induction¥ vs no induction

Number of studies that
assessed risk factor
5

Number of studies
with significance
2
1
1

Author, Effect measures*
(95% Confidence Interval)
Nikkel (2012), HR 0.69 (0.59-0.81) Reference steroidbased regimen
Nikkel (2012), HR 1.14 (1.08-1.20) Reference no
induction

Transplant date
3
1
Quartiles of transplant date (continuous: per
1
Abbott, OR 0.82 (0.72-0.92)
increase in quartile)‡
Note: Nikkel (09), Nikkel (12), Abbott and Ball all provided adjusted effect measures. We excluded four studies from the risk factor analysis that did not use
multivariable methods to ascertain risk factors. Therefore, five studies is the highest number of studies assessed for this risk factor. One additional study was included for
pre-transplant dialysis resulting in six studies as the maximum number of studies assessed for this risk factor
*A value greater than 1 indicates that the group of patients with the factor had a higher risk of fracture compared to the reference group and a value lower than 1
indicates that the group of patients with the factor had a lower risk of fracture compared to the reference group.
Abbreviations: ESRD, end stage renal disease; HLA-DR mismatch, human leukocyte antigen-DR mismatch
†t-score measured as the number of standard deviations below the average peak bone density of a young adult
¥ Dual induction is defined as a combination of methylprednisolone and an antibody-based induction agent
‡ Quartiles of transplant date defined as July 1, 1994-Apriil 12, 1995, April 13, 1995- January 9, 1996, January 10, 1996 –October 3, 1996, October 4, 1996 –June 30,
1997
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2.7 Bone Mineral Density Testing in Kidney Transplant Recipients
Kidney transplant recipients may be a high risk group for fracture and as a result
assessing bone health may be beneficial. One way to assess bone health is to perform a
bone mineral density (BMD) test; the results of the test are used to guide treatment
decisions for fracture prevention and to monitor the effectiveness of treatment (2, 111,
112). In the general population a lower BMD associates with a higher fracture risk and
higher mortality risk (113-116). Osteoporosis Canada guidelines recommend that in the
general population all individuals ≥ 65 years of age have a BMD test (2). Conversely, in
the kidney transplant population the KDIGO guidelines for CKD-MBD recommend
testing in the first three months after transplantation when kidney function is adequate
(defined as an eGFR > 30 mL/min/1.73 m2) and there is evidence of osteoporosis risk
factors or corticosteroid administration (44). However, this guideline received a weak
recommendation given the lack of evidence that BMD can accurately predict fracture in
kidney transplant recipients (44). Moreover, it is suggested by the KDIGO guidelines that
given the high prevalence of adynamic bone disease (i.e., low turnover bone disease) it is
reasonable to use a bone biopsy to guide treatment decisions instead of the result of the
BMD test; however, this recommendation was not graded (44).
Despite the lack of evidence in the literature demonstrating the benefit of BMD
testing in kidney transplant recipients, previous single centre studies describe a large
number of BMD tests in this population (117, 118). For example, Naylor et al. reported
more than 1000 BMD tests over an 8 year period in kidney transplant recipients (n=326)
from Manitoba, Canada (117). Similarly, Akaberi et al., reported more than 600 BMD
tests over a 12 year period in kidney transplant recipients (n=238) from Sweden (118).
However, both of these studies were performed at a single centre which mandated routine
BMD testing. No studies have assessed the frequency of BMD testing in Ontario, where
many transplant centers have no fixed protocol for BMD testing post-transplant (personal
communication with the centres). Given the negative impact of unwarranted screening
and the financial costs to the healthcare system this deserves further investigation (119,
120).
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2.8 Conclusion
Despite the health and economic impact of fractures, there is currently a gap in
knowledge about the epidemiology of fracture in adults with kidney disease. As
highlighted in this literature review, many questions remain unanswered and several
limitations of previous studies need to be addressed. As the kidney disease population
continues to increase and survival continues to improve the economic burden this
population may place on the healthcare system due to fracture events may increase. In the
non-kidney disease population fracture prevention therapies (e.g. bisphosphonates) have
proven successful (121-123); however, in the kidney disease population the efficacy and
safety of such therapies has not been determined (44, 124). Furthermore, many of the
KDIGO guideline’s for the evaluation and treatment of bone disease in kidney disease
patients received a weak grade of evidence or are ungraded (44). Therefore, it is crucial
that a paradigm shift in bone disease research occurs towards understudied populations
who have not experienced success in fracture prevention. This research will provide a
better understanding of the epidemiology of fracture in kidney disease patients which is
required before much needed well designed clinical trials and prospective cohort studies
can be conducted. Moreover, an improved understanding of fracture will provide the
information needed for an in-depth discussion of fracture in kidney disease patients in
future kidney disease guidelines and osteoporosis guidelines.

2.9 Conceptual Model
Figure 2.4 demonstrates the hypothesized relationship between kidney disease and
fracture.
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Comorbidities
Diabetes
Hypertension
Charlson Comorbidity Index

Pre-transplant dialysis
BMI

Previous
Fracture

Medical Conditions
(Causes of kidney
disease)
Diabetes
Renal Vascular
Disease
Cystic Disease
Glomerulonephritis
Other

Exposure
Kidney Disease

OOutcome
Fracture

Age
Race

Sex

Transplant
Year

Figure 2. 4. Conceptual model of the hypothesized relationship between kidney disease
and fracture.
*It is important to note that the word that is bolded and underlined is only specific to
kidney transplant recipients.
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CHAPTER 3: Comparison of fracture risk prediction among individuals with
reduced and normal kidney functiona

a

A version of this chapter has been published elsewhere as: Naylor KL, Garg AX, Zou G,
Langsetmo L, Leslie WD, Fraser LA, Adachi JD, Morin S, Goltzman D, Lentle B,
Jackson SA, Josse RG, Jamal SA. Comparison of fracture risk prediction among
individuals with reduced and normal kidney function. CJASN 2015; 10:646-653.
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3.1 Introduction
The World Health Organization’s Fracture Risk Assessment Tool (FRAX) is used
commonly in the general population to predict the 10-year probability of a major
osteoporotic fracture (defined as hip, forearm, clinical vertebral, and humerus fractures)
using an algorithm that includes age, sex, and several clinical risk factors for fracture
(bone mineral density optional) (1, 2). The clinical risk factors for fracture incorporated
in the FRAX algorithm include: parental hip fracture, previous fragility fracture,
rheumatoid arthritis, current smoking, secondary osteoporosis (which does not include
chronic kidney disease), low body mass index (<19 kg/m2), prolonged glucocorticoid use,
and excessive alcohol intake (3-7).
Men and women with chronic kidney disease (CKD) have a high fracture risk (811). For example, women with moderate declines in kidney function (estimated
glomerular filtrate rate 45-59 mL/min/1.73 m2) are at almost a 4-fold increased risk of
fracture compared to women with normal kidney function (11). The clinical utility of
FRAX in predicting fracture risk in patients with reduced kidney function is uncertain.
CKD is associated with disturbances in mineral metabolism including changes in
calcium, phosphate, and parathyroid hormone which likely alter bone volume, turnover,
and mineralization increasing fracture risk (12). Therefore, factors in the FRAX
algorithm that are associated with fracture risk in the general population may not
accurately predict fracture in individuals with reduced kidney function. One prior study
has reported on the prognostic value of FRAX in individuals with reduced kidney
function, however, this study was cross-sectional and did not include a comparison group
of individuals with normal kidney function (13). The current study addresses these
limitations. We utilized data from a multicentre cohort study (Canadian Multicentre
Osteoporosis Study – CaMos) to characterize the predictive ability of FRAX in patients
with reduced kidney function, and to determine if the predictive ability differs from
individuals with normal kidney function. As a secondary analysis we examined the
ability of FRAX to predict fracture when adding CKD as a secondary cause of
osteoporosis in individuals with reduced kidney function. We also assessed the ability of
age, T-score, and T-score with a history of fall to predict fractures in both groups.
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3.2 Methods
3.2.1 Canadian Multicentre Osteoporosis Study (CaMos)
CaMos is a prospective observational study that began in January 1996 (14).
Detailed methods concerning CaMos have been published elsewhere (14, 15) (Appendix
C). Briefly, non-institutionalized individuals were eligible to participate in CaMos if they
were ≥ 25 years of age at the start of the study, lived within a 50 kilometer radius of 1 of
9 major Canadian cities (St. John’s, Halifax, Quebec City, Toronto, Hamilton, Kingston,
Calgary, Vancouver, and Saskatoon) and could speak English, French or Chinese (14).
Residential phone numbers were used to randomly select households and within
households one member who met eligibility criteria was randomly selected; at baseline
interview 42% of participants contacted agreed to participate (14). In January 1996
participants completed a standardized interviewer-administered questionnaire; the
questionnaire was subsequently administered every 5 years. The questionnaire assessed
demographics, medication use, nutrition, general health, medical history, fracture risk
factors, and fracture events (14). Bone mineral density, weight and height were also
assessed at baseline and every five years (14). In year 10 blood samples were obtained
and serum stored from participants in 8 out of the 9 study centres. Serum creatinine was
analyzed by CDL Labs, Montreal. In agreement with the Helsinki Declaration, written
informed consent was provided by study participants. Ethics approval was obtained from
McGill University and from each study centre’s applicable ethic review board.
3.2.2 Cohort
The beginning date of our present study (cohort entry) was the CaMos study year
10 – the first time 8 out of the 9 centres assessed blood work. For this analysis, we
included individuals who met the following criteria at cohort entry: 1) men and women
who were ≥40 years of age, 2) those who had a creatinine value, 3) femoral neck bone
mineral density (BMD) measurement, and 4) no prior organ transplant. Creatinine values
were missing in those who did not sign the consent form for blood and in those who were
from Hamilton (centre that did not collect blood work). We calculated the estimated
glomerular filtration rate (eGFR) using the CKD epidemiology collaboration equation
(16). We defined kidney function at cohort entry using thresholds defined in the 2012
Kidney Disease Improving Global Outcomes (KDIGO) guidelines (17); an eGFR <60
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mL/min/1.73 m2 was defined as reduced kidney function and an eGFR ≥60 mL/min/1.73
m2 was defined as normal kidney function. We used this classification for our primary
analysis. To characterize the degree of renal impairment we further stratified kidney
function in individuals with an eGFR <60 mL/min/1.73 m2 according to the 2012
KDIGO guidelines: 45–59 (stage 3a), 30–44 (stage 3b), 15–29 (stage 4), and <15
mL/min/1.73 m2 (stage 5) (17).
3.2.3 Bone Mineral Density
Bone mineral density (BMD) was measured at the femoral neck using the Hologic
QDR dual energy x-ray absorptiometry scanner (Marlborough, MA, USA) at four centres
and the Lunar scanner (Piscataway, NJ, USA) at 5 centres. Each centre used a spine
phantom to monitor longitudinal stability. Standard methods were used to convert lunar
data to corresponding Hologic values (18-21). The Bio-Imaging Bona Fide Phantom
(Bio-Imaging Technologies, Newtown, PA, USA) was used to calibrate densitometers at
all centres and the coordinating centre re-analyzed measurements from each centre.
Details on the BMD quality assurance-quality control program and cross-calibration have
been published elsewhere (22). As recommended by the World Health Organization we
calculated femoral neck T-scores for both genders by comparing each individual’s BMD
to the Third National Health and Nutrition Examination Survey reference range for white
females aged 20-29 years (23).
3.2.4 Fracture Ascertainment
Data on incident clinical fractures were collected over 5 years after cohort entry
by self-report from a yearly postal questionnaire or in-person assessment (year 15 of the
CaMos study) (15). Fractures were confirmed by: structured interview to determine
further information (date, fracture location, medical treatment, and cause of fracture [i.e.,
fall]) and/or verification from the treating physician or hospital (15). We defined fracture
as a composite of incident clinical spine, hip, forearm/wrist, and humerus fractures
(major osteoporotic fractures) that resulted from low trauma.
3.2.5 Fracture Risk Assessment using FRAX
We used the Canadian FRAX tool (FRAX® Desktop Multi-Patient Entry, version
3.7) to calculate the 10-year probability of a major osteoporotic fracture (with and
without BMD).(3) The US and Canadian versions of FRAX are derived using identical
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methodology and give similar results with regards to fracture prediction (24, 25). A
complete list of the variables we used to calculate the FRAX score is provided in Table
3.1. Body mass index (BMI) was calculated at cohort entry by dividing weight (kg) by
height squared (m2). When BMI (kg/m2) was missing at year 10 we carried forward
values from year 5 of the CaMos study (<0.5% missing). We defined rheumatoid arthritis
as a self-report of a diagnosis of rheumatoid arthritis combined with evidence of
treatment (prednisone, betamethasone, methotrexate, hydroxychloroquine, leflunomide,
etanercept, infliximab, sulfasalazine, adalimumab). Prior corticosteroid use was defined
as use of intravenous or oral glucocorticoids for ≥ 3 months from baseline to cohort entry.
Previous fracture was defined as any low trauma fracture (excluding hands, feet, head,
and ankle) occurring prior to cohort entry. History of parental hip fracture was defined
using self-report at year 5 of CaMos. All other clinical risk factors were based on selfreport at cohort entry or before.

Table 3. 1. Variables used in FRAX Tool
Variable
Age
Sex
Weight (kg)
Height (cm)
Parental hip fracture
Previous fracture
Prolonged use of glucocorticoids
Current smoking
Alcohol use ≥ 3 units/day
Secondary osteoporosis (Defined as: chronic liver disease, type I diabetes, hyperthyroidism,
hypogonadism, premature menopause (<45 years), chronic malnutrition/malabsorption and osteogenesis
imperfect)
Rheumatoid arthritis
Femoral neck BMD (T-score) is optional
Sources: 1. FRAX World Health Organization Fracture Risk Assessment Tool [Internet]. World Health Organization;
2011. Available from http://www.shef.ac.uk/FRAX/index.aspx. 2. Kanis JA, McCloskey EV, Johansson H, Strom O,
Borgstrom F, Oden A. How to decide who to treat. Best Pract Res Clin Rheumatol 2009; 23: 711.

51
3.2.6 Statistical Analysis
We described continuous variables as means (±SD) or median (interquartile
range) and categorical variables as proportions. To compare baseline characteristics
between adults with an eGFR <60 versus ≥60 mL/min/ 1.73 m2 we used the Student t test
or Mann-Whitney U for continuous variables and chi-square test or the Fisher’s Exact
tests where appropriate for categorical variables. We used area under the receiver
operator characteristic curve to determine how well FRAX could discriminate between
individuals with a fracture and without a fracture (null value was defined as an area under
the curve value of 0.5 which indicates that the ability of FRAX to discriminate fracture is
no better than chance) (26). To assess differences in fracture discrimination between
individuals with an eGFR <60 and ≥60 mL/min/1.73 m2 we calculated mean differences
(95% confidence interval) using the two-tailed z test. In an additional analysis we
assessed the predictive discrimination of FRAX (without BMD) including CKD as a
cause of secondary osteoporosis in all individuals with an eGFR <60 mL/min/1.73 m2.
The rationale for this was that we wanted to capture some of the unique risk factors for
fracture in CKD patients that are currently not included in the FRAX algorithm (12). It is
important to note that only FRAX without BMD can be assessed when including CKD as
a secondary cause of osteoporosis because FRAX assumes that secondary causes of
osteoporosis effect fracture risk through lowering BMD. We had a maximum of 5 years
of follow up. As a result, to calculate the estimated fracture risk in the cohort using
FRAX we divided the FRAX 10-year risk by two. The 5-year observed fracture
probabilities and 95% confidence intervals were calculated using a survival analysis
method that adjusts for the competing risk of death (27). To assess calibration (defined as
the agreement between observed and predicted values) we compared the 5-year FRAX
estimated fracture risk with the 5-year observed fracture risk. We performed all statistical
analysis using the Statistical Analysis System (SAS version 9.3, SAS Institute, Cary, NC,
USA). We considered two-sided p-values <0.05 as statistically significant.
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3.3 Results
3.3.1 Baseline Characteristics
We included 320 adults with an eGFR <60 mL/min/1.73 m2 and 1787 adults with
an eGFR ≥60 mL/min/1.73 m2 (Figure 3.1). During follow-up, 3.3% (n=69) died (5.9%
[n=19] with an eGFR <60 and 2.8% [n=50] with an eGFR ≥60 mL/min/ 1.73 m2) and
3.8% (n=81) were lost to follow-up (8.4% [n=27] with an eGFR <60 and 3.0% [n=54]
with an eGFR ≥60 mL/min/ 1.73 m2). Of the adults with an eGFR <60 mL/min/1.73 m2
72.2% (n=231) had stage 3a CKD, 23.8% stage 3b (n=76), and 4.0% (n=13) had stage 4
or stage 5. Compared to individuals with an eGFR ≥60 individuals with an eGFR <60
mL/min/1.73 m2 were older (75.9 vs. 65.6 years; P<0.001) (Table 3.2). When comparing
individuals with an eGFR <60 to individuals with an eGFR ≥60 mL/min/1.73 m2
individuals with reduced kidney function were more likely to have type 2 diabetes
(13.1% vs. 6.6%; P<0.001), more likely to have sustained a previous fracture (25.3% vs.
17.1%; P<0.001), were less likely to report good, very good or excellent health (87.5%
vs. 93.6%; P<0.001), and self-reported bisphosphonate use was similar between the two
groups (26.9% vs. 23.5%; P=0.19).
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5569 individuals in the CaMos
study at year 10

161 individuals excluded who died
between year 10-11, were
unreachable at year 11 or refused to
participate at year 11†

3301 Individuals Excluded:
646 from Hamilton (no blood drawn at
this centre)
72 <40 years of age
11 with a previous organ transplant
2520 without a valid eGFR
2107 individuals included

52 without femoral neck bone mineral
density

Figure 3. 1. Study Cohort
†

Individuals who died or were not reachable at year 11 were excluded as we would not able to
obtain fracture data from these individuals.
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Table 3. 2. Baseline characteristics by estimated glomerular filtration rate¥
Characteristic

Estimated glomerular filtration rate (eGFR)
<60 mL/min/1.73 m2‡
(n=320)

≥60 mL/min/1.73 m2
(n=1787)

P Value

FRAX Variables
Women

227 (70.9%)

1258 (70.4%)

0.85

Age (yrs)

75.9 ± 7.2

65.6 ± 9.9

<0.001

Body mass index (kg/m2)

27.6 ± 4.6

27.1 ± 4.7

0.09

<18.5

1 (0.3%)

23 (1.3%)

18.5-24.9

102 (31.9%)

595 (33.3%)

25-29.9

134 (41.9%)

737 (41.2%)

≥30

83 (25.9%)

432 (24.2%)

Previous fracture

81 (25.3%)

306 (17.1%)

<0.001

Parent fractured hip

35 (10.9%)

232 (13.0%)

0.31

Current smoking

24 (7.5%)

156 (8.7%)

0.47

Corticosteroid use for >3 months

11 (3.4%)

22 (1.2%)

0.003

Rheumatoid arthritis

3 (0.94%)

13 (0.7%)

0.72

Secondary osteoporosis¶

22 (6.9%)

66 (3.7%)

0.009

0 (0%)

21 (1.2%)

0.06

-1.27 ± 0.96

-1.01 ± 1.02

<0.001

49.5 ± 9.0

81.3 ± 11.5

<0.001

≥ 3 alcoholic beverages per day
Femoral neck T-score
Comorbidities
Estimated glomerular filtration rate†
Stage 3a

231 (72.2%)

Stage 3b

76 (23.8%)

Stage 4/5

13 (4.0%)

Fall in the past 12 months

77 (24.1%)

465 (26.0%)

0.46

Bisphosphonate use€

86 (26.9%)

420 (23.5%)

0.19

Hypertension

186 (58.1%)

577 (32.3%)

<0.001

Type 2 Diabetes

42 (13.1%)

117 (6.6%)

<0.001

Kidney stones

37 (11.6%)

140 (7.8%)

0.03
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Excellent, very good or good selfreported current health

280 (87.5%)

1673 (93.6%)

<0.001

≥ Post-secondary education

154 (48.1%)

1067 (59.7%)

<0.001

43.7 ± 2.7

44.6 ± 2.5

<0.001

62.6 (48.0-85.4)

56.1 (44.2-71.1)

<0.001

Missing

36 (11.3%)

293 (16.4%)

Hyperparathyroidism (defined as >65
pg/mL)

126 (44.4%)

491 (32.9%)

<0.001

Serum 25(OH)D (ng/mL)

28.2± 10.6

28.3± 9.7

0.89

Missing

30 (9.4%)

262 (14.7%)

172 (59.3%)

914 (60.1%)

0.84

Serum calcium (mg/dL)

9.6 ± 0.5

9.5 ± 0.4

0.02

Serum phosphate ( mg/dL)

3.7 ± 0.5

3.4 ± 0.5

0.007

6.7 (0-16.3)

6.7 (0-15.0)

0.61

Lab Values
Albumin (g/L)
Parathyroid hormone* (pg/mL)

Low serum 25(OH)D (defined as <30
ng/mL)

Total vitamin D (includes supplements,
mcg/day)

Total Calcium (includes food and
1249.5 (782.9-1697.2)
1211.6 (764.5-1719.8)
0.94
supplements, mg/day)
Data are Mean ± SD, median (interquartile range), or N (%).
Abbreviations: BMD, bone mineral density; FRAX, Fracture Risk Assessment tool
¥
Baseline characteristics were taken at year 10 of the study.
†
eGFR calculated using the chronic kidney disease epidemiology collaboration equation
‡
Estimated glomerular filtration rate <60 mL/min/ 1.73 m2 encompasses stages 3a, 3b, 4, and 5 chronic kidney disease
as defined by the Kidney Disease Improving Global Outcomes Guidelines.
€
Defined as a composite of alendronate, clodronate, etidronate, risedronate, ibandronate, pamidronate, zoledronate at
cohort entry.
¶
Defined as any of the following: chronic liver disease, type I diabetes, hyperthyroidism, hypogonadism, premature
menopause (<45 years), chronic malnutrition/malabsorption and osteogenesis imperfecta. Source: World Health
Organization: FRAX World Health Organization Fracture Risk Assessment Tool, 2011. Available at:
http://www.shef.ac.uk/FRAX/index.aspx. Accessed May 20, 2014.
*
Reference range for the PTH assay was 21.8-104.5 pg/mL and was measured by the Liaison (Diasorin Incorporated)
assay.

3.3.2 Fracture Risk Prediction and Discrimination
Over an average of 4.8 years of follow-up, there were a total of 64 (3.0%) major
osteoporotic fractures events (16 [5.0%] with an eGFR <60 mL/min/1.73 m2 [2.5% stage
3a, 2.2% stage 3b, and 0.3% stage 4/5] and 48 [2.7%] with an eGFR ≥60 mL/min/1.73
m2). The area under the curve (AUC) values for the FRAX models, femoral neck T-score
alone, age alone, and T-score with a previous fall are presented in Table 3.3. We found
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that all AUC values were statistically significant (greater than 0.5) regardless of renal
function. The major osteoporotic fracture FRAX AUC values were higher in individuals
with an eGFR ≥60 mL/min/1.73 m2 compared to individuals with an eGFR <60
mL/min/1.73 m2. However, these differences did not reach statistical significance (Table
3.3). Moreover, there were no statistically significant differences in the predictive
discrimination of T-scores alone, age alone, and T-scores with previous falls between
individuals with an eGFR <60 versus ≥60 mL/min/1.73 m2 for major osteoporotic
fractures (Table 3.3).

Table 3. 3. Area under the curve for incident fracture prediction for major osteoporotic
fracture according to estimated glomerular filtration rate
<60 mL/min/1.73 m2

≥60 mL/min/1.73 m2

AUC

95% CI

AUC

95% CI

FRAX with BMD

0.69

0.54 to 0.83

0.76

0.70 to 0.82

FRAX without BMD

0.65

0.52 to 0.79

0.74

0.67 to 0.81

FRAX without BMD and
with secondary
osteoporosis

0.65

0.51 to 0.80

Femoral neck T-score

0.65

0.52 to 0.80

0.72

0.65 to 0.79

Femoral neck T-score and
prior history of fall

0.71

0.58 to 0.84

0.75

0.68 to 0.82

Age

0.70

0.56 to 0.83

0.69

0.62 to 0.77

Risk Factor

AUC
Difference,
95% CI
-0.07
(-0.23 to 0.09)
-0.09
(-0.24 to 0.06)

P
Value

-0.07
(-0.23 to 0.09)
-0.04
(-0.19 to 0.11)

0.39

0.01
(-0.14 to 0.16)

0.90

0.38
0.25

0.59

Abbreviations: AUC, area under the curve; BMD, bone mineral density; CI, confidence interval; FRAX, Fracture Risk
Assessment tool

3.3.3 Fracture Events and Fracture Risk Calibration
In individuals with an eGFR <60 mL/min/1.73 m2 the observed major
osteoporotic fracture risk (5.3%, 95% CI 3.3 to 8.6%), calculated using a survival
analysis method that adjusts for the competing risk of death (27), was slightly lower than
the FRAX predicted major osteoporotic fracture risk with BMD (6.4%, 95% CI 6.0 to
6.9%) and also slightly lower than the FRAX predicted major osteoporotic fracture risk
without BMD (8.2%, 95% CI 7.6 to 8.7%) (Figure 3.2); however, the observed and
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FRAX predicted fracture risks were concordant with the FRAX predicted fracture risk
within the observed fracture risk 95% CI. In individuals with an eGFR ≥60 mL/min/1.73
m2 the observed major osteoporotic fracture risk (2.7%, 95% CI, 2.1 to 3.6%) was lower
than the FRAX predicted major osteoporotic fracture risk with BMD (4.6%, 95% CI 4.5
to 4.8%) and lower than the FRAX predicted major osteoporotic fracture risk without
BMD (5.3%, 95% CI, 5.0 to 5.4%). When including CKD as a cause of secondary
osteoporosis in individuals with an eGFR <60 mL/min/1.73 m2 the calibration of FRAX
without BMD did not improve; the FRAX predicted risk in our cohort was 11.0% (95%
CI 10.3 to 11.7%) compared to an observed major osteoporotic fracture risk of 5.3%
(95% CI, 3.3 to 8.6%).

14

12

5-year fracture probability (%)

FRAX without BMD and
secondary osteoporosis
10

FRAX without BMD
8

6

FRAX with BMD

4
Observed major osteoporotic
fracture
2

0
2

eGFR<60mL/min/1.73
<60 mL/min/1.73 mm2
eGFR

eGFR
≥60 mL/min/1.73 m2
eGFR≥60mL/min/1.73

m2

Kidney function defined by estimated glomerular filtration rate (eGFR)

Figure 3. 2. Mean predicted 5-year fracture risk from the Canadian FRAX tool (with and
without bone mineral density [BMD]) and observed 5-year major osteoporotic fracture
risk (Kaplan-Meier) according to estimated glomerular filtration rate. Error bars are 95%
confidence intervals.

58
3.4 Discussion
We found that the discriminative ability of FRAX to predict major osteoporotic
fractures was similar and independent of renal function. Further, in individuals with an
eGFR <60 mL/min/1.73 m2 the FRAX predicted probabilities were comparable to the
observed major osteoporotic fracture probabilities. Our finding suggests that FRAX may
be a valuable tool for clinicians to accurately assess fracture risk in individuals with
reduced kidney function.
Area under the curve values in individuals with an eGFR <60 mL/min/1.73 m2
that we found were similar, although slightly lower, to the values found in a crosssectional study assessing the ability of FRAX to discriminate fracture status in
individuals with reduced kidney function (13). Jamal et al. included individuals with an
eGFR <90 mL/min/1.73 m2 and found an AUC of 0.72 (95% CI, 0.65 to 0.78) for FRAX
with BMD while we found an AUC of 0.69 (95% CI, 0.54 to 0.83) (13). The AUC
values in our study were also similar to average AUC values found in 11 international
FRAX validation cohorts (n= 230,486) performed in the general population for both
FRAX with BMD (AUC 0.62) and FRAX without BMD (AUC 0.60) (2).
In individuals with an eGFR <60 mL/min/1.73 m2 the AUC values for FRAX
with (0.69) and without BMD (0.65) were lower than the AUC value for age alone (0.70)
which might suggest that FRAX performs no better than age alone; however, similar
results have been found in studies conducted in the general population (28-30) and
comparison of AUC values has been criticized as insensitive (31-33). Moreover, due to
the small number of fractures in our study we were not able to test whether these results
reached statistical significance as thousands of individuals are required to test whether a
statistically significant difference occurs in correlated receiver operator characteristic
curves (2, 34, 35).
In individuals with an eGFR <60 mL/min/1.73 m2 the observed major
osteoporotic fracture risk (5.3%) and FRAX predicted probability of major osteoporotic
fracture risk were similar (6.4% with BMD and 8.2% without BMD). We found that the
calibration of FRAX without BMD did not improve when adding CKD as a cause of
secondary osteoporosis in individuals with an eGFR <60 mL/min/1.73 m2; we calculated
the FRAX predicted fracture risk to be 11.0% and the observed major osteoporotic
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fracture risk was 5.3%. It may be that adding CKD as a cause of secondary osteoporosis
does not accurately capture all the complexities of CKD-mineral and bone disorder (12).
In the future, large prospective studies that incorporate CKD specific fracture risk factors
(e.g. fibroblast growth factor 23) and include more individuals with advanced CKD are
needed.
Our study has several strengths. The prospective design enabled us to compare
observed and FRAX predicted fracture risks. Moreover, in accordance with FRAX,
which includes the death hazard, we accounted for the competing risk of death by using a
modified Kaplan-Meier method (27). To our knowledge this is the first study to assess
the discrimination and calibration of FRAX in predicting risk of incident fractures
comparing individuals with reduced kidney function to individuals with normal kidney
function. Our study had some limitations. The small number of fractures limited our
statistical power. Thus, we were unable to assess the prognostic value of FRAX for hip
fracture alone, compare different FRAX models (i.e., assess the performance of FRAX
versus age alone), and we were unable to further stratify kidney function into additional
eGFR categories. This last point is of particular clinical relevance because as eGFR
decreases the fracture rate increases which may be largely attributable to changes in bone
and mineral metabolism (8, 12); therefore, it may be valuable to assess the performance
of FRAX at each stage of CKD. However, even given the small number of fracture
events all of the AUC values for major osteoporotic fracture prediction were statistically
significant. The generalizability of our findings may be limited; the majority of our
sample was white (≥ 99%) and individuals with reduced kidney function were largely
community dwelling adults who were unaware they had decreased kidney function.
Therefore, these results may not be generalizable to individuals with more severe stages
of CKD and diagnosed CKD-mineral and bone disorder. Moreover, we were only able to
include Canadians which may limit the generalizability of the results to different
countries; due to the wide variability of fracture rates across countries FRAX needs to be
calibrated separately for each country (36). Additionally, a high proportion of individuals
with normal kidney function had hyperparathyroidism (> 30%) which may limit
generalizability to other populations; one potential explanation for this is previous
research has found individuals with moderate declines in kidney function (i.e., eGFR 60-
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69 mL/min/1.73 m2) are more likely to have hyperparathyroidism (> 20%) (37);
moreover, many individuals in our study had low vitamin D levels (approximately 60%);
as vitamin D levels decrease parathyroid hormone levels increase (38).
In summary, FRAX was able to accurately predict fracture risk in this cohort of
individuals with an eGFR <60 mL/min/1.73 m2 which was demonstrated by the similar
observed and FRAX predicted fracture rates. Moreover, FRAX demonstrated major
osteoporotic fracture predictive discrimination in individuals with an eGFR <60
mL/min/1.73 m2 which was similar to individuals with an eGFR ≥60 mL/min/1.73 m2.
Therefore, FRAX may be a useful tool for clinicians to use to assess fracture risk in
patients with reduced kidney function. However, given the limited sample size results
should be interpreted with caution and large prospective studies are needed before FRAX
can be recommended to be used routinely for fracture risk assessment in individuals with
reduced kidney function.
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4.1 Introduction
Declining kidney function is associated with changes in mineral metabolism that
contribute to an increased fracture risk (1). Of note, changes in mineral metabolism can
persist after a kidney transplant despite improvements in kidney function (1-3) and
fracture risk may be further increased due to the use of glucocorticoids (4, 5). Moreover,
kidney transplant recipients may be frail potentially predisposing them to falls, thereby
increasing fracture risk (6-11). However, it remains uncertain whether kidney transplant
recipients are a high risk group for fracture, defined in most clinical guidelines as a 10year hip fracture risk ≥ 3% (12, 13). Prior studies suggest recipients may have a higher
risk of fracture compared to the general population (14-22), with males aged 25-44 years
experiencing a five-time higher fracture risk compared to their counterparts in the general
population (18).
Current data concerning fracture risk post-transplant has several limitations. First,
few prior studies included kidney transplant recipients who received a transplant after the
year 2000 (this is important because characteristics of recipients [e.g. comorbidities] and
clinical practice patterns [e.g. trend towards decreased steroid use] have changed over
time (22-25)). Second, many previous studies had a short follow-up time, with median
follow-up times less than 6 years, which limits our ability to comment on the long term
risks of fracture post-transplant (26). Third, these studies did not compare fracture rates
in transplant recipients to a reference population which limits our ability to understand
the specific burden of fracture post-transplant. Moreover, large between-study variability
in fracture rates in recipients is recognized (incidence rates ranging from 3.3 to 99.6
fractures per 1000 person-years), with studies varying in their fracture locations (26).
A better understanding of fracture incidence remains important for estimating
sample size requirements for future fracture prevention trials, obtaining informed
consent, and clinical prognostication. Given the variability in fracture incidence across
the literature, limitations of previous studies, and because fracture rates can widely vary
across countries (27, 28) we conducted this study to provide a precise estimate of the 3year incidence of non-vertebral fracture according to age and sex in a cohort of adult
Canadian kidney transplant recipients. To provide a comprehensive examination of
fracture in a secondary analysis we examined the following: 3-year incidence of all
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fractures (excluding skull, toe, and fingers) and falls with hospitalization according to age
and sex; 5- and 10-year incidence of non-vertebral fracture according to age and sex; 10year incidence of hip fracture alone according to age and sex; and non-vertebral fracture
incidence in adult Canadian kidney recipients compared to several matched nontransplant reference groups (one group at a low fracture risk; two groups at increased
fracture risk).

4.2 Methods
4.2.1 Design and Setting
We used healthcare databases at the Institute for Clinical Evaluative Sciences in
Ontario, Canada to conduct a population-based cohort study. All residents of Ontario are
provided with universal access to physician and hospital services. We conducted this
study using a protocol approved by the Research Ethics Board at Sunnybrook Health
Sciences Centre (Ontario, Canada).
4.2.2. Data Sources
We used several linked databases to ascertain the study population, patient
characteristics, and outcome data. The Canadian Organ Replacement Register (CORR)
provided information on all kidney transplant recipients in Ontario. The Ontario Health
Insurance Plan reported information on Ontario physicians’ billing claims for inpatient
and outpatient services. Information on diagnostic and procedural codes for Ontario
hospitalizations were provided by the Canadian Institute for Health Information. The
National Ambulatory Care Reporting System provided information on emergency room
visits. Information on demographics and vital status was obtained from the Ontario
Registered Persons Database. The Ontario Drug Benefit Plan, a universal drug plan for
individuals aged ≥ 65 years, provided information on outpatient prescription drug usage.
Since April 1997 information was also provided for special populations < 65 years. Data
was complete except for race (10% missing), primary cause of end-stage renal disease
(11%), and donor type (1%).
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4.2.3 Primary Cohort
4.2.3.1 Kidney transplant recipients
We reviewed the CORR database from July 1st, 1994 to December 31st, 2009 for
evidence of a first kidney-only transplant. We excluded recipients who previously
received another organ transplant (including simultaneous transplants [e.g. kidneypancreas]), recipients who were < 18 years of age on the date of transplant, and recipients
who were non-Ontario residents at the time of transplant (defined by postal code). The
date of cohort entry (index date) was defined as the date of the kidney transplant.
4.2.4 Reference Cohorts
To help put the burden of fracture into context we matched a kidney transplant
recipient to three different reference cohorts (one group at a low fracture risk; two groups
at increased fracture risk) on age (± 1 year), sex, and index date (± 1 year). To increase
statistical power we matched one recipient to four non-transplant persons in two of the
three reference cohorts, and in the last cohort we matched one recipient to one nontransplant person due to a smaller sample size. Cohort creation for the reference groups is
described below.
4.2.4.1 Healthy segment of the population with no bone disease and no
kidney disease (low fracture risk)
We randomly assigned an index date to the entire adult (≥ 18 years) Ontario
population (n=18,184,929 from 1994 to 2009) based on the index date distribution of the
recipient cohort. We looked back to the initiation of the databases (July 1, 1991) and
excluded individuals with chronic kidney disease (including prior receipt of a kidney
transplant or dialysis), osteoporosis (defined as an osteoporosis diagnostic code within 1
year after a dual-energy x-ray absorptiometry examination) (29), or a previous nonvertebral fracture (proximal humerus, forearm, hip).
4.2.4.2 Healthy segment of the general population with no kidney disease
and a previous non-vertebral fracture (increased fracture risk)
As in the previous cohort we randomly assigned an index date based on the index
date distribution of the recipient cohort; however, in this cohort we only included
individuals who had a non-vertebral fracture (proximal humerus, forearm, hip) within the
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5 years prior to index date. We excluded individuals with chronic kidney disease
(including prior receipt of a kidney transplant or dialysis).
4.2.4.3 Non-dialysis chronic kidney disease (CKD) (increased fracture
risk)
We reviewed the databases from July 1st, 1994 to December 31st, 2009 for first
evidence of a CKD diagnostic code (date of the first CKD diagnosis defined as index
date); a CKD diagnostic code identifies Ontario individuals who have a median estimated
glomerular filtration rate of 38 mL/min/1.73 m2 (30).We excluded individuals who
received chronic dialysis or a previous transplant.
4.2.5 Outcomes
In the primary analysis we followed kidney transplant recipients for 3 years after
the date of transplant or until evidence of a non-vertebral fracture (including multiple
fractures on the same day) or death; if an individual had multiple fractures on the same
day we only counted one fracture as an event. We continued to follow recipients even if
they experienced graft failure (defined as return to chronic dialysis or re-transplant). The
last possible date of follow-up was December 31st, 2012. Our primary outcome was nonvertebral fracture with hospital presentation (emergency room visit or hospital admission)
which was defined as a composite of proximal humerus, forearm, and hip fracture. We
selected these locations as they are considered major osteoporotic fracture locations and
are associated with morbidity and mortality (31-33). Moreover, fracture codes for these
sites have been validated and have high accuracy (> 90% sensitivity, ≥ 85% specificity, >
80% positive predictive value) (34-38). All analyses were performed including fractures
accompanied by trauma codes; in addition to low-trauma fractures, fractures associated
with high-trauma are more likely to occur in individuals with reduced bone strength (39).
Although vertebral fractures are considered a major osteoporotic fracture, they were
excluded from the primary analysis because merely one-third are clinically detected (40).
In an additional analysis, we included the following fracture locations along with nonvertebral fractures: lower leg (ankle, tibia, fibula, patella), femoral shaft,
rib/sternum/trunk, scapula, clavicle, clinical vertebral, and pelvis fractures. We used the
9th version of the Canadian Modified International Classification of Disease (ICD) system
prior to April 1st, 2002 and the 10th version thereafter to ascertain fracture events.
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Diagnosis codes for hip, forearm, and femoral shaft fractures also had to have evidence of
associated procedural codes to increase fracture definition accuracy (37, 41, 42). We
identified procedural codes from hospital encounters and physician billing codes. Given
falls are associated with an increased fracture risk and are associated with significant
morbidity and economic costs we also assessed falls with hospital presentation using the
9th and 10th version of the Canadian Modified International Classification of Disease
system codes (9, 10, 43-45).
4.2.6 Statistical Analyses
We used median (interquartile range) to summarize baseline characteristics for
continuous data and percentages to summarize categorical data. We defined the 3-year
cumulative incidence of fracture as the proportion of recipients who sustained a fracture
in the 3 year follow-up period; no fracture could occur in follow-up if the recipient died
before fracture. We similarly calculated the 3-year cumulative incidence of falls. We also
calculated the 3-year incidence rate of fracture (rate per 1000 person-years) and censored
at death or fracture during the follow-up period. We presented the results for fracture and
falls by sex (male versus female) and age (< 50 versus ≥ 50 years) at date of transplant.
The age dichotomization was chosen for several reasons, including: based on previous
research we expected that the median age of kidney transplant recipients would be 50
years (46), average age of menopause is roughly 50 years (47, 48) (fracture risk increases
with menopause) (49, 50), and previous research has found kidney transplant recipients ≥
50 years have an increased fracture risk (22). To test the hypothesis that there was no
difference in non-vertebral fracture incidence between recipients and each reference
group we used the log-rank test stratifying on matched pairs; we also used Cox
proportional hazard analysis to assess the effect of transplant status (transplant versus no
transplant) on the hazard of fracture; we stratified on matched sets and tested for the
proportional hazard assumption (proportional hazard was met). In addition to matching
on age (± 1 year), sex, and index date (± 1 year) we performed an analysis adjusting for
diabetes (given diabetes is a strong risk factor for fracture (51)). We also examined the
5- and 10-year cumulative incidence and incidence rate of non-vertebral fracture and the
10-year incidence of hip fracture alone. We considered a two-tailed p-value < 0.05 as
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statistically significant for all tests. We conducted all analyses with SAS (Statistical
Analysis Software), version 9.3 (www.sas.com).
4.2.7 Additional Analyses
In a sensitivity analysis we only included kidney transplant recipients who
received a transplant between April 1st, 2002 and December 31st, 2009, providing a more
current representation of fracture rates and accounting for potential changes in coding
(Ontario switched to ICD-10 coding April 1st, 2002). To take into account graft failure we
performed an additional sensitivity analysis to determine the 3-year cumulative incidence
of non-vertebral fracture censoring at the time of graft failure (defined as return to
chronic dialysis or re-transplant).

4.3 Results
4.3.1 Baseline Characteristics
We studied 4821 kidney transplant recipients who received a transplant from
1994 to 2009. Baseline characteristics for the recipient cohort are described in Tables 4.1
and 4.2. The median age of recipients was 50 years (interquartile range, 38-59) and
36.9% were women. When known, the most common cause of end-stage renal disease
was glomerulonephritis, 74.1% had hypertension, and the median time on dialysis prior
to transplant was 2.4 years (interquartile range, 1.0-4.5). Baseline characteristics for the
reference groups (healthy segment of the general population with no previous nonvertebral fracture [n=19,284]; healthy segment of the general population with a previous
non-vertebral fracture [n=4821]; and non-dialysis CKD [n=19,284]) are described in
Table 4.1.
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Table 4. 1. Baseline characteristics of kidney transplant recipients compared to several
reference groups
Characteristic

Age, years

Kidney
transplant
recipients
(n=4821)

Healthy segment
of the general
population with
no bone disease
and no kidney
disease
(n=19,284)

Reference Groups
Healthy
segment of the
general
population with
no kidney
disease and a
previous nonvertebral
fracture
(n=4821)
49 (38-59)

Non-dialysis
Chronic kidney
disease
(n=19,284)

50 (38-59)

50 (38-59)

1781 (36.9%)

7124 (36.9%)

1781 (36.9%)

7124 (36.9%)

1994-1997

914 (18.9%)

3655 (19.0%)

906 (18.8%)

3643(18.9%)

1998-2001

1111 (23.1%)

4424 (22.9%)

1083 (22.4%)

4441 (23.0%)

2002-2005

1182 (24.5%)

4776 (24.8%)

1214 (25.2%)

4736 (24.6%)

2006-2009

1614 (33.5%)

6429 (33.3%)

1618 (33.6%)

6464 (33.5%)

Hypertension

3572 (74.1%)

3829 (19.9%)

1040 (21.5%)

9050 (46.9%)

Diabetes

1255 (26.0%)

1527 (7.9%)

503 (10.4%)

6371 (33.0%)

Cardiovascular disease¶

2068 (42.9%)

1424 (7.4%)

490 (10.2%)

4486 (23.3%)

Women

50 (38-59)

Era

Prior non-vertebral
fracture‡

106 (2.2%)

296 (1.5%)

Data are medians (interquartile range) or n(%).
¶
Cardiovascular disease was defined as the presence of peripheral vascular disease, congestive heart failure or
coronary artery disease.
‡
Prior non-vertebral fracture defined as a composite of proximal humerus, forearm, hip fractures from 1991 to cohort
entry. The median number of years (interquartile range) of baseline records prior to cohort entry is as follows: kidney
transplant recipients, 11.9 years (7.5-15.6); non-dialysis chronic kidney disease, 11.9 years (7.6-15.6).
Note: The reference group general population with no previous non-vertebral osteoporotic fracture has no previous
fracture as this was a requirement to enter the cohort. The reference group general population with a previous nonvertebral osteoporotic fracture has 100% sustaining a fracture prior to cohort entry as this was requirement for cohort
entry.
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Table 4. 2. Additional characteristics of kidney transplant recipients
Characteristic

Kidney transplant recipients
(n=4821)

Race
White

3277 (68.0%)

Black

272 (5.6%)

Asian

309 (6.4%)

Other

‡

485 (10.1%)

Missing

479 (9.9%)

Cause of end-stage renal disease
Glomerulonephritis

1710 (35.4%)

Cystic kidney disease

620 (12.9%)

Diabetes

843 (17.5%)

Renal vascular disease

448 (9.3%)

Other

665 (13.8%)

Unknown/missing

535 (11.1%)

Pre-transplant dialysis
Peritoneal dialysis

1441 (29.9%)

Hemodialysis

2880 (59.7%)

Pre-emptive

†

500 (10.4%)

Donor Type
Living

2007 (41.6%)

Deceased

2755 (57.2%)

Missing

59 (1.2%)

Dialysis (years prior to transplant)‖

2.4 (1.0-4.5)

Delayed graft function€

899 (18.6%)

Primary non-functionβ

143 (3.0%)

Pretransplant Parathyroidectomy

257 (5.3%)

Medications£
Glucocorticoids¶
Cyclosporine⃰
¥

Tacrolimus

22.5 (12.5-30)
367 (13.6%)
1417 (52.6%)
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Bisphosphonates**

646 (18.2%)

Data are median (interquartile range) or n (%).
‡
Other was defined as a composite of: Indian Sub-Continent, Pacific Islander, Aboriginal, Mid East/Arabian, Latin
American, Other/Multiracial.
†
If there was no evidence of hemodialysis or peritoneal dialysis prior to transplant the recipient was coded as having
a pre-emptive transplant.
‖
Includes individuals who received a pre-emptive transplant where the time spent on dialysis was defined as 0 years.
€
Delayed graft function was defined as presence of one dialysis code contained in administrative databases in the
first 7 days after transplant.
β
Primary non-function was defined as at least three codes for dialysis on three different days with at least one code
appearing in the first 7 days after the transplant date, one in the 8- 30 days after the transplant date, and one in the
31-60 days after the transplant date.
£
Medication information was obtained in the first 90 days after transplantation for glucocorticoids, cyclosporine and
tacrolimus. Medication information was obtained in the first 3 years after transplantation for bisphosphonates.
¶
Glucocorticoid information was available for 1896 kidney transplant recipients and was presented as the median
dose in the first 90 days after transplant (mg/day).
⃰Denominator was n=2695 (number of recipients eligible for prescription drug coverage in the first 90 days after
transplantation).
¥
Denominator was n=2695 (number of recipients eligible for prescription drug coverage in the first 90 days after
transplantation).
**
Denominator was n=3540 (number of recipients eligible for prescription drug coverage in the first 3-years after
transplantation).

Over 3 years of follow-up (13,850 person-years) 298 (6.2%) recipients died and
77 (1.6%) sustained a non-vertebral fracture. For the reference groups, during the 3 year
follow-up, 260 (1.3%) individuals from the healthy segment of the general population
with no previous non-vertebral fracture died and 98 (0.5%) sustained a non-vertebral
fracture, 170 (3.5%) from the healthy segment of the general population with a previous
non-vertebral fracture died and 113 (2.3%) sustained a non-vertebral fracture, and 2637
(13.7%) individuals with non-dialysis CKD died and 207 (1.1%) sustained a nonvertebral fracture.
4.3.2 Fracture Risk
The 3-year cumulative incidence and incidence rate of non-vertebral fracture
(proximal humerus, forearm, hip) according to age and sex is presented in Table 4.3.The
overall 3-year cumulative incidence of non-vertebral fracture in recipients was 1.6% (95%
CI 1.3-2.0%). In recipients, the number of non-vertebral fracture events increased linearly
over the 3 years after transplant (Figure 4.1). For hip fracture alone the overall 3-year
cumulative incidence in recipients was 0.4% (95% CI, 0.3-0.7%).The overall 5- and 10year cumulative incidence of non-vertebral fracture in recipients was 2.7% (95% CI, 2.23.2%) and 5.5% (95% CI 4.6-6.5%), respectively (Table 4.4). For hip fracture alone the
overall 10-year cumulative incidence in recipients was 1.7% (1.2-2.3%) (Table 4.5). For
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all analyses women recipients aged ≥ 50 years had the highest cumulative incidence of
fracture (Tables 4.3, 4.4, 4.5).

Figure 4. 1. Cumulative incidence of non-vertebral fracture (proximal humerus, forearm,
or hip) in recipients and non-transplant reference populations. Kidney transplant
recipients had a significantly higher fracture rate compared to the non-dialysis chronic
kidney disease population (P=0.03 by the log-rank test) and the healthy segment of the
general population with no bone disease and no kidney disease (P<0.0001 by the log-rank
test). Kidney transplant recipients had a significantly lower fracture rate compared to the
healthy segment of the general population with no kidney disease and a previous nonvertebral fracture (P=0.007 by the log-rank test).
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Table 4. 3. 3-year cumulative incidence and incidence rate of non-vertebral fracture
(proximal humerus, forearm, or hip) stratified by sex and age in kidney transplant
recipients¶
3-year cumulative
incidence, %
(95% CI)
1.6
(1.3-2.0)

Incidence rate per 1000
person years
(95% CI)
5.6
(4.4-7.0)

Women < 50
years (n=944)

0.6
(0.3-1.4)

2.2
(0.8-4.7)

Women ≥ 50
years (n=837)

3.1
(2.1-4.5)

11.1
(7.3-16.3)

Men < 50 years
(n=1463)

0.7
(0.4-1.3)

2.3
(1.1-4.1)

Men ≥ 50 years
(n=1577)

2.2
(1.6-3.1)

7.9
(5.5-11.0)

Overall
(n=4821)

Abbreviation: CI, confidence interval
3-year cumulative incidence defined as the proportion of kidney transplant recipients who sustained a non-vertebral
fracture within the 3 years of follow-up; no fracture could occur in follow-up if the kidney transplant recipient died
before fracture. Incidence rate defined as the rate per 1000 person years; censoring occurred at death or at the time of a
fracture event during the follow-up period.
¶

Table 4. 4. 5- and 10-year cumulative incidence and incidence rate of non-vertebral
fracture in kidney transplant recipients stratified by sex and age
5-year
cumulative
incidence, %
(95% CI)
2.7
(2.2-3.2)

Incidence rate
per 1000
person years
(95% CI)
5.8
(4.8-7.0)

Women < 50
years
(n=817)

1.5
(0.8-2.6)

3.1
(1.6-5.3)

Women ≥ 50
years
(n=682)

5.7
(4.2-7.7)

Men <50 years
(n=817)
Men ≥ 50 years
(n=1291)

Overall
(n=4070)

10-year
cumulative
incidence, %
(95% CI)
5.5
(4.6-6.5)

Incidence rate
per 1000
person years
(95% CI)
6.4
(5.3-7.6)

Women < 50
years
(n=536)

3.7
(2.4-5.6)

4.1
(2.5-6.3)

12.8
(9.1-17.5)

Women ≥ 50
years
(n=354)

13.3
(10.1-17.2)

17.3
(12.7-23.0)

1.3
(0.8-2.0)

2.6
(1.5-4.2)

Men <50 years
(n=817)

2.6
(1.7-3.9)

2.7
(1.7-4.2)

3.3
(2.5-4.5)

4.8
(2.9-7.5)

Men ≥ 50 years
(n=678)

6.3
(4.7-8.4)

8.1
(5.9-10.9)

Overall
(n=2385)

Note: For the 5-year cumulative incidence/incidence rate we only included kidney transplant recipients who received
a transplant before April 1, 2008 and for the 10-year cumulative incidence/incidence rate we only included kidney
transplant recipients who received a transplant before April 1, 2003. To increase the number of kidney transplant
recipients for this additional analysis we defined the maximum follow-up as March 31, 2013.
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Table 4. 5. 10-year cumulative incidence and incidence rate of hip fracture in kidney
transplant recipients stratified by sex and age
10-year
cumulative
incidence, %
(95% CI)
1.7
(1.2-2.3)

Incidence rate per
1000
person years
(95% CI)
1.9
(1.4-2.6)

Women ≥ 50 years
(n=354)

5.6
(3.7-8.6)

7.1
(4.3-10.9)

Men ≥ 50 years
(n=678)

2.5
(1.6-4.0)

3.2
(1.8-5.0)

Overall
(n=2385)

Note: For the 10-year cumulative incidence/incidence rate we only included kidney transplant recipients who
received a transplant before April 1, 2003. To increase the number of kidney transplant recipients for this additional
analysis we defined the maximum follow-up as March 31, 2013.
We were not able to report the 10-year cumulative incidence of hip fracture for women and men <50 years for
reasons of privacy (cell size, 1-5).

Recipients had a higher 3-year cumulative incidence of non-vertebral fracture
(1.6%, 95% CI 1.3-2.0%) compared to the healthy segment of the general population
(matched on age, sex, and index date) with no previous non-vertebral fracture (0.5%, 95%
CI 0.4-0.6%; P<0.0001) and compared to the non-dialysis CKD population (1.1%, 95% CI
0.9-1.2%; P=0.03) (Table 4.6) (Figure 4.1). However, recipients had a lower 3-year
cumulative incidence of non-vertebral fracture compared to the healthy segment of the
general population with a previous non-vertebral fracture (2.3%, 95% CI 1.9-2.8%;
P=0.007). After adjusting for diabetes in addition to matching all results remained
statistically significant (Table 4.6).
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Table 4. 6. 3-year cumulative incidence, incidence rate, and hazard ratios of nonvertebral fracture (proximal humerus, forearm, or hip) in several reference groups
compared to kidney transplant recipients matched on age, sex, and index date¥
3-year
cumulative
incidence,
% (95%
CI)
1.6
(1.3-2.0)

Incidence rate
per 1000
person years
(95% CI)

Hazard
¥
Ratio
(95% CI)

Hazard Ratio‡
(95% CI)

5.6
(4.4-6.9)

1.00
(reference)

1.00
(reference)

Healthy segment of the
general population with
no bone disease and no
kidney disease
(n=19,284)

0.5
(0.4-0.6)

1.7
(1.4-2.1)

0.3
(0.2- 0.4)

0.3
(0.2-0.4)

Healthy segment of the
general population with
no kidney disease and a
previous non-vertebral
fracture
(n=4821)

2.3
(2.0-2.8)

8.1
(6.6-9.7)

1.4
(1.1-1.9)

1.6
(1.1-2.2)

Non-dialysis chronic
kidney disease
(n=19,284)

1.1
(0.9-1.2)

4.0
(3.5-4.6)

0.8
(0.6-0.98)

0.7
(0.6-0.9)

Population

Kidney transplant
recipients
(n=4821)

¥

Matched on age (±1 year), sex, and index date (±1 year)
Matched on age (±1 year), sex, and index date (±1 year) and adjusting for diabetes.

‡

When including all fracture locations, the overall 3-year cumulative incidence in
recipients was 3.5% (95% CI 3.0-4.1%); amongst the four age and sex strata, the 3-year
cumulative incidence was highest in women recipients aged ≥ 50 years (5.7%, 95% CI
4.3-7.5%) (Table 4.7). The most common location of first clinically diagnosed fracture in
recipients was the lower leg (defined as a composite of tibia, fibula, patella, and ankle)
(32.5% of all fractures) and a similar result was found in the healthy segment of the
general population with a previous non-vertebral fracture (27.9% of all fractures) (Table
4.8).
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Table 4. 7. 3-year cumulative incidence and incidence rate of all fracture in kidney
transplant recipients stratified by sex and age‡
3-year cumulative incidence, %
(95% CI)

Incidence rate per 1000
person years
(95% CI)

Overall
(n=4821)

3.5
(3.0-4.1)

12.3
(10.5-14.3)

Women < 50 years
(n=944)

2.1
(1.4-3.3)

7.3
(4.5-11.3)

Women ≥ 50 years
(n=837)

5.7
(4.4- 7.5)

20.8
(15.3-27.5)

Men < 50 years
(n=1463)

2.4
(1.7- 3.3)

8.2
(5.7-11.4)

Men ≥ 50 years
(n=1577)

4.2
(3.3- 5.3)

15.0
(11.6-19.1)

‡

All fracture locations defined as a composite of hip, forearm, proximal humerus, lower leg (ankle, tibia, fibula,
patella), femoral shaft, rib/sternum/trunk, scapula, clavicle, vertebral, and pelvis fractures

Table 4. 8. Location of the first fracture in follow-up‡
Fracture location

Kidney transplant recipients
(n=4821)

Hip

17 (10.6%)

Healthy segment of the
general population with no
kidney disease and a
previous non-vertebral
fracture
(n=4821)
24 (10.6%)

Forearm

43 (26.9%)

60 (26.6%)

Proximal humerus

12 (7.5%)

24 (10.6%)

Lower leg†

52 (32.5%)

63 (27.9%)

Ribs/sternum/trunk

12 (7.5%)

33 (14.6%)

Pelvis

10 (6.2%)

7 (3.1%)

Other¥

14 (8.8%)

15 (6.6%)

‡

Multiple fracture events that occurred on the same day were excluded from this table; therefore, for kidney
transplant recipients there were a total of 160 events (n=9 excluded) and 226 (n=12 excluded) in the general
population with a previous non-vertebral fracture.
†
Lower leg includes a composite of tibia, fibula, patella and ankle fractures
¥
Other includes a composite of fracture locations that had ≤5 events including: vertebral, clavicle, femoral shaft,
scapula fractures
Note: The most common fracture location for each group is denoted in bold.
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4.3.3 Additional Analyses
When we limited the analysis to recipients who received a transplant in recent
years (transplant received from 2002 to 2009) the overall 3-year cumulative incidence of
non-vertebral fracture was similar to when we included all transplant years (1.8%, 95% CI
1.4-2.4%) and again was highest amongst women recipients aged ≥ 50 years (3.0%, 95%
CI 1.9-4.8%) (Table 4.9). When we censored after graft failure (308 returned to dialysis
[6.4%] and 14 re-transplanted [0.3%]) the overall 3-year cumulative incidence in
recipients decreased slightly (1.5%, 95% CI 1.2-1.9%) (Table 4.10). With respect to falls,
the overall 3-year cumulative incidence in recipients was 7.9% (95% CI 7.1-8.7%);
amongst the four age and sex strata, women recipients aged ≥50 years had the highest 3year cumulative incidence of falls (11.1%, 95% CI 9.1-13.4%) (Table 4.11).

Table 4. 9. 3-year cumulative incidence and incidence rate of fracture stratified by sex
and age only including kidney transplant recipients who received a transplant from 20022009
Fracture location

3-year
cumulative
incidence,
% (95% CI)

Incidence rate
per 1000
person years
(95% CI)

Fracture location

3-year
Incidence
cumulative rate per 1000
incidence, % person years
(95% CI)
(95% CI)

All fracture locations‡

Proximal humerus,
forearm, or hip
Overall
(n=2723)

1.8
(1.4-2.4)

6.3
(4.6-8.3)

Overall
(n=2723)

3.9
(3.2-4.7)

13.7
(11.2-16.6)

Women < 50 years
(n=461)

<1.5%

3.0
(0.8-7.6)

Women < 50 years
(n=461)

1.7
(0.9- 3.4)

6.0
(2.6-11.7)

Women ≥ 50 years
(n=531)

3.0
(1.9-4.8)

10.7
(6.1-17.4)

Women ≥ 50 years
(n=531)

5.5
(3.8- 7.6)

19.6
(13.2-28.2)

Men < 50 years
(n=721)

<1.5%

3.3
(1.3-6.8)

Men < 50 years
(n=721)

3.2
(2.1- 4.7)

11.0
(6.9-16.4)

Men ≥ 50 years
(n=1010)

2.2
(1.4-3.3)

7.8
(4.9-11.7)

Men ≥ 50 years
(n=1010)

4.6
(3.4- 6.0)

16.4
(12.0-21.8)

‡

All fracture locations defined as a composite of hip, forearm, proximal humerus, lower leg (ankle, tibia, fibula,
patella), femoral shaft, rib/sternum/trunk, scapula, clavicle, vertebral, and pelvis fractures.
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Table 4. 10. 3-year cumulative incidence and incidence rate of non-vertebral fracture
(proximal humerus, forearm, or hip) stratified by sex and age and censoring after graft
failure
3-year cumulative
incidence,
% (95% CI)
1.5
(1.2-1.9)

Incidence rate per 1000
person years (95% CI)

Women < 50 years
(n=944)

0.6
(0.3-1.4)

2.3
(0.8-5.0)

Women ≥ 50 years
(n=837)

2.9
(1.9-4.2)

10.7
(6.9-15.9)

Men < 50 years
(n=1463)

0.7
(0.4-1.3)

2.4
(1.2-4.5)

Men ≥ 50 years
(n=1577)

2.0
(1.4-2.9)

7.5
(5.1-10.5)

Overall
(n=4821)

5.4
(4.2-6.8)

Abbreviation: CI, confidence interval
¶
3-year cumulative incidence defined as the proportion of kidney transplant recipients who sustained a non-vertebral
fracture within the 3 years of follow-up; no fracture could occur in follow-up if the kidney transplant recipients died or
experienced graft failure before fracture. Incidence rate defined as the rate per 1000 person years of follow-up;
censoring at the time of death, graft failure, or fracture in follow-up

Table 4. 11. 3-year cumulative incidence, incidence rate of falls stratified by sex and age
3-year cumulative
incidence, %
(95% CI)
7.9
(7.1- 8.7)

Incidence rate per 1000
person years
(95% CI)
28.3
(25.5-31.3)

Women < 50 years
(n=944)

6.4
(5.0- 8.1)

22.3
(17.0-28.7)

Women ≥ 50 years
(n=837)

11.1
(9.2- 13.4)

41.4
(33.4-50.8)

Men < 50 years
(n=1463)

5.2
(4.2-6.5)

18.1
(14.2-22.6)

Men ≥ 50 years
(n=1577)

9.5
(8.2-11.1)

35.1
(29.7-41.2)

Overall
(n=4821)

Abbreviation: CI, confidence interval
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4.4 Discussion
The cumulative incidence of fracture in kidney transplant recipients was lower
than previously reported with approximately 1 in 50 sustaining a non-vertebral fracture in
the 3 years after transplant, approximately 1 in 20 sustaining a non-vertebral fracture in
the 10 years after transplant, and approximately 2% sustaining a hip fracture in the 10year follow-up (≥ 3% defines high risk). Among women recipients aged ≥ 50 years only
1 in 30 sustained a non-vertebral fracture in the 3 years after transplant. Further,
recipients had a lower fracture incidence compared to the healthy segment of the general
population with a previous non-vertebral fracture. Our results suggest that despite the
changes in mineral metabolism and use of steroids after kidney transplantation, recipients
may not be a high risk group for fracture.
The fracture incidence in our study is lower than many prior studies (15-21, 52);
however, it is important to note that a variety of locations are included across studies
making comparisons difficult. For example, Ball et al. found an incidence rate of 3.3 hip
fractures per 1000 person-years in kidney transplant recipients (20); in contrast, we found
an incidence rate of 1.9 hip fractures per 1000 person-years. However, not all previous
studies have found a high fracture incidence. For example, Opelz et al. conducted a study
including recipients from 32 countries and found a 5-year cumulative incidence of hip
fracture of 0.85%, similar to our study 3-year cumulative incidence estimate of 0.4% and
a 10-year cumulative incidence of 1.9% (53). Moreover, a recent Canadian study
suggests kidney transplant recipients are not a high risk fracture group (10-year major
osteoporotic fracture risk 6.3%) (54), but follow-up time for this analysis began an
average of one-year after kidney transplant (54); previous studies have suggested that an
accelerated loss in bone mineral density happens in the first one-year post-transplant
therefore early fractures may have been missed (55-57).
There are several explanations for the lower than expected fracture incidence.
First, 6 out of the 10 previous studies assessing fracture risk in kidney transplant
recipients did not include recipients who transplanted after the year 2000 (26). In recent
years there have been changes in maintenance immunosuppressive regimens.
Specifically, tacrolimus is now used more commonly than cyclosporine which may result
in less bone loss (58). In our study, of recipients eligible for prescription drug coverage,
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8.7% were on cyclosporine and 63.6% were on tacrolimus. There has also been a trend
towards decreasing prednisone dose after kidney transplantation; corticosteroids are well
known to promote bone loss (4, 5). In our study the median steroid dose in the first 90
days after transplant in 1997 was 27.6 mg/day compared to 20.2 mg/day in 2009. In
recent years there may be an increase in the number of recipients prescribed fracture
prevention therapy (bisphosphonates and vitamin D); the Kidney Disease Improving
Global Outcomes for Chronic Kidney Disease-Mineral and Bone Disorder guidelines
recommend that bisphosphonates and vitamin D are prescribed to recipients who have an
estimated glomerular filtration rate >30 mL/min/1.73 m2 and low bone mineral density
(1). In our study, of recipients eligible for prescription drug use, 5.5% of recipients who
received their transplant in 1997 were prescribed bisphosphonates in the first three years
after transplant compared to 11.5% in 2009, but the number of fracture events was too
small to detect any impacts from these interventions. Therefore, including recipients who
more recently transplanted may have decreased the overall incidence rate. Second, to
increase the accuracy of our fracture definition it was necessary that hip and forearm
fracture diagnostic codes were accompanied by associated procedural codes (37, 41, 42);
failure to include procedural codes may lead to over-ascertainment of fractures.
Therefore, previous transplant studies may have been overestimating fractures at these
locations. Last, the majority of previous studies have been conducted in the US (26);
fracture rates and patient characteristics may vary across countries. For example, Leslie et
al. found that in the general population proximal femoral fracture rates were 30% lower
in Canadian women compared to women from the US (28). Moreover, differences in
transplant characteristics have been found between the US and Canada, potentially
affecting fracture rates (e.g. more obese individuals in the US) (59).
The low fracture incidence provides an explanation for why previous clinical
trials assessing the efficacy of bisphosphonates in kidney transplant recipients have been
underpowered (60). To conduct a 2-arm parallel randomized control trial (80% power)
and to obtain a 60% relative risk reduction we would need a total of 9900 recipients
(based on 1.6% of recipients sustaining a non-vertebral fracture). However, we did not
include vertebral fractures; smaller sample sizes would likely be required if these fracture
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locations were included. Nevertheless, to conduct a fracture prevention trial with
adequate statistical power there would still need to be participation of multiple centres.
We found recipients had a significantly lower 3-year cumulative incidence of
non-vertebral fracture compared to the healthy segment of the general population with a
previous non-vertebral fracture, matching on age, sex, and index date. Although one of
the strongest risk factors for a future fracture is a previous fracture (61), we expected that
recipients would have a higher fracture incidence due to bone mineral metabolism
changes associated with CKD and steroid administration (1). Despite these factors, based
on clinical practice guidelines recipients would not be considered a high risk fracture
group with only 1.7% sustaining a hip fracture in the 10 years after transplant (high risk
defined as ≥ 3%). Only women recipients ≥ 50 years would be defined as a high risk
fracture group with 5.6% sustaining a hip fracture in the 10-years after transplant.
However, recipients did have a 3 time higher fracture risk compared to a healthy segment
of the general population (no kidney disease and no bone disease); previous studies
comparing recipients to the general population have found an even higher relative
fracture risk (14, 18, 19). For example, Ramsey-Goldman et al. found female recipients
between the ages of 45-64 years had almost a 35 times higher fracture risk compared to
similarly aged individuals from the general population (18). However, previous studies
comparing recipients to the general population did not include recipients who received a
transplant more recently (after the year 2000), therefore, potentially overestimating
fracture risk in more contemporary recipients.
Several strengths of our study deserve mention. No other study, to our knowledge,
has compared fracture rates in recipients to several matched reference groups to better
quantify incremental fracture risk. Moreover, our study’s large sample size and long-term
follow-up allowed us to meaningfully examine long-term fracture risk (10-year followup). We are also the first study to report the incidence of falls stratifying by age and sex.
Finally, to account for changes in recipient characteristics and changes in clinical practice,
we performed an additional analysis restricted to recipients who received a transplant after
the year 2002.
Limitations of this study should be recognized. First, we may not have captured all
fracture events; we did not include vertebral fracture in our primary fracture definition
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with merely one-third of these fractures being recognized in a clinical setting (40); this
may have underestimated fracture risk. However, using only hip fracture codes kidney
transplant recipients were not considered to have a high fracture risk (10-year risk <3%);
all hip fractures should be treated in the hospital and therefore will not be missed using
administrative databases. Moreover, even the upper bound of the 95% confidence interval
for non-vertebral fracture was low with only 2.0% of recipients fracturing. Second, we
were only able to capture fractures and falls that presented at the hospital or in the
emergency room. However, the majority of fractures are managed through the emergency
room or hospital; additionally, we used the same databases and codes to capture fracture
events in recipients and the reference groups. Third, we were not able to compare fracture
incidence in recipients to individuals on the transplant waitlist; our administrative
databases do not provide information on individuals on dialysis who were on the
transplant waitlist; therefore, we did not think individuals on dialysis would make an
accurate comparison given many of these individuals would have greater comorbidities
and not qualify for transplantation. However, one previous study has compared fracture
rates in waitlist patients to transplant recipients finding hip fracture risk was higher in the
first 600 days after transplant, however, it decreased after this time point (20). Fourth,
these results may not readily generalize to all races; 68% of recipients in our study were
white (whites have a higher fracture risk compared to blacks) (62). Moreover, these results
may not generalize to other countries given the large global variation in fracture rates (27).
Fifth, due to the small number of non-vertebral fracture events (n=77) we were not able to
assess trends in fracture incidence over time and delineate reasons for changes in fracture
rates. Sixth, we were only able to obtain drug information for a subset of recipients
eligible for prescription drug coverage. Finally, we were unable to obtain serum creatinine
values to define CKD and as a result some individuals with CKD may have been
misclassified; however, the specificity for the CKD codes was high (>90%) (30).
In conclusion, although kidney transplant recipients had a higher relative fracture
risk compared to other populations they had a low absolute fracture risk with few
recipients sustaining a fracture after transplantation. Further research is needed to identify
reasons for this lower than expected fracture risk.
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CHAPTER 5: Risk factors for fracture in adult kidney transplant recipientsa

a

A version of this chapter is being prepared for submission at Canadian Journal of kidney
health and diseases as, Naylor KL, Jamal SA, Zou GY, McArthur E, Lam NN, Leslie
WD, Hodsman AB, Kim SJ, Knoll GA, Fraser LA, Adachi JD, Garg AX. Risk factors
for fracture in adult kidney transplant recipients.
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5.1 Introduction
Kidney transplant recipients have an increased risk of fracture compared to the
general population (1-3). Reasons for the increased fracture risk are multifactorial, and
may include perturbations in bone and mineral metabolism that occur in renal bone
disease, and the administration of glucocorticoids after transplantation (4). However, we
remain uncertain of the risk factors for fracture after transplant; in a recent systematic
review many classical risk factors for fracture in the general population (e.g. older age,
female sex) were inconsistently associated with fractures in kidney transplant recipients
(5). Unlike the transplant population, risk factors for fracture in the general population
are well-established and are included in the World Health Organization’s (WHO)
Fracture Risk Assessment tool (FRAX). FRAX is used to guide treatment decisions in the
general population through incorporating age, sex, clinical risk factors (body mass index,
parental hip fracture, glucocorticoid use, rheumatoid arthritis, smoking, high alcohol
intake [≥ 3 units of alcohol a day]), and bone mineral density (optional) to predict the 10year hip fracture or major osteoporotic fracture probability (proximal humerus, forearm,
hip, or clinical vertebral) (6-8). However, kidney transplant recipients may have different
risk factors for fracture given the unique pathophysiology that underlies their bone
disease (9). For example, in a recent cohort study the only classical risk factor for fracture
that reached statistical significance in kidney transplant recipients was high alcohol use
(10); however, this study had only 21 fracture events and may have had inadequate
statistical power to identify other risk factors (10). The same study also found that FRAX
may be a useful tool to predict fracture in kidney transplant recipients (area under the
receiver operating characteristic curve 0.62); however, the authors hypothesized that
incorporating transplant-specific risk factors for fracture may improve the accuracy of
FRAX (10). FRAX currently does not incorporate kidney transplantation or chronic
kidney disease into its algorithm.
The WHO has called for a global strategy on fracture prevention and management
(11). Such strategies require an understanding of well-validated fracture risk factors and
prediction tools so populations at high risk can be targeted for diagnosis, treatment, and
therapeutic trials. Given that risk factors for fracture in kidney transplant recipients have
not been well-established, in a modern cohort of Canadian adult kidney transplant
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recipients we conducted this study to determine transplant-specific risk factors (e.g.
length of time on dialysis prior to transplant) and general risk factors (e.g. age, sex,
previous fracture, previous fall) associated with major fractures (proximal humerus,
forearm, hip, and clinical vertebral). In a secondary analysis we assessed risk factors for
other fracture locations (excluding major fractures, and those of the skull, fingers, and
toes).

5.2 Methods
5.2.1 Design and Setting
This was a population-based cohort study using the Institute for Clinical
Evaluative Sciences (ICES) healthcare databases in Ontario, Canada. Ontario residents
are given universal access to hospital and physician services. Study approval was
obtained from Sunnybrook Health Sciences Centre’s Research Ethics Board (Toronto,
Ontario, Canada).
5.2.2 Data Sources
We utilized several databases to establish our study cohort, patient characteristics,
risk factors, and outcome data. Information on all kidney transplant recipients who
received their transplant in Ontario was provided by the Canadian Organ Replacement
Register (CORR). Information on provincial physicians’ billing claims was provided by
the Ontario Health Insurance Plan. The Canadian Institute for Health Information
database provided information on diagnostic and procedural codes during Ontario
hospitalizations and information on emergency room visits was provided by the National
Ambulatory Care Reporting System. The Ontario Registered Persons Database provided
information on vital status and demographics.
5.2.3 Cohort
We utilized the CORR database from April 1st, 2002 to December 31st, 2009 to
identify individuals from Ontario with a first kidney-only transplant who had not
previously received another organ transplant and were ≥ 18 years of age at the transplant
date. We selected April 1st, 2002 as our cohort entry date as this was when the Canadian
International Classification of Disease (ICD) system changed from version 9 to 10. The
cohort entry date (index date) was the date an individual received their kidney transplant.
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5.2.4 Risk Factors
We assessed several general risk factors for fracture (age, sex, and prior major
fracture) which are incorporated in the WHO FRAX algorithm. We also assessed other
general risk factors found to increase fracture risk in the non-transplant population,
including: a fall with hospitalization in the year prior to transplantation, race/ethnicity,
and diabetes (only type 1 diabetes is included in FRAX) (12-14). We assessed several
transplant-specific risk factors including: length of time on dialysis prior to transplant
(years), type of donor (living vs. deceased), cause of end-stage renal disease (ESRD, e.g.,
diabetes mellitus, glomerulonephritis, renal vascular disease, cystic kidney disease, or
other [i.e., any cause of ESRD not included in the aforementioned categories such as
pyelonephritis]), pre-transplant dialysis modality (peritoneal, hemodialysis, or preemptive), and donor characteristics (age and sex).
5.2.5 Outcomes
We followed kidney transplant recipients from the date of transplant until
fracture, death, or end of follow-up (March 31st, 2013). We did not censor kidney
transplant recipients if they returned to chronic dialysis or if they had another transplant
(graft failure) during follow-up. Our primary outcome was major fractures which were
defined as a composite of hip, forearm, proximal humerus, and clinical vertebral
fractures. We chose to assess risk factors for major fractures with hospital presentation
(emergency room visit or hospital admission) as these fracture locations are associated
with excess morbidity and mortality in the general population (15-17). In an additional
analysis we assessed other fracture locations, defined as: lower leg (ankle, tibia, fibula,
patella), femoral shaft, rib/sternum/trunk, scapula, clavicle, and pelvis fractures. We
assessed these fractures as a secondary outcome as they may be more common in kidney
transplant recipients (9). For example, in prior studies ankle fractures were common in
kidney transplant recipients (1, 18). We included both high and low trauma fractures
because, similar to low-trauma fractures, high-trauma fractures occur more commonly
when an individual has compromised bone strength (19). We identified fracture events
using the 10th version of the ICD system. To increase accuracy, diagnosis codes for hip,
forearm, and femoral shaft fractures were accompanied by procedural codes identified
from hospital encounters and physician billing codes (20).
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5.2.6 Statistical Analysis
We compared differences in baseline characteristics of recipients with a fracture
and without a fracture using the Mann Whitney U test for continuous variables and the
chi-square test for categorical variables. We calculated the incidence rate of fracture (per
1000 person-years) censoring the observation period on the date of death, first fracture, or
end of follow-up (March 31, 2013). We used the Cox proportional hazards model to
relate the hazard of the first fracture to risk factors. Prior to obtaining the adjusted hazard
ratio (aHR) to quantify the effect of each risk factor model assumptions such as the
proportional hazards assumption and linearity of continuous factors (martingale
residuals) were assessed with a P-value <0.05 used as criteria for a violation (21-23). We
used the backward elimination strategy to select risk factors that would be entered into
the final model, with recipient age and sex forced into the model. A priori we chose a pvalue of ≤0.2 to determine variables that would be included in the final model (24). We
chose this p-value to decrease the possibility of missing important risk factors for fracture
post-transplant. We assessed multicollinearity among variables prior to entering variables
into the backward elimination model. We found limited concern for multicollinearity,
since all variance inflation factors were less than 2 (25). We were missing data for the
following variables: donor age (2.2%), donor sex (0.9%), cause of ESRD (11.6%), race
(10.7%), and donor type (0.8%). We handled missing data by randomly assigning values
based on the distribution of variables that were not missing with the exception of donor
age for which we supplemented missing values with the median age. We performed all
analyses using SAS (Statistical Analysis Software), version 9.4 (www.sas.com).

5.3 Results
5.3.1 Incidence of Fracture
Of the 2723 kidney transplant recipients the total follow-up was 16,274 personyears (average 6 years). Over this time, there were 402 (14.8%) deaths in follow-up and
132 (4.8%) sustained a major fracture (8.1 fractures per 1000 person-years, 95%
confidence interval [CI] 6.8-9.6).
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5.3.2 Baseline Characteristics
Recipients who sustained a major fracture in follow-up compared to recipients
with no major fracture had a significantly higher median age (57 vs 51 years), were more
likely to be women (48.5% vs 35.8%), and were less likely to have glomerulonephritis as
their cause of ESRD (29.6% vs 36.7%) (Table 5.1).

Table 5. 1. Characteristics of kidney transplant recipients classified by major fracture
status†
No fracture
(n=2591)

Major Fracture
(n=132)

P-value

General risk factors
Age, years

50.5 (41-61)

56.5 (45-63)

0.01

Women

928 (35.8%)

66 (48.5%)

0.004
0.40

Race
White

1845 (71.2%)

103 (78%)

Asian

208 (8.0%)

8 (6.1%)

Black

198 (7.6%)

7 (5.3%)

Other€

340 (13.1%)

14 (10.6%)

673 (25.6%)

40 (30.3%)

0.27

92 (3.6%)

8 (6.1%)

0.15

2.8 (1.2-5.4)

2.7 (0.92-5.1)

0.56

Diabetes
Fall with hospitalization in the year
prior to the transplant date
Major fracture prior to the
transplant date‡
Transplant specific risk factors
Length of time on dialysis prior to
transplant (measured in years)¶

0.47

Type of donor
Deceased (vs. Living)

1458 (56.3%)

70 (53.0%)

Cause of end-stage renal disease¥
Glomerulonephritis

0.004
951 (36.7%)

39 (29.6%)
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Cystic kidney disease

385 (14.9%)

31 (23.5%)

Diabetes

560 (21.6%)

37 (28.0%)

Other

695 (26.8%)

25 (18.9%)

Pre-transplant dialysis modality‖

0.99

Peritoneal dialysis

701 (27.1%)

35 (26.5%)

Hemodialysis

1622 (62.6%)

83 (62.9%)

Pre-emptive

268 (10.3%)

14 (11.6%)

46 (36-54)

47.5 (41-55)

Donor age, years

0.73

Donor sex
Women

0.16

1295 (50.0%)

68 (51.5%)

Data are median (interquartile range) or n (%).
†
Major fracture events were comprised of forearm (n=81), hip (n=22), proximal humerus (n=18), and clinical vertebral
fractures (n=13).
€
Other was defined as a composite of: Indian Sub-Continent, Pacific Islander, Aboriginal, Mid East/Arabian, Latin
American, Other/Multiracial.
‡
Due to the small number of recipients with a prior major fracture this risk factor was not able to be assessed.
¶
Includes individuals who received a pre-emptive transplant where the time spent on dialysis was defined as 0 years.
¥
Due to the small number of recipients with a major fracture who had renal vascular disease as the cause of their ESRD
this category was combined into the other category.
‖We defined hemodialysis and peritoneal dialysis based on the modality the recipient first received. We defined preemptive transplant as no evidence of hemodialysis or peritoneal dialysis prior to transplant.

5.3.3 Univariable Analysis
We found older recipient age and female recipient sex were the general risk
factors associated with an increased risk of major fracture (Table 5.2). For example,
female recipients had almost a two-fold greater risk of major fracture (hazard ratio [HR]
1.65, 95% CI 1.18-2.33). Regarding transplant-specific risk factors, cystic kidney disease
(HR 1.93, 95% CI 1.20-3.08) and diabetes (HR 1.80, 95% CI 1.15-2.82) as the cause of
ESRD (compared to glomerulonephritis as the reference cause) were both associated with
a higher risk of major fracture. Each 5-year increase in donor age was also associated
with a greater risk of major fracture (HR 1.11, 95% CI 1.04-1.18).
5.3.4 Multivariable Analysis
In the multivariable model, older recipient age (5-year increase) (aHR 1.11, 95%
CI 1.03-1.19) and female recipient sex (aHR 1.81, 95% CI 1.28-2.57) were the general
risk factors associated with a greater risk of major fracture (Table 5.2). Regarding
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transplant-specific risk factors diabetes (aHR 1.72, 95% CI 1.09-2.72) and cystic kidney
disease (aHR 1.73, 95% CI 1.08-2.78) as the cause of ESRD (compared to
glomerulonephritis as the reference cause), and older donor age (5-year increase) (aHR
1.09, 95% CI 1.02-1.17) were associated with a greater risk of major fracture.

Table 5. 2. Univariable and multivariable analysis of risk factors for major fracture in
kidney transplant recipients
Risk Factors
Age (per 5 year increase)

Univariable analysis
Hazard ratio
(95% CI)
1.13 (1.06-1.21)

Multivariable analysis
Hazard ratio
(95% CI)
1.11 (1.03-1.19)

Sex
Men
Women

Reference
1.65 (1.18-2.33)

1.81 (1.28-2.57)

Race
White

Reference

Asian

0.72 (0.35-1.47)

Black

0.65 (0.30-1.39)

Other€

0.78 (0.44-1.36)

Diabetes (vs. none)

1.40 (0.96-2.02)

Fall with hospitalization in the year prior to
the transplant date (vs. none)

2.00 (0.98-4.09)

Major fracture prior to the transplant
date‡(vs. none)

Length of time on dialysis prior to
transplant (measured in years)¶

1.06 (0.61-1.84)

Type of donor
Living
Deceased
Cause of end-stage renal disease¥

0.99 (0.70-1.39)
Reference

1.72 (0.84-3.50)
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Glomerulonephritis

Reference

Reference

Cystic kidney disease

1.93 (1.20-3.08)

1.73 (1.08-2.78)

Diabetes

1.80 (1.15-2.82)

1.72 (1.09-2.72)

Other

0.92 (0.56-1.53)

0.88 (0.53-1.46)

Pre-transplant dialysis modality‖
Hemodialysis

Reference

Peritoneal dialysis

0.99 (0.67-1.47)

Pre-emptive

0.96 (0.54-1.68)

Donor age (per 5 year increase)

1.11 (1.04-1.18)

1.09 (1.02-1.17)

Donor sex
Men

Reference

Women

1.03 (0.73-1.44)

‡

Due to the small number of recipients with a prior major fracture this risk factor was not able to be assessed.
Other was defined as a composite of: Indian Sub-Continent, Pacific Islander, Aboriginal, Mid East/Arabian, Latin
American, Other/Multiracial.
¥
Due to the small number of recipients with a major fracture who had renal vascular disease as the cause of their ESRD
this category was combined into the other category.
¶
Includes individuals who received a pre-emptive transplant where the time spent on dialysis was defined as 0 years.
‖
We defined hemodialysis and peritoneal dialysis based on the modality the recipient first received. We defined preemptive transplant as no evidence of hemodialysis or peritoneal dialysis prior to transplant.
€

5.3.5 Other Fractures
When we assessed other fracture events (excluding the major fractures, and the
skull, fingers, and toes) kidney transplant recipients had 141 fractures (8.7 fractures per
1000 person-years, 95% CI 7.3-10.2). Recipients with such fractures compared to those
without such fractures were significantly more likely to have diabetes (40.4% vs 25.4%)
and were more likely to have had a fall with hospitalization in the year prior to transplant
(7.1% vs 3.5%) (Table 5.3). In the multivariable model we found diabetes and a fall
with hospitalization prior to transplantation were the general risk factors associated with
an increased risk of fracture, while length of time on dialysis, and renal vascular disease
and other causes of ESRD were the transplant-specific risk factors associated with a
greater risk of other fractures (Table 5.4).
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Table 5. 3. Characteristics of kidney transplant recipients classified by other fractures
status¥
No fracture
(n=2582)

Other fracture
(n=141)

P-value

52 (42-61)

54 (44-61)

0.18

944 (36.6%)

48 (34.0%)

0.55

General risk factors
Age, years
Women

0.33

Race
White

1838 (71.2%)

110 (78.0%)

Asian

208 (8.1%)

8 (5.7%)

Black

198 (7.8%)

7 (5.0%)

Other€

338 (13.1%)

16 (11.4%)

Diabetes

656 (25.4%)

57 (40.4%)

<0.001

Fall with hospitalization in the
year prior to the transplant index

90 (3.5%)

10 (7.1%)

0.03

Major fracture prior to the
transplant dateβ

69 (2.7%)

13 (9.2%)

<0.001

2.7 (1.1-5.4)

3.0 (1.7-5.3)

0.068

1439 (55.7%)

89 (63.1%)

0.09

Transplant specific risk factors
Length of time on dialysis prior
to transplant (measured in years)¶
Type of donor
Deceased

0.003

Cause of end-stage renal
disease
Glomerulonephritis

958 (37.1%)

32 (22.7%)

Cystic kidney disease

397 (15.4%)

19 (13.5%)

Diabetes

555 (21.5%)

42 (29.8%)

Renal Vascular Disease

294 (11.4%)

23 (16.3%)

Other

378 (14.6%)

25 (17.7%)
0.09

Pre-transplant dialysis
modality‖
Peritoneal dialysis

694 (26.7%)

42 (29.8%)
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Hemodialysis

1613 (62.5%)

92 (65.3%)

Pre-emptive

275 (10.7%)

7 (5.0%)

46 (36-54)

48 (40-54)

0.13

1298 (50.3%)

65 (46.1%)

0.33

Donor age, years
Donor sex
Women

Data are median (interquartile range) or n (%).
¥
Other fracture events were comprised of pelvis (n=15), ankle (n=37), patella (n=8), tibia/fibula (n=37), rib/sternum
(n=34), and other (femoral shaft, scapula, clavicle; n=16).
€
Other was defined as a composite of: Indian Sub-Continent, Pacific Islander, Aboriginal, Mid East/Arabian, Latin
American, Other/Multiracial.
β
Prior major fracture had to occur from 1991 to cohort entry (date of transplant).
¶
Includes individuals who received a pre-emptive transplant where the time spent on dialysis was defined as 0 years.
‖We defined hemodialysis and peritoneal dialysis based on the modality the recipient first received. We defined preemptive transplant as no evidence of hemodialysis or peritoneal dialysis prior to transplant.

Table 5. 4. Univariable and multivariable analysis of risk factors for other fracture in
kidney transplant recipients
Risk Factor
Age (per 5 year increase)

Univariable analysis
Hazard ratio
(95% CI)
1.09 (1.02-1.17)

Multivariable analysis
Hazard ratio
(95% CI)
1.03 (0.96-1.10)

Sex
Men
Women

Reference
0.99 (0.63-1.26)

0.97 (0.68-1.39)

Race
White

Reference

Asian

0.67 (0.33-1.37)

0.67 (0.32-1.39)

Black

0.59 (0.27-1.26)

0.47 (0.21-1.02)

Other€

0.82 (0.49-1.39)

0.73 (0.43-1.26)

Diabetes (vs. none)

2.2 (1.57-3.08)

2.19 (1.38-3.49)

Fall with hospitalization in the year prior
to the transplant date (vs. none)

2.37 (1.25-4.52)

2.05 (1.07-3.93)

Length of time on dialysis prior to
transplant (measured in years)¶

1.06 (1.00-1.12)

1.07 (1.01-1.14)

Type of donor
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Living
Deceased

Reference
0.67 (0.47-0.92)

Cause of end-stage renal disease
Glomerulonephritis

Reference

Reference

1.4 (0.8-2.47)

1.35 (0.76-2.39)

Diabetes

2.47 (1.56-3.91)

1.40 (0.78-2.49)

Renal vascular disease

2.40 (1.41-4.10)

2.11 (1.22-3.65)

Other

2.04 (1.21-3.44)

2.03 (1.20-3.45)

Cystic kidney disease

Pre-transplant dialysis modality‖
Hemodialysis

Reference

Peritoneal dialysis

1.06 (0.74-1.53)

Pre-emptive

0.43 (0.2-0.92)

Donor age (per 5 year increase)

1.07 (1.01-1.14)

1.06 (0.99-1.12)

Donor sex
Men

Reference

Women

0.83 (0.6-1.16)

€

Other was defined as a composite of: Indian Sub-Continent, Pacific Islander, Aboriginal, Mid East/Arabian, Latin
American, Other/Multiracial.
¶
Includes individuals who received a pre-emptive transplant where the time spent on dialysis was defined as 0 years.
‖We defined hemodialysis and peritoneal dialysis based on the modality they first received. We defined pre-emptive
transplant as no evidence of hemodialysis or peritoneal dialysis prior to transplant.

5.4 Discussion
Of the transplant-specific risk factors available to us in this study, we found only
diabetes or cystic kidney disease as the cause of ESRD and increasing age of the kidney
donor were associated with a significantly increased major fracture risk; however, the
strength of the association for the hazard ratios was only modest. Our results suggest that
fracture prediction tools used in the general population may also be suitable to use in the
transplant population given few transplant-specific risk factors predicted major fractures.
We previously published a study of 321 kidney transplant recipients from
Manitoba, Canada and found that FRAX was able to predict fracture risk; the area under
the receiver operating characteristic curve value was 0.62; FRAX also seemed to be
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reasonably calibrated with a similar observed and 10-year FRAX predicted major
osteoporotic fracture probability (6.3% versus 5.6%) (10). However, the number of
major osteoporotic fracture events was small (n=21), with correspondingly wide 95%
confidence intervals (10). We hypothesized that a fracture prediction tool incorporating
both general and transplant-specific risk factors may improve fracture prediction (10). In
the current study only the cause of ESRD (diabetes and cystic kidney disease) and
increasing age of the kidney donor reached statistical significance suggesting that a
modified fracture prediction tool which includes transplant-specific risk factors may not
be needed. Moreover, the low absolute fracture rate, the moderate strength of the
transplant-specific risk factors, the large sample size needed to update a model, and the
reasonable performance of the original FRAX model in kidney transplant recipients
further suggests model updating may not be needed. However, diabetes may be important
for clinicians to consider as an independent risk factor for fracture in kidney transplant
recipients; similar to our study, previous studies have consistently found diabetes to be
associated with an increased fracture risk in kidney transplant recipients (2, 18, 26).
Future research should assess other potential transplant-specific risk factors (unavailable
in our current analyses), including: change in body mass index after transplantation
(weight changes found to increase fracture risk in the general population) and fibroblast
growth factor 23 (suppresses mineralization of the bone matrix) (27, 28).
Of concern, several of the risk factors for fracture identified in this study are
becoming more common in recent eras of kidney transplant recipients. For example, we
found diabetes as the cause of ESRD and older recipient age were significant risk factors
for major fractures. The number of recipients with diabetes and the average recipient age
has been increasing (29). Similar to results found in a previous study (30), increasing
donor age was also associated with an increased risk of major fracture. This is concerning
as there has been an increase in the number of recipients receiving a kidney from older
donors (31, 32). It is important to note that donor age may only be a surrogate measure
for recipient age, with kidneys from older donors often being allocated to older
recipients; however, we found that the correlation between these two variables was weak.
Nevertheless, the increase in the aforementioned risk factors may have important
implications for fracture risk in future recipients.
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Unfortunately, none of the risk factors for major fractures found in this study are
easily modifiable. However, a hospitalized fall in the year prior to transplant was a
significant risk factor for other fractures; falls are potentially modifiable through the use
of fall prevention programs (33-35). The paucity of modifiable risk factors is concerning
as one of the best ways to prevent fractures in the general population is to provide therapy
(e.g. bisphosphonates); the efficacy of these therapies in kidney transplant recipients is
unclear (36). However, given that not many recipients sustained a fracture the lack of
modifiable risk factors may be less of a concern.
We found that risk factors for fracture may vary across fracture locations. For
example, there were different risk factors for fracture between our two fracture
classifications (major fracture locations versus other fracture locations). A possible
explanation for this finding is that in the kidney transplant population risk factors for
fractures are site specific. For example, similar to what some studies have found in the
general population, in our study increasing recipient age and female recipient sex were
both associated with an increased major fracture risk (37-39). However, increasing age
and female recipient sex were not associated with an increased risk of other fractures.
This provides a potential explanation for the results of a previous systematic review
which found risk factors for fracture in kidney transplant recipients were inconsistent;
studies in the review included different fracture locations (5). However, we cannot
discount the possibility that the differences in risk factors across fracture locations found
in this study were the result of a type II error.
Strengths of this research deserve discussion. First, we are the first study to assess
transplant-specific and general risk factors for major fractures. Given these fractures are
associated with mortality and morbidity it is important to understand their risk factors
(15-17). Second, to our knowledge, this is the first study to look at a previous fall with
hospitalization as a risk factor for fracture in kidney transplant recipients. Limitations of
the study are noted. First, we were unable to assess drug use (e.g. glucocorticoids) as a
potential risk factor for fracture; drug information in our databases was only available for
a sub-cohort of kidney transplant recipients; therefore, our sample size would have been
decreased, limiting statistical power. Second, we were unable to assess several risk
factors, such as body mass index, due to a high proportion of missingness (>50%). Third,
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the small number of fracture events may have limited statistical power and increased
concerns about the validity of the model. However, we selected a liberal p-value in our
backward elimination analysis to ensure we were not excluding potentially important
variables. Additionally, for risk factors that did not reach statistical significance the
confidence intervals were narrow with values gathered around the null value, decreasing
our concerns about type II errors (40). Moreover, there were at least 10 events per
variable with previous research suggesting type I errors and relative bias are uncommon
when there are 5 or more events per variable (41). Finally, due to the small number of
fracture events we were also not able to assess several of the other risk factors included in
the FRAX algorithm (e.g. rheumatoid arthritis). Last, the generalizability of these results
to other races/ethnic groups may be limited as the majority (72%) of our sample was
white.
In conclusion, these results provide further support for the use of prediction tools
used in the general population to guide prognostication and treatment decisions in kidney
transplant recipients. However, future studies with a larger sample size should assess the
ability of other transplant-specific risk factors to predict fracture.
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CHAPTER 6: Frequency of bone mineral density testing in adult kidney transplant
recipientsa

a

A version of this chapter was submitted for publication at Canadian Journal of Kidney
Health and Disease as, Naylor KL, Jamal SA, Zou GY, McArthur E, Lam NN, Leslie
WD, Hodsman AB, Kim SJ, Knoll GA, Fraser LA, Adachi JD, Garg AX. Frequency of
bone mineral density testing in adult kidney transplant recipients.
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6.1 Introduction
Kidney transplant recipients have a higher risk of fracture compared to the general
population (1-3), although recent observations suggest that the absolute incidence is still
low (4). The reasons for this higher risk are multifactorial and include pre-existing
chronic kidney disease-mineral and bone disorder (CKD-MBD) and glucocorticoid
administration after transplantation (5). In the general population Osteoporosis Canada
guidelines recommend bone mineral density (BMD) testing be done in individuals at a
high risk of fracture, as a decreased BMD can help risk stratify those individuals at a
higher risk of fracture (6-8). However, in the kidney transplant population the ability of
BMD to predict fracture is unclear (9-11). Limited evidence can lead to substantial
practice variability. Therefore, we conducted a population-based study to determine the
frequency, total cost, and the variability in BMD testing across all six transplant centres
in Ontario, Canada. We also compared the frequency of BMD testing in transplant
recipients to non-transplant reference groups (matching on age, sex, and date of cohort
entry).

6.2 Methods
6.2.1 Design and Setting
We used healthcare databases form Ontario, Canada contained at the Institute for
Clinical Evaluative Sciences (ICES). These data sets were held securely in linkable files
without direct personal identifiers, and were analyzed at ICES. In Ontario residents have
universal healthcare. Ethics approval was obtained from Sunnybrook Health Sciences
Centre (Toronto, Ontario, Canada).
6.2.2 Data Sources
Information on Ontario kidney transplant recipients is provided by the Canadian
Organ Replacement Register. Information on Ontario physicians’ billing claims for
inpatient and outpatient services is reported by the Ontario Health Insurance Plan
(OHIP). The Ontario Registered Persons Database provides information on demographics
and vital status. Prescription drug utilization data is provided from the Ontario Drug
Benefit Plan (individuals who are ≥ 65 years are provided with drug coverage). It also
provides information since April 1997 on special populations aged < 65 years who are
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eligible for the program. The ICES Physician Database provides information on
physician specialty. Emigration from the province was the only reason for loss to followup (0.5% per year) (12).
6.2.3 Primary Cohort
6.2.3.1 Kidney Transplant Recipients
We included all Ontario adults (age ≥ 18 years) with a first kidney transplant from
July 1st, 1994 to December 31st, 2009 (excluding individuals with a previous transplant).
We defined the date of the kidney transplant as the date of cohort entry (also referred to
as the index date).
6.2.4 Reference Cohorts
We matched recipients on age (± 1 year), sex, and index date (± 1 year) to two
non-transplant reference cohorts (healthy segment of the general population with no
previous non-vertebral fracture [defined as proximal humerus, forearm, hip]; and healthy
segment of the general population with a previous non-vertebral fracture). When
permitted by the available sample, we matched one recipient to four persons from the
non-transplant reference cohort.
6.2.4.1 Healthy Segment of the General Population with No Previous Nonvertebral Fracture
Using the index date distribution of the recipient cohort we randomly assigned an
index date to the Ontario population (≥ 18 years). We excluded individuals with chronic
kidney disease (including evidence of kidney transplantation or dialysis), osteoporosis
(defined as a dual-energy x-ray absorptiometry examination followed by an osteoporosis
diagnostic code within 1 year) (13), or a previous non-vertebral fracture (proximal
humerus, forearm, hip) prior to index date (looked back to July 1, 1991).
6.2.4.2 Healthy Segment of the General Population with a History of Nonvertebral Fracture
As described above, using the index date distribution of the recipient cohort we
randomly assigned an index date to the Ontario population; however, to enter the cohort
the individual had to have sustained a non-vertebral fracture (proximal humerus, forearm,
hip) in the 5 years prior to entering the cohort. Our cohort excluded chronic kidney
disease patients (including evidence of kidney transplantation or dialysis).
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6.2.5 Outcomes
We used physician fee-for-service billings to identify BMD by dual energy x-ray
absorptiometry and, prior to April 1998, dual-photon absorptiometry tests (14). In
Ontario, these data are largely complete with approximately 94% of physicians
submitting such billing (15). These BMD billing codes have been successfully used in
several prior studies (Table 6.1 describes codes utilized) (13, 16). We tabulated the
number of BMD tests in the three years following kidney transplantation; multiple
billings for a BMD test for a given person on the same day were counted as one test. To
calculate the total cost of the BMD tests we included all associated billings, even if there
were multiple billings on the same day, and accounted for inflation. We included fee
suffixes A, B, and C in the OHIP fee schedule. Fee suffix A was used prior to April 1,
2001 to describe both the technical and physical component of the exam (17). After
April 1, 2001 fee suffixes B (technical component of the exam) and C (professional
component) were required to be billed separately (17).
Table 6. 1. Database codes for bone mineral density tests
OHIP Fee Codes
Dual-photon
absorptiometry

J654 Bone mineral density by single proton method
J655 Total boday calcium proton actiation
J656 Bone min. content dual-photon absorbtiomet. 2 or more sites
J688 Bone mineral content by dual photon single site
J854 Bone mineral density by single photon method
J855 Total body calcium - neutron activation
J856 Bone min. content dual-photon absorbtiomet. 2 or more sites
J888 Bone mineral content by dual photon absorb

Dual energy x-ray
absorptiometry

X145 Bmd - baseline test, one site
X146 Bmd - baseline test, two or more sites
X149 Bone mineral density high risk 1 site
X152 Bone mineral density low risk 1 site
X153 Bone mineral density low risk 2+ sites
X155 Bone mineral density high risk 2+sites
X157 Diag. rad. bone density (mineral content) measurement

Abbreviations: OHIP, Ontario Health Insurance Plan

6.2.6 Statistical Analysis
To describe baseline characteristics for continuous data we used medians
(interquartile range [IQR]) or means (standard deviation) and we used proportions to
describe categorical data. To compare baseline characteristics between recipients with at

115
least one BMD test to those without a BMD test we used the chi-square test, MannWhitney U test, or Student’s t-test as appropriate. We stratified the frequency of BMD
testing by sex (men versus women) and age at the time of transplantation (< 50 versus ≥
50 years). We used logistic regression to determine if there was a statistically significant
difference across transplant centres in the decision to perform at least one BMD test after
transplantation. We adjusted for covariates that may influence a physician’s decision to
order a BMD test (age, sex, previous fracture, and comorbidities [as measured by the
Charlson comorbidity index(18)]). To determine if there were changes over time in the
number of BMD tests performed we used the Cochran-Armitage test for trend. To
compare the number of recipients who had at least one BMD test to the matched nontransplant reference groups we used the McNemar’s test. We considered a two-sided pvalue < 0.05 as statistically significant. We conducted the analyses using the Statistical
Analysis Software (SAS version 9.3).

6.3 Results
6.3.1 Baseline Characteristics
We included 4821 kidney transplant recipients with a total observation time of
13,943 person-years; 304 (6.3%) recipients died within three years. Comparing
recipients who had at least one BMD (n=2786) to recipients who did not (n=2035),
recipients with at least one BMD were significantly more likely to be women (66.4
versus 33.6%; P<0.001), to have received a transplant in the later years of cohort entry
(2006-2009 versus 1994-1997) (67.9 vs. 32.1%; P<0.001), and were older (50 versus 49
years; P=0.04); there was no significant difference in history of a previous non-vertebral
fracture prior to transplant (2.4% vs. 2.0%) (Table 6.2). Matching characteristics were
similar between recipients and the non-transplant reference groups (Table 6.3).
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Table 6. 2. Characteristics of kidney transplant recipients classified by presence of at
least one bone mineral density (BMD) test in the 3 years after transplantation

Characteristic
Age, years
Women

Bone Mineral Density Test
Yes
No
(n=2786)
(n=2035)
50 (39-59)
49 (38-59)

P-value
0.04

1182 (66.4%)

599 (33.6%)

1994-1997

290 (31.7%)

624 (68.3%)

1998-2001

631 (56.8%)

480 (43.2%)

2002-2005

769 (65.1%)

413 (34.9%)

2006-2009

1096 (67.9%)

518 (32.1%)

690 (24.8%)

565 (27.8%)

0.02

Previous non-vertebral
fracture‡

68 (2.4%)

41 (2.0%)

0.33

Charlson Comorbidity
Index¥

2.6 ± 1.0

2.7 ± 1.2

0.002

Transplant era

Diabetes

<0.001
<0.001

Data are median (interquartile range), mean (± SD) or n (%)
Abbreviation: BMD, bone mineral density; SD, standard deviation
‡
Prior non-vertebral fracture was defined as a composite of proximal humerus, forearm, hip fractures from 1991 to
transplant date (cohort entry).
¥
All recipients with a Charlson Comorbidity Index (CCI) of 0 were given a score of 2 and those with a score of 1 were
given a score of 3; one of the variables in the CCI is presence of end-stage renal disease which automatically results in
recipients receiving a score of 2.
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Table 6. 3. Baseline characteristics of reference groups¥
Characteristic

50 (38-59)

Healthy segment of the
general population
with no previous nonvertebral fracture
(n=19,284)
50 (38-59)

Healthy segment of the
general population
with a previous nonvertebral fracture
(n=4821)
49 (38-59)

1781 (36.9%)

7124 (36.9%)

1781 (36.9%)

1994-1997

914 (18.9%)

3655 (19.0%)

906 (18.8%)

1998-2001

1111 (23.1%)

4424 (22.9%)

1083 (22.4%)

2002-2005

1182 (24.5%)

4776 (24.8%)

1214 (25.2%)

2006-2009

1614 (33.5%)

6429 (33.3%)

1618 (33.6%)

Diabetes

1255 (26.0%)

1527 (7.9%)

503 (10.4%)

Age, years
Women

Kidney transplant
recipients
(n=4821)

Era

Prior non-vertebral
fracture‡

109 (2.3%)

Data are median (interquartile range) or n (%)
¥
Matched on age (±1 year), sex, and index date (±1 year)
‡
Prior non-vertebral fracture defined as a composite of proximal humerus, forearm, hip fractures from 1991 to
cohort entry.
Note: The reference group healthy segment of the general population with no previous non-vertebral fracture has no
previous fracture as this was a requirement to enter the cohort. The reference group healthy segment of the general
population with a previous non-vertebral fracture has 100% sustaining a fracture prior to cohort entry as this was a
requirement for cohort entry.

6.3.2 Bone Mineral Density (BMD)
Approximately 58% (n=2786) of kidney transplant recipients had at least one
BMD test within three years of receiving their transplant and 22% (n=1047) of recipients
had received a BMD test in the three months following transplant. Among those with at
least one BMD test, the median time after transplant to first BMD was 133 days
(interquartile range 62-372 days). A total of 68.1% of female recipients aged ≥ 50 years
received a BMD test, a higher proportion than the other three age and sex strata
(P<0.005) (Table 6.4). There were a total of 4802 BMD tests (median 1, range 0-6 tests
per recipient) and almost one-third (31.7%) of recipients received more than one BMD
test in the three years after transplant (Table 6.5). The total cost of these tests was
$614,997 (CAD 2014 equivalent dollars) (approximately $128 per recipient) across the
18-year study period.
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Table 6. 4. Number (proportion) of kidney transplant recipients with at least one bone
mineral density test in the 3 years after transplantation by age and sex
Kidney transplant recipients
(n=4821)
2786 (57.8%)

Overall
Women < 50 years
(n=944)

612 (64.8%)

Women ≥ 50 years
(n=837)

570 (68.1%)

Men < 50 years
(n=1463)

741 (50.7%)

Men ≥ 50 years
(n=1577)

863 (54.7%)

Table 6. 5. Frequency of bone mineral density tests performed in kidney transplant
recipients (n=4821)
Number of BMD
tests per recipient

N (%)

0

2035 (42.2%)

1

1259 (26.1%)

2

1081 (22.4%)

3

412 (8.5%)

4

27 (0.6%)

≥5

7 (0.1%)

Abbreviation: BMD, bone mineral density

The proportion of recipients who received at least one BMD test in follow-up
varied from 15.6 to 92.1% (P<0.001) across the six Ontario transplant centres. The
variation across transplant centres persisted after adjustment for recipient age, sex,
history of a previous non-vertebral fracture, and comorbidities (logistic regression model,
P<0.001). When information on the ordering physician was available (96% of tests),
BMD tests for recipients were most commonly ordered by nephrologists (67.8%) and
family physicians (16.5%), followed by general internists (5.0%), rheumatologists
(3.4%), and endocrinologists (2.4%).
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6.3.3 Non-transplant Reference Groups
In the healthy segment of the general population with a previous non-vertebral
fracture (n=4821), there were 863 BMD tests (range 0-4) in the three years after the index
date compared to 4802 BMD tests in the recipient population. In the healthy segment of
the general population with no previous non-vertebral fracture (n=19,284), there were
1936 BMD tests (range 0-4). There were a significantly higher number of kidney
transplant recipients with at least one BMD (58%) in the three year follow-up versus both
matched reference groups (13.8 % healthy segment of the general population with a
previous non-vertebral fracture and 8.5% healthy segment of the general population with
no previous non-vertebral fracture, respectively, P value < 0.001 for each paired
comparison) (Table 6.6). The proportion of individuals who received at least one BMD
test in follow-up significantly increased over time in all three groups (recipients, 20.9%
in 1994 and 66.4% in 2009; healthy segment of the general population with a previous
non-vertebral fracture, 3.5% in 1994 and 15.6% in 2009; healthy segment of the general
population with no previous non-vertebral fracture, 2.6% in 1994 and 8.5% in 2009; P for
trend < 0.001) (Figure 6.1).

Table 6. 6. Number (proportion) of kidney transplant recipients with at least one bone
mineral density test in the 3 years of follow-up compared to reference groups matched on
age, sex, and index date¥
Population
Kidney transplant recipients
(n=4821)

N
(%)
2786
(57.8%)

P-value‡
Reference

Healthy segment of the general population
with no previous non-vertebral fracture
(n=19,284)

1645
(8.5%)

<0.001

Healthy segment of the general population
with a previous non-vertebral fracture
(n=4821)

665
(13.8%)

<0.001

¥

Matched on age (±1 year), sex, and index date (±1 year)
Paired P-value

‡
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Figure 6. 1. Kidney transplant recipients, individuals from the healthy segment of the
general population with a previous non-vertebral fracture (GPPF), and individuals from
the healthy segment of the general population with no previous non-vertebral fracture
(GPNPF) with at least one bone mineral density test in the 3 years after cohort entry,
presented by year of cohort entry (P for trend <0.001 for all 3 cohorts).
6.3.4 Bisphosphonates
Of the 3540 recipients who had prescription drug coverage through universal
healthcare benefits, 646 (18.2%) were prescribed bisphosphonates in the first 3 years
after transplant. Of recipients prescribed bisphosphonates, 548 (84.8%) of these
prescriptions were filled at a median of 57 days (IQR 21 to 175 days) after the BMD test,
with 417 receiving a bisphosphonate prescription in the first six months after a BMD test.

6.4 Discussion
In Ontario, Canada we found that over half of the kidney transplant recipients
received at least one BMD test in the subsequent three years after transplant and many
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recipients received multiple tests. The frequency of BMD testing varied widely by centre
– from as few as 15% of recipients receiving a BMD test to as many as 92%, and this
variability was not explained by recipient characteristics. Kidney transplant recipients
were significantly more likely to receive a BMD compared to two matched non-transplant
reference groups. Our results suggest that BMD testing is commonly performed in kidney
transplant recipients despite conflicting evidence in the literature supporting its
widespread use.
The results of our population-based multicentre study extend the findings of two
prior single centre reports with smaller sample sizes. In the first study of kidney transplant
recipients (n=326) from Manitoba, Canada, almost 60% of recipients were found to have
had at least two BMD tests within approximately eight years of their transplant (19). The
second study from Akaberi et al. found that 670 BMD tests were performed in 238 kidney
transplant recipients (75% had at least two BMD tests) from Sweden over 12 years (9).
The centres in these two prior studies had protocols in place for routine BMD testing, and
so the frequency of BMD testing would be expected to be high. In contrast, in our study
only a few of the transplant programs had a protocol for BMD testing (information
provided by the six Ontario transplant centres, personal communication).
Particularly striking are the high number of kidney transplant recipients who had
multiple BMD tests in the three years after transplantation, at a high cost to the healthcare
system. For example, almost one-third of kidney transplant recipients received two or
more BMD tests within three years of their transplant; in the non-transplant population
the benefits of performing multiple BMD tests over several years has been questioned
(20, 21), especially given the increasing knowledge of unwarranted screening harms (22,
23).
The variability in BMD testing we observed across transplant centres was in the
setting of universal healthcare benefits. It is possible BMD testing variability across
transplant centres might be even greater in jurisdictions without such healthcare benefits,
as economic factors may also influence testing.
The benefit of BMD tests in kidney transplant recipients remains uncertain. First,
the utility of BMD in predicting fracture in kidney transplant recipients is unclear (9-11).
For example, the Kidney Disease Improving Global Outcomes (KDIGO) guidelines for
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Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) suggest that patients
with an estimated glomerular filtration rate > 30 mL/min/1.73 m2 have their BMD
assessed in the first three months after kidney transplant if they received glucocorticoids
or have other risk factors for osteoporosis (5); given the limited evidence, this suggestion
was given the weakest grade of evidence (5). It is important to note that this
recommendation is being reassessed in the revised version of the guidelines in light of
recent evidence finding that BMD may be predictive of fracture in individuals with CKD,
including dialysis (24-26); however, there is still conflicting evidence in kidney
transplant recipients (9-11). Second, given the high incidence of adynamic bone disease
(i.e., low turnover) in kidney transplant recipients, the KDIGO guidelines suggest that a
bone biopsy may be needed to guide treatment decisions; this limits the clinical
usefulness of BMD testing post-transplant (5). Last, and perhaps most relevant, recent
research suggests in contrast to what has been previously reported, most kidney
transplant recipients will not fracture and have an average mean BMD for age and sex (4,
9, 19, 27). Note, however, that the lower than expected fracture incidence and normal
BMD may be the result of increased monitoring of bone health after transplant. Taken
together this suggests there may be little need to perform BMD tests routinely. New highquality information from prospective observational studies and clinical trials is needed to
guide the optimal recommended timing and frequency of BMD testing. Such studies
should also assess the ability of BMD to predict fracture and its cost-effectiveness.
It is important to note that BMD testing may alter clinical practice. Many kidney
transplant recipients were prescribed a bisphosphonate in the first six months after
receiving a BMD test. However, the efficacy of this and other fracture prevention
strategies in kidney transplant recipients remains uncertain (28).
Strengths of this study should be recognized. To our knowledge we are the first
multicentre study and largest study (n=4821) to assess BMD testing practices across
several kidney transplant centres. Moreover, to help put the frequency of BMD testing into
context we are the first study to compare BMD frequency in recipients to matched nontransplant reference groups.
Study limitations are worth noting. We did not have drug dispensing information
for the entire transplant cohort (only those who were covered by provincial drug
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benefits). While we were unable to characterize immunosuppression use at the patient
level, during the time frame of this study steroids were nearly universally prescribed at
the Ontario transplant centres. Additionally, we only knew if a BMD was done, without
information on the BMD value. However, the former supported the primary objective of
this study - to determine the frequency of BMD testing in the first three years after
transplant across several kidney transplant centres. Finally, we did not assess the impact
of the KDIGO CKD-MBD guidelines on BMD testing. However, this guideline received
the weakest grade of evidence; therefore, its uptake would likely be variable across
transplant centres as demonstrated in this study.
In conclusion, many kidney transplant recipients receive a BMD test in the three
years after transplantation but there was wide practice pattern variation. These results
highlight the need for further studies to investigate the utility, frequency, timing, and
cost-effectiveness of BMD testing in kidney transplant recipients.
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CHAPTER 7: Discussion and Conclusions
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7.1 Introduction
The overall goal of this thesis was to better understand the epidemiology of
fracture in adults with kidney disease and to use this information in the care of this
unique patient population. The specific objectives were 1) to summarize the incidence
and risk factors for fracture in kidney transplant recipients; 2) to determine the predictive
ability of FRAX in individuals with reduced kidney function compared to individuals
with normal kidney function; 3) to estimate the incidence of fracture in kidney transplant
recipients; 4) to determine risk factors for fracture in kidney transplant recipients; and 5)
to examine the frequency, total cost, and the variability in bone mineral density (BMD)
testing in kidney transplant recipients across Ontario transplant centres. Data sources
utilized in this thesis allowed for a comprehensive examination of the epidemiology of
fracture in a Canadian context, addressing many limitations of previous research.

7.2 Summary of Key Findings
7.2.1 Systematic Review of Fracture Risk in Kidney Transplant Recipients
Chapter 2 systematically summarized cohort studies that provided information on
fracture incidence and risk factors in kidney transplant recipients.
The incidence and risk factors for fracture in kidney transplant recipients were
variable across studies. Potential reasons for this variability across studies included
differences in study methodological quality, inclusion of different fracture locations, and
differences in recipient characteristics. The results of this study allowed for the
identification of several knowledge gaps in the literature. Specifically, previous studies
had a short follow-up time; given recipients are surviving longer there is a need for
studies with an increased follow-up time (1). Moreover, few previous studies included
recipients who recently received a transplant; given changes in clinical practice (2-4) and
changes in recipient characteristics there was a need for studies that included recently
transplanted kidney transplant recipients (4, 5). With respect to risk factors there was a
need to assess other potentially relevant risk factors (e.g. falls) and a need to assess risk
factors specific to different fracture locations. Therefore, these results provided the
information required to design high quality studies in chapters 4 and 5 of this thesis.
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7.2.2 Comparison of Fracture Prediction among Individuals with Reduced and
Normal Kidney Function
Chapter 3 examined the predictive ability of FRAX in individuals with reduced
kidney function (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2)
compared to individuals with normal kidney function (eGFR ≥ 60 mL/min/1.73 m2) using
data from the Canadian Multicentre Osteoporosis Study (CaMos).
FRAX was able to predict major osteoporotic fractures in individuals with
reduced kidney function with similar accuracy to individuals with normal kidney
function. Specifically, the 5-year observed major osteoporotic fracture risk in individuals
with reduced kidney function was comparable to the FRAX predicted fracture risk.
Moreover, there were no significant differences in the area under the curve (AUC) values
for FRAX when comparing individuals with reduced and normal kidney function. These
results paralleled findings from a study conducted by Jamal et al. which found FRAX
may be an accurate tool for clinicians to use to predict fractures in individuals with
reduced kidney function (6). Similarly, these results are consistent with findings from a
study conducted by Naylor et al. in kidney transplant recipients (a group that experiences
similar changes in bone mineral metabolism to those with non-transplant chronic kidney
disease [CKD]) which found observed and FRAX predicted fracture risks were
concordant and AUC values were statistically significant (7).
Taken together the results of chapter 3 suggest that FRAX may be a useful tool
for clinicians to use to predict fracture and help guide treatment decisions in individuals
with reduced kidney function. However, validation of FRAX with a different data source
is needed before it can be routinely used in clinical practice. In particular, the
discrimination and calibration of FRAX should be assessed across different levels of
kidney dysfunction (i.e., stage 3a, stage 3b, stage 4 and stage 5 CKD). Moreover, given
the limited sample size in this study, larger studies are also needed before its use is
implemented into routine clinical practice.
7.2.3 Fracture Incidence in Kidney Transplant Recipients
Chapter 4 used several of Ontario’s large healthcare databases held at the Institute
for Clinical Evaluative Sciences (ICES) to examine the incidence of fracture and falls in
kidney transplant recipients.
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In contrast to previous studies which found kidney transplant recipients have a
high fracture risk (3, 8-15) in this study the 10-year cumulative incidence of hip fracture
was 1.7% (where a high risk is defined as ≥ 3% in clinical guidelines) (16, 17). These
findings are consistent with a previous Canadian study conducted by Naylor et al. where
the 10-year incidence of major osteoporotic fracture in kidney transplant recipients from
Manitoba, Canada was approximately 6% (where a low risk is defined as <10%) (7, 17,
18); however, cohort entry was an average of 1-year post-transplant preventing an
accurate estimation of fracture (7). These findings are also consistent with another study
conducted by Naylor et al. which found that bone mineral density (BMD) in kidney
transplant recipients from Manitoba, Canada was not below the average for age and sex
(19).
Kidney transplant recipients had a significantly higher incidence of non-vertebral
fracture compared to a healthy segment of the general population (no kidney disease and
no bone disease; low fracture risk group) and the non-dialysis CKD population (group
with an increased fracture risk), but had a significantly lower incidence of non-vertebral
fracture compared to a healthy segment of the general population with no kidney disease
and a previous non-vertebral fracture (group with an increased fracture risk). Therefore,
although kidney transplant recipients had a low absolute fracture risk they still had a high
relative fracture risk.
Many kidney transplant recipients experienced a fall with hospitalization with a 3year cumulative incidence of 11.1% in women aged ≥ 50 years. These findings are
comparable to a Canadian study conducted by Naylor et al. where the 3-year cumulative
incidence of falls with hospitalization in the non-transplant CKD population was 9.1% in
women aged ≥65 years with stage 4 CKD and 13.1% in individuals with stage 5 CKD
(end-stage renal disease) (20). The high incidence of falls highlights the need for further
study assessing the effectiveness of interventions to prevent falls in kidney transplant
recipients.
Despite bone mineral metabolism changes and administration of steroids after
transplantation results from chapter 4 suggest that bone health in kidney transplant
recipients is better than previous research has suggested. However, it is important to
emphasize that these encouraging results may be unique to Canadian recipients due to
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variability in fracture rates across countries (21, 22), differences in recipient
comorbidities (23), and potential practice pattern differences. Moreover, it is important to
note that even though a low absolute fracture risk was observed in this study, fracture
rates in this population should be continually monitored due to several factors which
could potentially increase fracture rates, including: an increasing average recipient age
(5), an increase in recipients with comorbidities (e.g. diabetes) (5), and an increase in
suboptimal quality kidneys (24, 25).
7.2.4 Risk Factors for Fracture in Kidney Transplant Recipients
Chapter 5 used healthcare administrative databases to examine transplant
specific (e.g. donor age) and general (e.g. sex) risk factors for major fractures (hip,
forearm, proximal humerus, and clinical vertebral) and other fractures (excluding the
major fractures, and the skull, fingers, and toes).
The multivariable analysis revealed that the general risk factors associated with a
greater risk of major fracture were older recipient age and female sex. Transplant-specific
risk factors associated with a greater risk of major fracture included diabetes or cystic
kidney disease as the cause of end-stage renal disease (ESRD) (compared to
glomerulonephritis as the reference cause) and older donor age. General risk factors
associated with a greater risk of other fractures were diabetes and a prior fall with
hospitalization. The transplant-specific risk factors associated with an increased risk of
other fractures were length of time on dialysis prior to transplant and renal vascular
disease or other as the cause of ESRD (compared to glomerulonephritis as the reference
cause).
Few of the transplant-specific risk factors that were available to assess in chapter
5 predicted major fractures in the post-transplant period with any significance. Therefore,
there may not be a need to create a modified FRAX tool that incorporates transplantspecific risk factors; as previously discussed, Naylor et al. found FRAX may be a useful
tool for fracture prediction in kidney transplant recipients with an area under the receiver
operating characteristic curve value of 0.62 and a comparable observed and FRAX
predicted fracture risk (7). Rather, fracture prediction tools used in the general population
in combination with the use of a few independent transplant-specific risk factors could be
used for prognostication. For example, clinicians could use the FRAX score in
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combination with information on whether the recipient had diabetes as the cause of their
ESRD to guide treatment decisions. Unfortunately, risk factors for fracture identified in
chapter 5 are not easy to modify; this is concerning given that the efficacy of fracture
prevention therapy (e.g. bisphosphonates) in kidney transplant recipients is uncertain
(26).
7.2.5 Bone Mineral Density Testing in Kidney Transplant Recipients
Chapter 6 examined the frequency, total cost, and variability in bone mineral
density (BMD) testing in kidney transplant recipients across the six transplant centres in
Ontario, Canada, from 1994 to 2009 using ICES databases.
There were a total of 4802 BMD tests performed in 4821 kidney transplant
recipients in the first three years after transplant (range 0 to 6), costing approximately
$600,000 (2014 CAD equivalent dollars). The proportion of recipients who received at
least one BMD test varied widely across the six transplant centres (15.6 to 92.1%). This
finding is similar to a study conducted in the general population which examined BMD
testing patterns in Ontario from 1992-1998, a time period when there was a lack of
consensus on BMD guidelines, finding there was significant regional variation across
Ontario in the number of BMD tests performed (range 0.2 to 47.1 tests per 1000 women)
(27).
Overall the results of chapter 6 demonstrate that a large number of BMD tests
were performed in kidney transplant recipients with many recipients receiving multiple
tests, despite conflicting evidence to support their ability to predict fracture (28-30). Even
in the general population, where the utility of BMD has been well established, the
frequency and timing of BMD tests has been questioned with recent studies finding there
is little benefit of repeating BMD tests within several years (31, 32). This is an important
finding as the harms of unwarranted screening have become increasingly recognized, and
many guidelines now recommend less frequent screening (33, 34). Given how frequently
these tests are being performed, prospective studies are needed to determine the optimal
timing and frequency of BMD testing and the ability of BMD to predict fracture.
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7.3 Implications
7.3.1 Clinical Practice Guidelines
Currently kidney disease patients are not discussed in the Osteoporosis Canada
Clinical Practice guidelines and are minimally discussed in the United States National
Osteoporosis Foundation guidelines (35, 36). Given greater than 30% of adults over the
age of 60 years have CKD these guidelines are failing to provide advice for a large
segment of the population who are at an increased fracture risk (37). The results in
chapter 3 combined with results from a study conducted by Jamal et al. (6) provide some
evidence to support the use of FRAX in the non-transplant CKD population; currently,
Osteoporosis Canada and the National Osteoporosis Foundation only support the use of
FRAX in the non-kidney disease general population (35, 38). Results from chapter 4
suggest guidelines should highlight that kidney transplant recipients have a significantly
higher relative fracture risk compared to the healthy general population; therefore, these
individuals should be monitored more closely by clinicians and counseled on potential
preventative actions for fracture (e.g. weight bearing exercise, bisphosphonates).
The results of this thesis also indicate that a discussion on falls is needed in the
Kidney Disease Improving Global Outcomes (KDIGO) guidelines for Chronic Kidney
Disease-Mineral and Bone Disorder (CKD-MBD) (43). Chapter 4 found falls were
common in recipients and chapter 5 found falls were a significant risk factor for other
fractures (excluding the major fractures, and the skull, fingers, and toes). However,
currently the guidelines provide no discussion of falls in the context of kidney transplant
recipients. Regarding the non-transplant CKD population falls were minimally discussed
with the guidelines simply stating that these individuals may experience more falls which
may impact fracture risk (43). In chapter 3 a previous fall in combination with T-scores
was found to discriminate between individuals who did and did not fracture providing
support that kidney disease patients who fall should be given a fracture risk assessment.
Recognizing the important relationship between falls and fractures (39), in the general
population Osteoporosis Canada guidelines provide an in-depth discussion of falls and
strategies to prevent falls (e.g. exercise programs); the guidelines also state that
management of falls is integral to reducing the number of fracture events in Canada (18).
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7.3.2 Clinical Prognostication
Accurately identifying kidney disease patients who are at a high fracture risk is
important to appropriately target high risk groups for fracture prevention, diagnosis, and
therapeutic trials. Chapter 3 revealed FRAX may be an accurate tool to predict fractures
in individuals with reduced kidney function and guide treatment decisions. Given
concerns about the safety and efficacy of bisphosphonates in individuals with more
severe decrements in kidney function applying early therapeutic intervention could
conceivably prevent fractures later on when bisphosphonates are contraindicated (40, 41);
research in the general population has found that due to bisphosphonates long half-life
(40) residual effects of the drug may occur years after discontinuation (42-44). With 1 in
10 women > 65 years of age with ESRD sustaining a fracture over three years (20) and
over 60% of dialysis patients dying after sustaining a hip fracture, early preventative
therapy could be particularly important (45). Regarding kidney transplant recipients,
Naylor et al. previously concluded that the discrimination and calibration of FRAX in
kidney transplant recipients may be improved by adding transplant specific risk factors
(7). However, chapter 5 found few transplant-specific risk factors reached statistical
significance suggesting a modified version of FRAX may not need to be developed for
kidney transplant recipients. However, diabetes might be an additional risk factor for
clinicians to use to help identify recipients who have a high fracture risk, and who may
benefit from fracture prevention strategies such as a lower dose of steroids.
7.3.3 Clinical Trials
Therapies are needed to safely prevent fractures in individuals with advanced
kidney disease (26, 46, 47). Clinical trials that assess these therapies need to enroll
individuals who have a high risk of the outcome to ensure adequate power (48). The
results of chapter 3 demonstrate that FRAX may be useful to identify non-transplant
CKD patients who have a high fracture risk and would benefit from the inclusion in
clinical trials. Regarding kidney transplant recipients, chapter 4 found that due to the low
number of fracture events thousands of recipients would need to be enrolled in clinical
trials to ensure adequate power. As a result, multicentre collaboration would be required
to obtain an adequate sample size. However, given the low absolute fracture risk in
kidney transplant recipients there may not be a need for these trials.
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7.3.4 Informed Consent
Previous research suggests that in the early post-transplant period recipients have
a higher fracture risk compared to individuals on dialysis (14); however, chapter 4
revealed that post-transplant the absolute fracture risk is low. This is reassuring as
individuals who receive a transplant not only have improved survival and quality of life
compared to dialysis patients but also have a low absolute fracture risk (1, 49, 50). Given
fractures are associated with morbidity, mortality, and a decreased quality of life this
information is important to provide to potential kidney transplant recipients as part of the
informed consent process (51-53).

7.4 Strengths and Limitations
7.4.1 Study Strengths
Strengths of this thesis have been highlighted in the discussion section of each
chapter; however, several key strengths of this thesis deserve mention. First, this thesis
provided a comprehensive examination of fracture in Canadian kidney disease patients. It
was crucial that Canadian studies were conducted as several factors may result in
differential fracture rates across countries, including: Canadians have lower vitamin D
levels (low vitamin D is a risk factor for fracture) (54, 55); universal healthcare access
(Americans less likely to regularly see a doctor and be on needed medications) (56);
different patient population (e.g. different racial distribution in the US) (23); and potential
differences in immunosuppressant protocols. Indeed, the results of chapter 4 confirmed
that fracture rates in recipients were lower than fracture rates found in the United States.
Second, in this thesis several methods were employed to ensure fracture events
were accurately captured. In chapter 3 self-reported fractures were required to be verified
by structured interviews to obtain more detailed information about the fracture event
and/or by the treating physician or hospital (57). The fracture codes used in chapters 4
and 5 were valid (>90% sensitivity, ≥ 85% specificity, > 80% positive predictive value)
(58-65). Moreover, procedural codes were required to accompany hip, forearm, and
femoral shaft diagnostic codes to increase their accuracy (58, 64, 66); previous literature
has found this combination increases accuracy compared to diagnostic or procedural
codes alone (58, 64, 66) . For example, Hudson et al., conducted a systematic review and
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found that when using diagnostic codes alone the positive predictive value for hip
fracture was 63-96% but increased to 86-98% when including both diagnostic and
procedural codes (58); therefore, previous studies may have been overestimating the
number of fractures in recipients.
Third, loss to follow-up was minimal. In chapter 3 multiple methods were
employed to retain over 96% of participants, including: sending a yearly birthday card,
sending a yearly non-denominational Christmas card (67), and obtaining contact
information from next of kin (57). For chapters 4, 5, and 6 loss to follow-up was also
minimal as data from Ontario healthcare administrative databases was utilized where all
residents of Ontario are provided with universal access to physician and hospital services.
We also only included permanent residents from Ontario with less than 0.5% emigrating
from the province each year (68).
Last, the studies in this thesis were the first to understand the epidemiology of
fracture in kidney disease patients in the context of several reference groups. In chapter 3
the utility of FRAX in individuals with reduced kidney function was compared to
individuals with normal kidney function to determine if kidney function affected FRAX’s
performance. Similarly, in chapters 4 and 6 fracture risk and the number of BMD tests
performed in recipients were compared to several reference groups.
7.4.2 Study Limitations
Limitations of this thesis are recognized and described in the discussion section of
each chapter. Overall this research had some limitations. First, some data was missing
from both data sources used in this thesis. In chapter 3 many individuals were excluded
due to a missing eGFR measurement in the CaMos database. However, in an additional
analysis multiple imputation was used to handle missing eGFR values and similar results
to the complete case analysis were found (Appendix C). Although many of the data
sources contained at ICES are robust, there was a considerable amount of missingness for
several transplant variables that would have been of interest to assess as potential risk
factors for fracture (e.g. body mass index). Moreover, drug information was missing for
individuals who were <65 years and were not covered under the Ontario Special Drug
Benefits Plan. However, the many benefits of secondary datasets (large sample size;
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generalizability; feasibility) made using ICES datasets the most appropriate option to
study kidney transplant recipients in this thesis.
Second, the studies contained in this thesis may have under-captured fracture
events. Using ICES databases vertebral fractures were not able to be included in the
primary analysis of fracture incidence with only one-third coming to clinical attention
(69). To increase the reliability of capturing vertebral fractures a prospective study design
that utilizes x-rays (e.g. CaMos) would need to be utilized. However, prospective studies
are costly and would take several years to complete. In the CaMos database fracture
events were self-reported and therefore, some events may have been missed. However,
previous studies comparing self-reported fractures to hospital records have found that the
number of false negatives is low (<3%) and self-report of fractures is more accurate
compared to many other self-reported items (e.g. myocardial infarction) (70-73).
Additionally, CaMos requires individuals to complete a fracture questionnaire each year
and if individuals failed to return the questionnaire they were censored at the time of the
last questionnaire. Although this could potentially introduce selection bias (individuals
who left the study could be sicker and thus might be more likely to fracture), as
previously discussed loss to follow-up was minimal.
Third, the low number of fracture events prevented the conduction of some
meaningful analyses and decreased statistical power. In chapter 3 it would have been of
value to assess the discrimination and calibration of FRAX for hip fracture alone given
the significant morbidity and mortality associated with these fractures (74, 75). The small
number of fracture events also limited statistical power and as a result it was emphasized
in chapter 3 that further studies with larger sample sizes are needed before FRAX should
be used regularly in clinical practice. In chapter 4 it would have been of value to stratify
the incidence of non-vertebral fracture in kidney transplant recipients by presence of a
previous non-vertebral fracture, given a previous fracture is a strong risk factor for a
future fracture in the general population (76). Moreover, assessing secular trends in
fractures would have provided insight about potential reasons for the low absolute
fracture risk in kidney transplant recipients. To account for the small number of fracture
events in chapter 4 each recipient was matched to a minimum of one individual from the
reference groups to increase statistical power (77, 78). For chapter 5 the small number of
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fracture events prevented several risk factors for fracture from being assessed and risk
factors were not able to be stratified by sex (risk factors for fracture differ by sex in the
general population) (79, 80). Given the low number of fracture events in chapter 5 the
issue of power was discussed as a limitation and a recommendation for the conduction of
future studies with larger sample sizes was provided.
Lastly, the external generalizability of these results may be limited. The majority
of individuals in this thesis were of white race; therefore, results may not be generalizable
to non-white races. Fracture rates have been found to be variable across races; for
example, white individuals have been found to have a higher fracture risk compared to
black individuals (81). Risk factors for fracture have also been found to vary across races
(82). Moreover, given the variation in fracture rates across countries these results may
only generalize to the Canadian population (83).

7.5 Future Directions
This thesis addressed numerous limitations of previous studies done in the field;
however, there are still many unanswered questions regarding the epidemiology of
fracture in kidney disease patients which require further research. These knowledge gaps
are reflected in the minimal number of recommendations from the KDIGO CKD-MBD
guidelines which are currently being reassessed for updating (84).
First, future research should determine reasons for the low observed fracture rate
in kidney transplant recipients. Specifically, secular trends in fracture preventative
therapy (e.g. bisphosphonates and vitamin D) need to be studied to determine if an
increase in bisphosphonate use has decreased fracture rates. Additionally, research needs
to examine the effects of increased BMD monitoring, decreased steroid dose, and
changes in recipient characteristics (e.g. increasing age, body mass index, and diabetics)
on fracture rates.
Second, studies that assess fracture prevention strategies are needed, particularly
in individuals with more severe declines in kidney function. For example, the efficacy of
fracture prevention therapies, fall prevention programs, and the utility of BMD to predict
fracture need to be better understood.
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Third, although FRAX may be an accurate tool to use in kidney disease patients,
given the complex pathophysiology of bone disease, other risk factors that are unique to
the kidney disease population and were not assessed in this thesis may also be useful to
use as markers for fracture (6, 7). For example, risk factors that may be unique to the
kidney disease population, such as fibroblast growth factor 23, may play an accurate role
in fracture prediction (85, 86). Moreover, in the general population a relatively new
method to assess bone texture (bone microarchitecture) called the trabecular bone score
has been found to accurately predict fracture (87-89) and could be useful at predicting
fracture in the kidney disease population.
Fourth, improvements in the data quality of kidney disease information contained
in administrative healthcare databases are needed. As previously discussed, drug
information for only a sub-cohort of kidney transplant recipients was available in ICES
databases and some important kidney transplant recipient variables (e.g. body mass
index) had considerable missingness. One method to obtain more detailed information on
Ontario kidney transplant recipients is to perform a medical chart abstraction as was done
for living kidney donor studies at ICES (90, 91); however, this takes a considerable
amount of time and funding. Chart abstraction could also be used to ensure the accuracy
of information contained in the recipient database through conducting validation studies.
Last, family physicians are often the primary care providers for individuals with
mild to moderate reductions in kidney function (92) and once an individual receives a
kidney transplant they are often managed by a family physician in tandem with a
nephrologist. Therefore, family physicians can play a critical role in preventing fractures
in the kidney disease population. The Canadian Society of Nephrologists recognizes this
stating that it is important that fracture prevention guidelines specific to CKD patients be
provided to family physicians (93). Survey research should be conducted to determine
family physicians’ knowledge of bone disease in kidney disease patients and their
fracture prevention practices. The results would assist with determining areas for
improvement in the medical school curriculum and in determining how to better
disseminate this information to family physicians.
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7.6 Conclusions
As improvements in survival have been achieved in kidney disease patients (5,
94), associated long-term complications have become an increasing concern. This thesis
examined one important complication of kidney disease, fracture. The knowledge gained
from this thesis provided information to improve prognostication, advance osteoporosis
and transplant guidelines, guide the allocation of healthcare resources, assist with sample
size estimations for future fracture prevention trials, clarify fracture incidence, and guide
informed consent.
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A.1 Additional Methods
For objectives 3 and 4 a systematic review was performed as part of the literature
review. Detailed methods for this systematic review are described below.
A.1.1 Design and Study Selection
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines were used in the reporting of this systematic review (1). Inclusion
and exclusion criteria were developed a priori. Studies were included if they met the
following criteria:1) full-text English articles, 2) cohort study, 3) more than 50 kidney
transplant recipients, 4) mean age ≥ 18 years (the mechanisms underlying fracture in
children are different than in adults) (2), 5) reported any type of fracture (including low
or high trauma), 6) earliest accrual period after 1984 (1984 was the year cyclosporine was
introduced into clinical practice) (3), 7) time zero (start of follow-up) the day of kidney
transplant or thereafter, and 8) mean follow-up greater than one year. The following
studies were excluded from the review: 1) no incidence of fracture reported (i.e., only
bone mineral density, which is controversial in kidney transplant recipients) (4, 5), and 2)
insufficient information on when the fracture occurred (see Figure A.1 for final study
selection).

Identification
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Records identified through
database searching
(n = 2715 )

Screening

Records after duplicates
removed
(n=1891)
(n =1891 )
Not relevant (n=1810)

Eligibility

Records screened
(n =1891 )

Full-text articles
assessed for eligibility
(n = 81)

Total full-text articles
excluded*
(n =71)
Fracture incidence not
reported
(n=43)

Included

Cross-sectional study
(n=16)

Studies included in
review
(n = 10 )

Other study design
(n=4)

Less than 50 patients
(n=1)
Patients accrued before 1984
(n=6)

Figure A. 1. Study selection
*Excluded if met first exclusion criteria

Insufficient information
provided
(n=1)
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A.1.2 Identifying Relevant Studies
Both MEDLINE (1984 to November, 2012) and EMBASE (1984 to December,
2012) were searched. For both databases, the search strategies were pilot tested and
modified to ensure known relevant articles were identified. The final search strategy
consisted of keywords such as kidney transplantation, renal transplant, fracture, bone, and
falls (Tables A.1 and A.2). The search strategy was modified for each database used. The
related articles option was also used in Google Scholar to search for additional articles.
Table A. 1. Search strategies: Embase search strategy <1984 to 2012 Week 50>
1 exp kidney transplantation/
2 kidney transplant$.tw.
3 renal transplant$.tw.
4 kidney graft$.tw.
5 renal graft$.tw.
6 kidney allograft$.tw.
7 renal allograft$.tw.
8 1 or 2 or 3 or 4 or 5 or 6 or 7
9 exp fracture/
10 exp bone/
11 posttraumatic osteoporosis/ or primary osteoporosis/ or senile osteoporosis/ or
involutional
osteoporosis/ or secondary osteoporosis/ or idiopathic osteoporosis/ or osteoporosis/ or
corticosteroid
induced osteoporosis/ or osteoporosis.mp. orpostmenopause osteoporosis/
12 osteoporosis$.tw.
13 fracture$.tw.
14 (mineral$ adj2 bone$ adj2 disease$).tw.
15 exp falling/
16 fall$.tw.
17 BMD.tw.
18 exp renal osteodystrophy/co, di, dm, dr, dt, ep, et, pc, si, su, thYOU
19 renal osteodystrophy$.tw.
20 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19
21 8 and 20
22 limit 21 to yr="1984 -Current"
23 limit 22 to english language
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Table A. 2. Search strategies: Medline search strategy (1946 to November Week 3 2012)
1. exp Kidney Transplantation/
2. kidney transplant$.tw.
3. renal transplant$.tw.
4. kidney graft$.tw.
5. renal graft$.tw.
6. kidney allograft$.tw.
7. renal allograft$.tw.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp Fractures, Bone/
10. fracture$.tw.
11. exp Osteoporosis/
12. osteoporosis$.tw.
13. exp Renal Osteodystrophy/
14. exp Accidental Falls/
15. fall$.tw.
16. 9 or 10 or 11 or 12 or 13 or 14 or 15
17. 8 and 16
18 limit 17 to yr="1984 -Current"
19 limit 18 to English

A.1.3 Article Eligibility Criteria
Two reviewers (K.N. and A.L.) independently screened each citation’s title and/or
abstract to determine eligibility. Full-text articles were retrieved for citations that were
identified by either reviewer as potentially relevant. Both reviewers independently
assessed the eligibility of full-text articles. Discrepancies among the two reviewers were
resolved through re-evaluation and discussion.
A.1.4 Data Abstraction
The data abstraction form was designed and pilot tested. The following data was
abstracted independently by paired reviewers: study design, patient characteristics,
fracture incidence, and fracture risk factors. Differences in abstracted data were discussed
by two reviewers and were resolved.
The methodological quality was assessed using a modified version of the Downs
and Black checklist for nonrandomized studies (Table A.3) (6). The completeness and
clarity of reporting, bias, and external validity was assessed. On the modified scale, all
included studies were given a score from 0 to 17, with a higher score indicative of greater
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quality. Attempts were made to obtain additional study information by contacting
corresponding authors.

Table A. 3. Modified Downs and Black checklist for non-randomized studies
(Prospective and Retrospective Studies) r
ALL
CRITERIA
1

DESCRIPTION OF CRITERIA (with additional explanation as
required, determined by consensus raters)
Is the hypothesis/aim/objective of the study clearly described? Must
be explicit

POSSIBLE
ANSWERS
Yes/No

2

Are the main outcomes to be measured clearly described in the
Introduction or Methods section? If the main outcomes are first
mentioned in the Results section, the question should be answered no.
ALL primary outcomes should be described for YES

Yes/No

3

Are the characteristics of the patients included in the study clearly
described? In cohort studies and trials, inclusion and/or exclusion criteria
should be given. In case-control studies, a case-definition and the source
for controls should be given. Single case studies must state source of
patient. *Are baseline characteristics of individuals clearly described.

Yes/No

4

Are the main findings of the study clearly described? Simple outcome
data (including denominators and numerators) should be reported for all
major findings so that the reader can check the major analyses and
conclusions.

Yes/No

5

Does the study provide estimates of the random variability in the
data for the main outcomes? In nonnormally distributed data the interquartile range of results should be reported. In normally distributed data
the standard error, standard deviation or confidence intervals should be
reported

Yes/No

6

Have the characteristics of patients lost to follow-up been described?
If not explicit = NO. RETROSPECTIVE –
if not described = UTD; if not explicit re: numbers agreeing to participate
= NO. Needs to be >85%

Yes/No

7

Have actual probability values been reported (e.g. 0.035 rather than
<0.05) for the main outcomes except where the probability value is
less than 0.001?

Yes/No

8

Were the subjects asked to participate in the study representative of
the entire population from which they were recruited? The study must
identify the source population for patients and describe how the patients
were selected.

Yes/No/UTD

9

Were those subjects who were prepared to participate representative
of the entire population from which they were recruited? The
proportion of those asked who agreed should be stated.

Yes/No/UTD

10

Were the staff, places, and facilities where the patients were treated,
representative of the treatment the majority of patients receive? For

Yes/No/UTD

156
the question to be answered yes the study should demonstrate that the
intervention was representative of that in use in the source population.
Must state type of hospital and country for YES.
11

If any of the results of the study were based on “data dredging”, was
this made clear? Any analyses that had not been planned at the outset of
the study should be clearly indicated. Retrospective = NO. Prospective=
YES

Yes/No/UTD

12

In trials and cohort studies, do the analyses adjust for different
lengths of follow-up of patients, or in case-control studies, is the time
period between the intervention and outcome the same for cases and
controls? Where follow-up was the same for all study patients the answer
should yes. Studies where differences in follow-up are ignored should be
answered no. Acceptable range 1 yr follow up = 1 month each way; 2
years follow up = 2 months; 3 years follow up = 3months........10years
follow up = 10 months

Yes/No/UTD

13

Were the statistical tests used to assess the main outcomes
appropriate? The statistical techniques used must be appropriate to the
data. If no tests done, but would have been appropriate to do = NO

Yes/No/UTD

14

*Were the main outcome measures used accurate (valid and
reliable)? YES=used radiographs, codes, patient records or multiple
methods (i.e. questionnaires verified by codes). NO=questionnaires only
used to determine if patient fractured. UTD=no method was reported

Yes/No/UTD

15

*Was a case definition of fracture provided? YES=stated that a
fracture was a fall from standing height or less and/or stated that they
excluded/included high trauma fractures NO=not reported

YES/NO

16

Was there adequate adjustment for confounding in the analyses from
which the main findings were drawn? In nonrandomised studies if the
effect of the main confounders was not investigated or no
adjustment was made in the final analyses the question should be
answered as NO. If no significant difference between groups shown then
YES

Yes/No/UTD

17

Were losses of patients to follow-up taken into account? If the
numbers of patients lost to follow-up are not reported = unable to
determine.

Yes/No/UTD

YES=1
NO=0
UTD (unable to determine)=0

Total Score:____/17

*Items that have been added.
Source: Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality
both of randomized and non-randomised studies of health care interventions. J Epidemiol Community Health 1998; 52:
377.

A.1.5 Data Analysis
Where possible, incidence rates were normalized to 1000 person-years, although
in some studies only cumulative incidence was reported. Risk factors were summarized if
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they were determined by multivariable analysis and were statistically significant in at
least one study. A meta-analysis was not performed because the studies were too
heterogeneous.
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C.1 Detailed Methods
C.1.1 FRAX Development and Validation Cohorts
To develop the original FRAX model nine prospective population-based cohorts
were used, including populations from around the world (1). Detailed information on the
aforementioned studies has been previously described (2-12). In the validation cohort
eleven independent cohorts were used, including populations from around the world (1).
The validation cohort was comprised of randomized control trials, prospective and
retrospective cohorts, and case-control studies (1). Detailed information on the
aforementioned cohorts has been previously described (13-23). The major differences
between the development and validation cohorts and the cohort used in chapter 3,
include: the mean age of individuals is higher in chapter 3, the time frame is in a later
calendar period, and the percentage of females is lower (compared to the validation
cohort) (Table C.1).
Table C. 1. Comparison of the FRAX development cohort, internal validation cohort and
the CaMos cohort
Development Cohort
(n=46,340)

Internal
Validation
Cohort
(n=230,486)

CaMos cohort (eGFR
<60 mL/min/1.73 m2)
(n=320)

68%

100%

71%

65

63

75

26.2

26.7

27.6%

7%

12%

10.9%

4%

2%

3.4%

Prior fracture

29%

16%

25.3%

Ever smoked

20%

27%

7.5%

High alcohol use

11%

21%

0

Rheumatoid arthritis

5%

3%

0.94%

Outcome

-Self-report and/or
verified by hospital or
databases
-Locations: differed by
cohort (two cohorts: hip,
forearm, spine, humerus;
one cohort: spine, pelvis,

-Self-report and/or
verified by
hospital, imaging
databases, family
physician
-Locations: not
specified

-Self-report and /or
verified by hospital
-Locations: hip, forearm,
clinical spine, humerus

Predictors
Women
Age (yr)
Body mass index kg/m
Maternal history of
fracture†
Glucocorticoids

2
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Cohort eligibility years

ribs, distal forearm,
forearm, and hip; other
cohorts osteoporotic
fracture sites)
1980s-late 1990s¥

1970s-2000s¥

2006-2011

Abbreviation: eGFR, estimated glomerular filtration rate
†
The CaMos cohort used in this study looked at parent fracture hip not just maternal.
¥
Years were not clearly described
Source: Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, et al. The use of clinical risk factors enhances
the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int
2007;18:1033-1046.

To develop the FRAX prediction model Poisson regression was used and
predictors were selected into the model using stepwise regression (1). Risk factors for
fracture and interaction terms to potentially be included in the final predictive model
were determined through meta-analyses (1). To evaluate the performance of the model
gradients of risk (risk ratios) per standard deviation increase in FRAX score were used
(1).
C.1.2 Data Source Details
To determine the prognostic value of the Fracture Risk Assessment tool (FRAX)
in individuals with reduced kidney function data from the Canadian Multicentre
Osteoporosis Study (CaMos) was utilized. CaMos is an ongoing prospective cohort study
which includes non-institutionalized adults aged ≥ 25 years and began in 1996 (2). The
original objective of CaMos was to determine the incidence of fracture and the impact
that osteoporosis has on adults across Canada to aid in the development of fracture and
osteoporosis prevention programs (2). Adult Canadians were selected to participate in
CaMos through identifying a region-,sex-, and age- stratified random sample of
individuals who lived within 50 kilometers of the following Canadian cities: St.John’s,
Halifax, Quebec City, Toronto, Hamilton, Kingston, Saskatoon, and Calgary (2). This
criteria covered approximately 40% of Canadians (2). The only major group that was
excluded were individuals living in northern Canada (2). Based on postal codes from the
pre-specified geographic regions a random sample of telephone numbers was generated
(2). At baseline approximately 72% (n=9423) of contacted individuals participated (fully
42%; partially 30%) (24). Partial participation was defined as individuals who refused to
participate in the study but agreed to complete a refusal questionnaire; the refusal
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questionnaire obtained information on key risk factors for osteoporosis (e.g. sex, previous
fracture) (24). Starting at baseline, standardized interviewer-administered questionnaires
were given every 5 years (2). For this chapter data was utilized from years 10-15 of the
CaMos study; however, baseline information, such as sex, that was collected at year 1
was also utilized. At year 1 of CaMos an in-person interviewer-administered
questionnaire (Appendix B), two questionnaires that focused on health status (SF-36 (25)
and McMaster University’s health status assessment [Health Utilities Index Mark 2 and
3] (26, 27)), Mini-Mental State exam (28), and a variety of physical measurements
(height, weight, dual energy x-ray absorptiometry, ultrasound assessment of the
calcaneus, and x-ray of lateral thoracic and lumbar spine for individuals aged ≥ 50 years)
were given (2). Follow-up was maintained through the following mechanisms: greeting
cards, birthday cards, and a yearly questionnaire was mailed to obtain information on
fractures and other new diagnoses that may have occurred within the last year (2).
Moreover, contact information for next of kin was obtained to help contact individuals
who may have moved (24).
The questionnaire used in the study was developed specifically for CaMos. No
previously validated questionnaires covered the scope of information that the CaMos
questionnaire wanted to capture and therefore a new questionnaire was developed.
Nadalin et al. assessed the test-retest reliability of a section of the CaMos questionnaire
through first collecting information by personal interview then three to five months later
the participants were administered the same questions by telephone interview (29).
Employment status, height, weight, and female reproductive history had a high reliability
(kappa >0.80 or intra-class correlation coefficient >0.80) (29). However, physical
activity, sun exposure, and previous weight loss demonstrated lower reliability (kappa
ranged from 0.30 to 0.58). Kmetic et al. evaluated nonresponse bias for the CaMos
questionnaire through using multiple imputation to adjust for nonresponse bias (30).
Individuals who did not agree to participate in the study were asked to complete a brief
questionnaire which assessed major risk factors for osteoporosis (30). Multiple
imputation then used osteoporotic risk factors to estimate the osteoporosis status for
individuals who did not agree to participate (30). The results found that selection bias is
of most concern in elderly individuals (>80 years) (30).
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C.1.3 Data Cleaning
Data cleaning and data checking for the CaMos data was performed at McGill
University (CaMos coordinating centre) by a biostatistician. Kyla Naylor performed
additional data checking through the use of histograms and minimum and maximum
values for categorical variables. Means (standard deviations), medians (interquartile
range), and minimum and maximum values were assessed for continuous variables. All
fracture dates were also checked by Kyla Naylor. Any concerns about potentially
implausible values were brought to the coordinating centre’s attention. For example,
several fracture dates were brought to the coordinating centre’s attention and were
checked by contacting the hospital in which the fracture occurred to confirm the date of
the fracture; if there were any discrepancies the date was then corrected using the date
recorded at the hospital as the gold-standard.
C.1.4 Sample Size Calculations
Based on data from a Jamal et al. study which used CaMos data to examine
fracture risk in individuals with reduced kidney function it was estimated that 7% of
individuals with reduced kidney function would fracture over 5-years of follow-up (31).
Sample size was calculated using the area under the receiver operating characteristic
curve sample size method proposed by Hanley et al. (32). An alpha of 0.05, 80% power,
and a null area under the curve (AUC) value of 0.5 were used (Table C.2). Based on
2251 individuals with a serum creatinine measurement at year 10 of CaMos it was
expected that 20% of individuals would have CKD (n=450) (based on results from the
Jamal et al. study using CaMos data) (31). Therefore, based on our sample size estimates
it was expected that we would have 80% power to detect an AUC of 0.65 (Table C.2).
Based on a study conducted by Jamal et al. assessing the predictive ability of FRAX in
patients with CKD it was hypothesized that an AUC of approximately 0.7 would be
found (33). In chapter 3 there were only 16 major osteoporotic fracture events in
individuals with CKD; as a result of the low number of fracture events and corresponding
wide 95% confidence intervals, conclusions from chapter 3 were very cautious.
Specifically, it was emphasized in the conclusion of chapter 3 and the overall discussion
section in chapter 7 of this thesis that further study is needed with larger samples before
FRAX should be routinely used in clinical practice.
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Table C. 2. Estimated sample size requirements for individuals with CKD
Number of Individuals with a
Fracture
286
32
18
12

Number of Individuals without
a Fracture
3718
416
234
156

Area Under the Curve Value
0.55
0.65
0.7
0.75

Sources: Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC)
curve. Radiology 1982; 143: 29-36. Obuchowski NA. Sample size calculations in studies of test accuracy. Statistical
Methods in Medical Research 1998; 7: 371-392.

C.2 Additional Analyses
C.2.1 Missing Data
For this chapter the main analyses were all done with a complete case analysis. A
large number of individuals were excluded (n=2520) due to missing an estimated
glomerular filtration rate (eGFR). The reason for missing data was the refusal to
participate in blood collection. Those who did not participate may be systematically
different than those who consented and exclusion of these people could bias estimates.
Therefore, in a secondary analysis multiple imputation was performed to impute missing
eGFR values for individuals who refused to participate to determine the robustness of the
results on the basis of all available data. Multiple imputation was not performed in the
primary analysis as previous research has suggested that caution should be exercised
when imputing exposures (eGFR), particularly when the missingness is high (excluded
n=2520, 45.3% of individuals due to missing eGFR) (34, 35); additionally the benefits of
imputing the exposure have been found to be low (35). Individuals who did not have a
BMD measurement at year 10 were also excluded from the study (n=52, 0.9%); previous
research has found that when the missingness is <10% minimal differences exist between
complete case analysis and multiple imputation (36). Individuals were missing a BMD
measurement if they did not consent to getting the test done.
Multiple imputation deals with missing data through imputing each missing value
multiple times while accounting for the uncertainty of the data through creating numerous
imputed data sets (37); the results of the imputed data sets are then combined to provide a
single estimate (37). Multiple imputation was also used to handle missing FRAX with
BMD (approximately 19% of individuals with a missing eGFR were missing FRAX with
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BMD) in addition to missing eGFR. Given that only approximately 10% (n=269) of
individuals with a missing eGFR were missing a body mass index (BMI) measurement,
single mean imputation was used to impute the missing BMI value for these individuals.
Previous research has found that when approximately 10% of the data is missing single
mean imputation produces similar results to multiple imputation (38, 39).
Missing data can be described as missing completely at random (MCAR), missing
at random (MAR), or missing not at random (MNAR). MCAR is often considered an
unrealistic assumption and only occurs when the pattern of missingness is not related to
any of the variables under study (40). MAR is more realistic, although you are not able to
test for this assumption; it assumes that missingness does not depend on unobserved
values but rather on observed values (40). NMAR assumes that observed and unobserved
values determine missingness. In this analysis it was assumed the data was MAR as
previous literature has stated it is reasonable to assume this pattern of missingness unless
previous knowledge about the data indicates missing values are dependent on unobserved
values (40).
Multiple imputation requires several steps. To determine which covariates to
include in the imputation model an extensive literature search was performed to
determine which variables were associated with the imputed variables (FRAX with BMD
and eGFR). Associations between eGFR and the other variables were assessed using
Pearson correlation for two continuous variables or the two-sample t-test for a continuous
and binary variable. Variables were also included in the imputation model that were
possibly related to the missingness of the variable based on comparing baseline
characteristics between individuals with an eGFR (or FRAX with BMD) and individuals
who were missing an eGFR (Tables C.3 and C.4). The dependent variable of interest was
also included in the model (major osteoporotic fracture). The literature suggests that the
imputation model should include the following variables: all variables included in the
complete case analysis model (including the dependent variable), variables related to the
missingness of the imputed variable, and variables associated with the imputed variable
(41). The pattern of missingness was explored using PROC MI in SAS. The data did not
demonstrate a monotone pattern of missingness; therefore, the fully conditional
specification method was used to handle the arbitrary pattern of the data (42). The models
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were then created and imputation was applied. FRAX with BMD was imputed first
(variable with the least missingness is imputed first). The variables that were included in
the model to predict FRAX with BMD were: major osteoporotic fracture, FRAX without
BMD, age, sex, BMI, previous fracture, high alcohol use, corticosteroid use, rheumatoid
arthritis, secondary osteoporosis, smoking, femoral neck BMD, and parental hip fracture.
The variables that were included in the model to predict eGFR were: major osteoporotic
fracture, FRAX without BMD, FRAX with BMD, diabetes, hypertension, health, age,
sex, prior fracture, smoking and femoral neck BMD.

Ten imputations were performed

to ensure the efficiency of the model was ≥ 95% (36). SAS PROC LOGISTIC was used
to analyze each imputed dataset. Finally, the average AUC values were calculated after
imputing the missing eGFR and FRAX with BMD values. To calculate the Kaplan-Meier
estimates 12 imputations were performed to ensure the efficiency was ≥ 95% for all
imputed variables. To ensure all terms that were in the survival model were included in
the imputation model total follow-up was included in addition to the variables described
above. All imputation was performed using Statistical Analysis System (SAS version 9.3,
SAS Institute, Cary, NC, USA).

Table C. 3. Comparison of characteristics in individuals with and without a missing
estimated glomerular filtration rate measurement
Characteristic

No Missing eGFR
(n=2107)
67 ± 10

p-value

Age

Missing eGFR
(n=2520)
70.6 ± 11.8

Women

1857 (73.7%)

1485 (70.5%)

0.02

Kidney Disease

44 (1.7%)

30 (1.4%)

0.38

Body Mass Index (kg/m2)

27.3 ± 4.9

27.2 ± 4.7

0.53

Previous fracture

537 (21.3%)

387 (18.4%)

0.013

Parent fractured hip

296 (11.8%)

267 (12.7%)

0.34

Current smoking

279 (11.1%)

180 (8.5%)

0.004

Corticosteroid use for >3

59 (2.3%)

33 (1.6%)

0.06

Rheumatoid arthritis

27 (1.1%)

16 (0.8%)

0.27

Secondary osteoporosis

105 (4.2%)

88 (4.2%)

0.99

≥ 3 alcoholic beverages per

28 (1.1%)

21(1.0%)

0.70

<0.0001

months

day
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Femoral neck BMD

0.71± 0.12

0.73 ± 0.12

<0.0001

Missing

477 (18.9%)

FRAX without BMD

7.2 (95% CI 7.0-7.4)

5.7 (95% CI 5.5-5.9)

FRAX with BMD

5.9 (95% CI 5.7-6.1)

4.9 (95% CI 4.8-5.1)

<0.0001
<0.0001

Missing

477 (18.9%)

Fall in the past 12 months

670 (26.6%)

542 (25.7%)

0.51

Bisphosphonate use€

667 (26.5%)

506 (24.0%)

0.06

Type 2 Diabetes

262 (10.4%)

159 (7.5%)

0.0008

Excellent, very good or
good self-reported current
health
Outcome Variable

2250 (89.3%)

1953 (92.7%)

<0.0001

Major osteoporotic
fracture¶

121 (4.8%)

64 (3.0%)

0.0023

Data are Mean ± SD, mean (95% CI), or n (%)
Abbreviations: BMD, bone mineral density; FRAX, Fracture Risk Assessment tool
¶
Major osteoporotic fracture events occurred between years 11-15 of the study

Table C. 4. Comparison of characteristics in individuals with and without a missing
FRAX with BMD
Characteristic

No Missing FRAX with
BMD
(n=4150)
68.4 ± 11.0

p-value

Age

Missing FRAX with
BMD
(n=477)
74.9 ± 11.8

Women

370 (77.6%)

2972 (71.6%)

0.006

10 (2.1%)

64 (1.5%)

0.36

Body Mass Index (kg/m )

27.2 ± 4.8

27.2 ± 4.8

0.9

Previous fracture

113 (23.7%)

811 (19.5%)

0.03

Parent fractured hip

61 (12.8%)

502 (12.1%)

0.66

Current smoking

50 (10.5%)

409 (9.9%)

0.66

Corticosteroid use for >3

12 (2.5%)

80 (1.9%)

0.38

Rheumatoid arthritis

4 (0.84%)

39 (0.94%)

1.00

Secondary osteoporosis

25 (5.2%)

168 (4.1%)

0.22

≥ 3 alcoholic beverages per

0 (0%)

49 (1.2%)

0.008

FRAX without BMD

9.1 (8.6-9.7)

6.2 (6.0-6.3)

<0.0001

Fall in the past 12 months

138 (28.9%)

1074 (25.9%)

0.15

124 (26.0%)

1049 (25.3%)

0.73

56 (11.7%)

365 (8.8%)

0.03

Kidney Disease
2

<0.0001

months

day

Bisphosphonate use
Type 2 Diabetes

€
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Excellent, very good or
good self-reported current
health
Outcome Variable

406 (85.1%)

3797 (91.5%)

<0.0001

Major osteoporotic
fracture¶

34 (7.1%)

151 (3.6%)

0.0002

Data are Mean ± SD, mean (95% CI), or n (%)
Abbreviations: BMD, bone mineral density; FRAX, Fracture Risk Assessment tool
¶
Major osteoporotic fracture events occurred between years 11-15 of the study

To determine if the results from multiple imputation were different from when
complete case analysis was used, AUC values from the complete case analysis were
compared to values obtained from multiple imputation (AUC values for FRAX and
FRAX without BMD) (Table C.5). The results were similar to the complete case analysis
with all AUC values still reaching statistical significance for individuals with reduced
kidney function (eGFR <60 mL/min/1.73 m2); however, the AUC confidence intervals
were narrower reflecting increased precision. Similar to what was found in the complete
case analysis, the 5-year observed major osteoporotic fracture risk (7.4%, 95%
confidence interval [CI] 5.7 to 9.4%) was comparable to the FRAX predicted fracture
risk (7.4%, 95% CI 7.1-7.7% with BMD; 9.4%, 95% CI 9.0%-9.7% without BMD) in
individuals with an eGFR <60 mL/min/1.73 m2; the fracture risk predicted by FRAX was
within the observed fracture risks 95% CI. The observed fracture risk was higher than
what was observed in the complete case analysis; however, this would be expected as
individuals with a missing eGFR had more comorbidities.

Table C. 5. Comparison of area under the curve values for incident major osteoporotic
fracture prediction according to complete case analysis versus multiple imputation
Complete Case Analysis
<60 mL/min/1.73 m2

≥60 mL/min/1.73 m2

Risk Factor

AUC

95% CI

AUC

95% CI

FRAX with BMD

0.69

0.54- 0.83

0.76

0.70- 0.82

FRAX without BMD

0.65

Risk Factor

0.52 - 0.79
0.74
0.67- 0.81
Multiple Imputation
<60 mL/min/1.73 m2
≥60 mL/min/1.73 m2

AUC

95% CI

AUC

95% CI
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FRAX with BMD

0.70

0.62-0.77

0.76

0.72-0.80

FRAX without BMD

0.67

0.60-0.74

0.74

0.70-0.78

Abbreviations: AUC, area under the curve; BMD, bone mineral density; CI, confidence interval; FRAX, Fracture Risk
Assessment tool

C.2.2 Loss to follow-up
Loss to follow-up is a concern as losses can bias results, decrease statistical
power, and decrease generalizability (43, 44). Specifically, loss to follow-up can result in
attrition bias (defined as systematic differences in the characteristics of individuals who
are lost to follow-up resulting in selection bias) (45). The external and internal validity of
results can be affected by attrition bias (46). In the literature there is a lack of consensus
on acceptable levels of loss to follow-up, however, some journals require that a minimum
of 80% follow-up is achieved (47). In this study there were a total of 81 (3.8%)
individuals lost to follow-up (8.4% [n=27] with an eGFR <60 and 3.0% [n=54] with an
eGFR ≥60 mL/min/ 1.73 m2). Table C.6 (eGFR <60 mL/min/1.73 m2) and Table C.7
(eGFR ≥60 mL/min/1.73 m2) demonstrate differences in baseline characteristics between
individuals with complete follow-up and individuals who were lost to follow-up.

Table C. 6. Comparison of baseline characteristics for individuals with complete followup versus lost to follow-up (eGFR <60 mL/min/1.73 m2)
Characteristic

Complete follow-up
(n=293)

Loss to follow-up
(n=27)

p-value

75.4 ± 7.1

81.6 ± 4.8

<0.0001

205 (70.0%)

22 (81.5%)

0.21

Body Mass Index (kg/m )

27.5 ± 4.6

28.1 ± 4.3

0.53

Previous fracture

72 (24.6%)

9 (33.3%)

0.32

Parent fractured hip

34 (11.6%)

1 (3.7%)

0.33

Current smoking

21 (7.2%)

3 (11.1%)

0.44

Corticosteroid use for >3 months

10 (3.4%)

1 (3.7%)

1.00

Rheumatoid arthritis

2 (0.7%)

1 (3.7%)

0.23

Secondary osteoporosis¶

22 (7.5%)

0

0.24

≥ 3 alcoholic beverages per day

0

0

_____

FRAX Variables
Age
Women
2
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Femoral neck T-score

-1.2 ± 0.96

-1.6 ± 0.95

0.05

FRAX without BMD

8.0 (7.4-8.5)

10.6 (8.7-12.5)

0.01

FRAX with BMD

6.2 (5.7-6.7)

8.6 (6.9-10.3)

0.01

eGFR

49.6 ± 9.1

47.5 ± 8.3

0.23

Fall in the past 12 months

68 (23.2%)

9 (33.3%)

0.24

Bisphosphonate use€

75 (25.6%)

11 (40.7%)

0.09

Type 2 Diabetes

35 (12.0%)

FRAX Score

Comorbidities

0.07
7 (25.9%)

Excellent, very good or good selfreported current health

261 (89.1%)

19 (70.4%)

0.01

Note: Bolded p-values denote statistical significance
¶
Defined as any of the following: chronic liver disease, type I diabetes, hyperthyroidism, hypogonadism, premature
menopause (<45 years), chronic malnutrition/malabsorption and osteogenesis imperfecta. Source: World Health
Organization: FRAX World Health Organization Fracture Risk Assessment Tool, 2011. Available at:
http://www.shef.ac.uk/FRAX/index.aspx. Accessed May 20, 2014.
€
Defined as a composite of alendronate, clodronate, etidronate, risedronate, ibandronate, pamidronate, zoledronate at
cohort entry

Table C. 7. Comparison of baseline characteristics for individuals with complete followup versus lost to follow-up (eGFR ≥60 mL/min/1.73 m2)
Characteristic

Complete follow-up
(n=1733)

Loss to follow-up
(n=54)

p-value

65.5 ± 9.9

70.8 ± 10.9

0.0001

1218 (70.3%)

40 (74.1%)

0.55

Body Mass Index (kg/m )

27.1 ± 4.7

25.9 ± 4.5

0.06

Previous fracture

293 (16.9%)

13 (24.1%)

0.17

Parent fractured hip

223 (12.9%)

9 (16.7%)

0.41

Current smoking

153 (8.8%)

3 (5.6%)

0.62

Corticosteroid use for >3 months

22 (1.3%)

0

________

Rheumatoid arthritis

13 (0.8%)

0

________

Secondary osteoporosis¶

65 (3.8%)

1 (1.9%)

0.72

≥ 3 alcoholic beverages per day

21 (1.2%)

0

________

Femoral neck T-score

-0.99 ± 1.0

-1.3 ± 0.9

0.03

FRAX Variables
Age
Women
2
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FRAX Score
FRAX without BMD

5.1 (4.9-5.3)

7.6 (6.1-9.1)

<0.0001

FRAX with BMD

4.6 (4.4-4.7)

6.0 (4.9-7.1)

0.01

eGFR

81.4 ± 11.4

77.9 ± 12.3

0.03

Fall in the past 12 months

451 (26.0%)

14 (25.9%)

0.99

Bisphosphonate use€

407 (23.5%)

13 (24.1%)

0.87

Type 2 Diabetes

112 (6.5%)

5 (9.3%)

0.40

Excellent, very good or good selfreported current health

1626 (93.8%)

47 (87.0%)

0.08

Comorbidities

Note: Bolded p-values denote statistical significance
¶Defined as any of the following: chronic liver disease, type I diabetes, hyperthyroidism, hypogonadism, premature
menopause (<45 years), chronic malnutrition/malabsorption and osteogenesis imperfecta. Source: World Health
Organization: FRAX World Health Organization Fracture Risk Assessment Tool, 2011. Available at:
http://www.shef.ac.uk/FRAX/index.aspx. Accessed May 20, 2014.
€
Defined as a composite of alendronate, clodronate, etidronate, risedronate, ibandronate, pamidronate, zoledronate at
cohort entry

For individuals with an eGFR <60 mL/min/1.73 m2 individuals who were lost to
follow-up were significantly older (81.6 versus 75.4 years; P<0.0001), significantly less
likely to report excellent, very good or good health (87.0% versus 93.8%; P=0.001), and
had a significantly higher FRAX with and without BMD score compared to individuals
with complete follow-up. For individuals with an eGFR ≥ 60 mL/min/1.73 m2
individuals who were lost to follow-up were significantly older (70.8 versus 65.5 years;
P=0.0001), had a significantly lower mean eGFR (77.9 versus 81.4 mL/min/1.73 m2;
P=0.03), a significantly lower mean femoral neck T-score (-1.3 versus -0.99; P=0.03),
and had a significantly higher FRAX with and without BMD score compared to
individuals with complete follow-up. Bias due to loss to follow-up could potentially
affect the external generalizability of the results; the results may not be generalizable to
older and sicker individuals.
C.2.3 Competing Risk
A competing risk can be defined as an event (e.g. death) that eliminates an
individual from being at risk for the event of interest (e.g. fracture) (45). If competing
risks are not accounted for the outcome may be overestimated (44). In this study death
was a potential competing risk with fracture. For example, if an individual dies before
they fracture then death is considered a competing event. The traditional Kaplan-Meier
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method would simply censor individuals at death; however, this is not the best method as
after death a fracture can no longer occur (48). The competing risk of death is particularly
important to consider when assessing fracture risk as many of the fracture risk factors
(e.g. older age) are also risk factors for death (48). Therefore, the risk of fracture may be
particularly overestimated in groups of individuals with higher mortality (e.g., older
individuals) (48). FRAX already accounts for the competing risk of death when
estimating the 10-year fracture probability (1). Therefore, when the observed probability
of fracture is calculated the competing risk of death should also be taken into account
particularly given the older mean age in this study (75.9 years in individuals with an
eGFR <60 mL/min/1.73 m2). To account for the competing risk of death a modified
Kaplan-Meier method was used. Leslie et al. developed this modified Kaplan-Meier
method and assessed it on a cohort of older men and women (aged ≥ 50 years) (48). They
found that in subgroups that had a high risk of mortality (e.g. men) not accounting for the
competing risk of death resulted in overestimating fracture risk using the traditional
Kaplan-Meier method by 16-56% (48). This modified Kaplan-Meier method produced
fracture estimates that were within 2% of the estimates produced by the cumulative
incidence function (method that also takes into account competing risks) (48). The
modified Kaplan-Meier method does not censor individuals when they die; individuals
who die are instead followed until the end of follow-up and considered to remain fracture
free (48); therefore, the only censoring event that was considered was loss to follow-up
(48). In this chapter only 3.3% (n=69) died (5.9% [n=19] with an eGFR <60 and 2.8%
[n=50] with an eGFR ≥60 mL/min/ 1.73 m2), therefore, the competing risk of death was
less of a concern. Table C.8 demonstrates that the traditional Kaplan-Meier method and
the modified Kaplan-Meier method produced estimates that were similar.
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Table C. 8. Kaplan-Meier estimates (traditional and modified) of fracture risk by
estimated glomerular filtration rate

Major
osteoporotic
fracture

<60 mL/min/1.73 m2
(n=320)
Traditional
Kaplan-Meier
Kaplan-Meier,
taking into
95% CI
account
competing risk of
death,
95% CI
5.6
5.3
(3.4-9.0)
(3.3-8.6)

≥60 mL/min/1.73 m2
(n=1787)
Traditional KaplanKaplan-Meier
Meier,
taking into
95% CI
account competing
risk of death,
95% CI
2.7
(2.0-3.6)

2.7
(2.1-3.6)

C.2.4 Observed and FRAX Predicted Fracture Estimates
In this chapter only information on years 10-15 of the CaMos data was able to be
utilized; therefore, the 10-year FRAX predicted fracture risk was divided by two to get
the 5-year FRAX predicted fracture risk. To ensure that this method was accurate the
observed 5- and 10-year fracture risks of the entire CaMos cohort was analysed by sex
and age group (Table C.9). It was found that the relationship between the 5-year and 10year estimates was consistent. Specifically, the 5-year risk was close to half the 10-year
risk even in older age groups.

Table C. 9. 5- and 10-year observed fracture risks in the entire CaMos cohort
10-year risks
Men

Women
Fracture

95% CI

Fracture

95% CI

8.2%

(6.6%-10.0%)

Age
45-54

8.0%

(5.9%-10.6%)

Age
45-54

55-64

7.6%

(5.6%-9.9%)

55-64

13.5%

(11.8%-15.3%)

65-74

11.1%

(9.0%-13.6%)

65-74

19.9%

(18.1%-21.7%)

75-84

16.7%

(12.8%-21.1%)

75-84

27.2%

(24.2%-30.3%)

Fracture

95% CI

3.5%

(2.5%-4.7%)

5-year risks
Men

Women
Fracture

95% CI

Age
45-54

4.5%

(3.0%-6.5%)

Age
45-54

55-64

4.7%

(3.2%-6.6%)

55-64

6.9%

(5.8%-8.3%)

65-74

6.3%

(4.8%-8.2%)

65-74

10.1%

(8.8%-11.4%)
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75-84

8.3%

(5.8%-11.5%)

75-84

16.1%

(13.8%-18.5%)

Ratios comparing the 5- and 10-year risks of fracture
Men

Women

Age

Ratio

Age

Ratio

45-54

0.56

45-54

0.43

55-64

0.62

55-64

0.51

65-74

0.57

65-74

0.51

75-84

0.50

75-84

0.59

*Unreliable estimates for age <45 because of the low number of fracture events.

C.2.5 Hazard Ratio per Standard Deviation for Incident Fracture Prediction
To further examine the discriminative ability of FRAX hazard ratios per standard
deviation were also assessed to provide information on the gradient of risk for fracture
prediction. Cox proportional hazard regression was used to model time to first major
osteoporotic fracture event. The proportional hazard assumption was assessed using the
time-dependent covariate approach (e.g. FRAX*log(time)) and the ASSESS option in the
SAS PROC PHREG command which plots the follow-up time against the observed score
process (49). A p-value <0.05 was assumed to have violated the proportional hazard
assumption. To ensure there were no departures from linearity martingale residuals were
assessed for each continuous variable using SAS's PROC PHREG ASSESS statement
which plots the cumulative martingale residuals against the continuous covariate; a pvalue <0.05 was considered a violation of linearity (50). The proportional hazard
assumption was met and there were no departures from linearity for all variables. Similar
results to the area under the receiver operating characteristic curve analysis were found
with all hazard ratios for incident major osteoporotic fracture prediction reaching
statistical significance. These results (hazard ratio [HR] per standard deviation increase in
FRAX with BMD 1.6, 95% CI 1.2-2.3; without BMD 1.5, 95% CI 1.02-2.2) were also
comparable to the average hazard ratios found in the original FRAX validation study that
included 11 international cohorts (HR FRAX with BMD 1.6; without BMD 1.5) (Table
C.10) (1).
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Table C. 10. Hazard ratio (HR) for incident major osteoporotic fracture prediction*
<60 mL/min/1.73 m2

≥60 mL/min/1.73 m2

Risk Factor

HR

95% CI

HR

95% CI

FRAX with BMD
FRAX without BMD
FRAX without BMD and with secondary
osteoporosis
Femoral neck T-score
Femoral neck T-score and prior history of fall
Age

1.6
1.5
1.6

1.2-2.3
1.02-2.2
1.05-2.3

1.6
1.65

1.4-1.8
1.4-1.9

2.1
2.0
2.5

1.2-3.7
1.1-3.6
1.4-4.6

2.4
2.5
2.0

1.7-3.3
1.8-3.5
1.5-2.8

⃰

All hazard ratios are presented by standard deviation increase except for femoral neck T-score which is presented by
standard deviation decrease.

C.2.6 Fracture Discrimination for All Fractures
A separate analysis was performed to assess the discrimination of FRAX
including all fracture sites (excluding fingers, toes, and skull) resulting from low or high
trauma (Table C.11). The rationale for assessing all fracture sites is that in contrast to the
general population where major osteoporotic fractures are common fracture sites,
individuals with reduced kidney function may have other fracture sites that are common
(51). For example, in kidney transplant recipients, who have similar changes in bone
mineral metabolism as chronic kidney disease patients, ankle fractures have been found
to be common (52-54). Therefore, it would be useful to know if FRAX could also be used
to accurately predict all fracture locations. There were a total of 202 (9.6%) all fracture
events (46 [14.4%] with an eGFR <60 mL/min/1.73 m2 and 156 [8.7%] with an eGFR
≥60 mL/min/1.73 m2). There were no statistically significant differences in the predictive
discrimination of T-scores alone, age alone, and T-scores with previous falls between
individuals with an eGFR <60 versus ≥60 mL/min/1.73 m2 for any fracture similar to
when major osteoporotic fractures was assessed (P>0.05). Moreover, all AUC values
were statistically significant (Table C.12)

Table C. 11. Fracture locations included for all fracture locations
Locations
Back
Hip
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Ribs
Forearm/wrist
Pelvis
Arm/shoulder
Elbow
Hands
Knee
Ankle
Foot
Leg
Shoulder
Clavicle
Scapula
Neck
Sacrum
Coccyx

Table C. 12. Area under the curve for incident fracture prediction according to estimated
glomerular filtration rate for any fracture
<60 mL/min/1.73 m2

≥60 mL/min/1.73 m2

Risk Factor

AUC

95% CI

AUC

95% CI

FRAX with BMD

0.71

0.62 to 0.80

0.64

0.59 to 0.68

FRAX without BMD

0.67

0.59 to 0.76

0.63

0.58 to 0.67

FRAX without BMD
and with secondary
osteoporosis

0.68

0.59 to 0.76

Femoral neck T-score

0.66

0.57 to 0.74

0.61

0.56 to 0.66

Femoral neck T-score
and prior history of
fall

0.67

0.59 to 0.76

0.61

0.56 to 0.66

Age

0.60

0.51 to 0.69

0.57

0.53 to 0.62

AUC Difference,
95% CI
0.07
(-0.03 to 0.17)
0.04
(-0.06 to 0.14)

pValue
0.16

0.05
(-0.05 to 0.15)
0.06
(-0.04 to 0.16)

0.31

0.03
(-0.07 to 0.13)

0.56

Abbreviations: AUC, area under the curve; BMD, bone mineral density; FRAX, Fracture Risk Assessment tool

0.42

0.23
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APPENDIX D: Chapter 4 Details

a

A version of this appendix, in particular Figure D.2 and Tables D.2 and Table D.3, was
published as, Naylor KL, Jamal SA, Zou G, McArthur E, Lam NN, Leslie WD,
Hodsman AB, Kim SJ, Knoll GA, Fraser LA, Adachi JD, Garg AX. Fracture risk in
adult kidney transplant recipients. Transplantation 2015.

232
D.1 Detailed Methods
D.1.1 Database Codes and Data Sources
Database codes used for cohort creation, baseline characteristics, and censoring
events are detailed in Table D.1. Databases codes used to identify fracture and fall events
are detailed in Tables D.2 and D.3. A detailed summary of validation studies and the
accuracy of database codes used to define fracture events are described in Tables D.4 and
D.5 (1-8). A detailed description of Ontario’s large healthcare databases used to
investigate fracture in kidney transplant recipients (Chapters 4, 5, and 6) is provided
below.
i) Canadian Organ Replacement Register (CORR): CORR is an information system that
provides data on transplant recipients. CORR has excellent coverage with 98.5% of
transplants recorded in CORR also being recorded in the Canadian Institutes for Health
Information Discharge Abstract Database (9). A previous study assessing the validity of
the CORR database found that there was >95% agreement for sex, date of birth, and
health card number between CORR and the medical chart (10).
ii) The Canadian Institute for Health Information Discharge Abstract Database, Same
Day Surgery, and National Ambulatory Care Reporting System (CIHI-DAD, SDS,
NACRS): NACRS provides information on outpatient hospital visits, emergency
department visits, and dialysis clinic visits (11). CIHI-DAD and SDS provide information
on Ontario’s acute, rehab, chronic, and day surgery institutions (11). Diagnostics are
provided using the International Classification of Disease codes (ICD). These codes were
used to identify fracture events, morbidities, and exclusion criteria. In a study
determining the agreement between the CIHI databases and data collected from
abstractors both the femoral fracture and ankle fracture code had a high (≥ 95) kappa,
sensitivity, and positive predictive value (5).
iii) The Ontario Health Insurance Plan (OHIP): OHIP provides information on billing
claims from Ontario physicians and laboratories. OHIP has good population coverage
with approximately 94% of physician services billed through OHIP (12). Chart
abstraction studies have found that agreement between abstracted fee codes and physician
recorded codes on the chart was high; agreement for the most responsible diagnosis was
over 90% and over 88% for procedural codes (13).
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iv)The Registered Persons Database (RPDB): The RPDB provides information on
demographics such as sex, age, and vital status (14). Information in the RPBD
corresponds with information on population characteristics held at Statistics Canada (15).
v) The Ontario Drug Benefit Plan (ODB): ODB is a universal drug plan for individuals
aged ≥ 65 years, which includes a wide range of routine outpatient medication
prescriptions. Since April 1997 information is provided for individuals < 65 years of age
who are eligible for the Trillium Drug Program or the Special Drugs Program, individuals
with social assistance or individuals residing in long-term care facilities. The error rate in
this database is minimal (~0.7%, 95% CI: 0.5 to 0.9%) (16).
vi) Institute for Clinical Evaluative Sciences Physician Database (IPDB): This database
contains information on all Ontario physicians, including information on physician
speciality, physician demographics, and physician activity (i.e., workload) (17). This
database was used to determine physician speciality.
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Table D. 1. Database codes used to define cohorts, baseline characteristics, and censoring events for chapters 4, 5, and 6
Characteristic
Inclusion criteria for kidney
transplant recipients
Kidney transplant recipients

Exclusion criteria for kidney
transplant recipients
Non-Ontario resident

Database

Database Codes

CORR

Treatment_code
171, 181
Transplanted_organ_type_code [1-3]
10, 11, 12, 18, 19

RPDB

Prcddablk
Not equal to province code 35
GRAFT_NUM
2
ICD-9
V420, 99681
ICD-10
T861, N165, Z940
CCP
6743, 675
CCI
1PC85
OHIP Feecode
E762, S435, E769, S434, E771, Z631, G347, G348, G412, G408, G409
Transplanted_organ_type_code [1-3]

Previous transplant

CORR
CIHI-DAD
OHIP

Evidence of combination transplant
(e.g. kidney pancreas)
Baseline characteristics
Age

CORR

Sex
Year of Transplant

RPDB
CORR

Hypertension

CIHI-DAD
OHIP

RPDB
Treatment_date
ICD-9
401, 402, 403, 404, 405
ICD-10
I10, I11, I12, I13, I15
OHIP DX
401, 402, 403
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Diabetes

CIHI-DAD
OHIP

Peripheral Vascular Disease

CIHI-DAD
OHIP

Congestive heart failure

CIHI-DAD
OHIP

Coronary artery disease

CIHI-DAD
OHIP

ICD-9
250
ICD-10 Codes
E10, E11, E13, E14
OHIP DX
250
OHIP Feecode
Q040, K029,K030
ICD 9
4402, 4403, 4408, 4409, 5571, 4439, 444
ICD 10
I700, I702, I708, I709, I731, I738, I739, K551
CCP
5125, 5129, 5014, 5016, 5018, 5028, 5038
CCI
1KA76, 1KA50, 1KE76, 1KG26, 1KG50, 1KG57, 1KG76MI, 1KG87
OHIP Feecode
R787, R780, R797, R804, R809, R875, R815, R936, R783, R784,R785,
E626, R814, R786, R937, R860, R861, R855, R856, R933, R934, R791,
E672, R794, E672, R813, R867,E649
ICD9
425, 5184, 514, 428
ICD10
I500, I501, I509, I255, J81
CCP
4961, 4962, 4963, 4964
CCI
1HP53, 1HP55, 1HZ53GRFR, 1HZ53LAFR, 1HZ53SYFR
OHIP Feecode
R701, R702, Z429
OHIP DX
428
ICD9
412, 410, 413, 414, 4292, 4295, 4296, 4297
ICD10
I20, I21, I22, I23, I24, I25, Z955, Z958, Z959, R931, T822
CCI
1IJ26, 1IJ27, 1IJ54, 1IJ57, 1IJ50, 1IJ76
CCP
4801, 4802, "4803, 4804, 4805, 481, 482, 483
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Race

CIHI-DAD
OHIP
NACRS
CORR

Cause of end-stage renal disease

CORR

Donor type

CORR

Dialysis Modality‖

CORR

Dialysis¶ (years prior to transplant)

CORR

Delayed graft function

CIHI-DAD
OHIP

Prior non-vertebral fracture

OHIP Feecode
R741, R742, R743, G298, E646, E651, E652, E654, E655, G262, Z434,
Z448
OHIP DX
410, 412, 413
Please refer to Table D.2.

Racial_Origin_Code
Caucasian: 01
Asian: 02
Black: 03
Unknown: 98
Other/Multiracial:11, 99, 10, 08, 05, 09
Primary_Diagnosis_Kidney
Glomerulonephritis: 05, 06, 07, 08, 09, 10, 12, 13, 14, 15, 16, 19, 73, 74,
84, 85, 86, 88
Cystic Kidney Disease: 40, 41, 42, 43, 49
Diabetes: 80, 81
Renal Vascular Disease: 70, 71, 72, 79
Other: 20, 21, 22, 23, 24, 25,29, 30, 31, 32, 33, 39, 50, 51, 52, 53, 54, 55, 56,
57, 58, 59, 60, 61, 62, 63, 66, 78, 82, 83, 87, 89, 90, 91, 92, 93, 94, 95, 96,
97, 99
Donor_Type_Code
Living: 02, 03, 04, 05, 06, 07, 10, 12, 13, 14, 15
Deceased: 01
Unknown/Missing: 98
Treatment_Code
Hemodialysis: 060,111, 112, 113, 121, 122, 123, 131, 132, 133, 211, 221,
231, 311, 312,313,321, 322, 323, 331, 332, 333, 413,423, 433
Peritoneal: 141,151, 152, 241, 242, 251, 252, 443, 453
Dialysis: Treatment_Date & Treatment_Code: 060, 111, 112, 113, 121,
122, 123, 131, 132, 133, 141, 151, 152, 211, 221, 231, 241, 242, 251, 252,
311,312, 313, 321, 322, 323, 331, 332, 333, 413, 423, 433, 443, 453
Transplant: Treatment_Date & Treatment_Code: 171
At least one code for dialysis appearing in the first 7 days after the
transplant date.
CCP
5195, 6698
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Primary non-function

CIHI-DAD
OHIP

Pretransplant parathyroidectomy

CIHI-DAD
OHIP

Charles Comorbidity Index*
Glucocorticoids
Cyclosporine
Tacrolimus
Bisphosphonates

CIHI-DAD
ODB
ODB
ODB
ODB

Reference Groups Inclusion and Exclusion criteria
Osteoporosis
CIHI-DAD
NACRS
OHIP

CCI
1PZ21
OHIP Feecode
R849, G323, G325, G326, G860, G863, G866, G330, G331, G332, G861,
G082, G083, G085, G090, G091, G092, G093, G094, G095, G096, G294,
G295
At least three codes for dialysis on three different days with at least one code
appearing in the first 7 days after the transplant date, in the 8- 30 days after
the transplant date, and in the 31-60 days after the transplant date.
CCP
5195, 6698
CCI
1PZ21
OHIP Feecode
R849, G323, G325, G326, G860, G863, G866, G330, G331, G332, G861,
G082, G083, G085, G090, G091, G092, G093, G094, G095, G096, G294,
G295
CCP
1FV59HAX7, 1FV83NZ, 1FV83NZAG, 1FV83PZ, 1FV83PZAG,
1FV87NZ, 1FV87NZAG, 1FV87PZ, 1FV87PZAG, 1FV89NZ,
1FV89NZAG, 1FV89PZ, 1FV89PZAG
CCI
197, 1971, 1972, 1996
OHIP Feecodes
S795, S796, E880, E885 , S792, E882, E883, E884
ICD-9 and ICD-10 codes
Prednisone
Cyclosporine
Tacrolimus
Etidronic acid disodium, Clodronic acid disodium, Pamidronic acid
disodium, Etidronic acid disodium, Calcium carbonate & etidronic acid
sodium, Alendronate sodium, Risedronate sodium, Zoledronic acid,
Alendronate, Alendronate sodium & cholecalciferol, Pamidronate disodium
ICD-9 Codes
Osteoporosis unspecified: 733.00
Senile osteoporosis: 733.01
Idiopathic osteoporosis: 733.02
Disuse osteoporosis: 733.03
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Dual energy x-ray absorptiometry

OHIP

Chronic kidney disease

CIHI-DAD
NACRS
OHIP

Other osteoporosis :733.09
ICD-10 Codes
Osteoporosis with pathological fracture:M80
Osteoporosis without pathological fracture: M81:
Osteoporosis in diseases classified elsewhere: M82
OHIP DX
Osteoporosis:733
OHIP Feecode
Bone mineral density by single proton method: J654
Total boday calcium proton actiation: J655
Bone min. content dual-photon absorbtiomet. 2 or more sites: J656
Bone mineral content by dual photon single site: J688
Bone mineral density by single photon method: J854
Total body calcium - neutron activation: J855
Bone min. content dual-photon absorbtiomet. 2 or more sites: J856
Bone mineral content by dual photon absorb: J888
BMD - baseline test, one site: X145
BMD - baseline test, two or more sites: X146
Bone mineral density high risk 1 site: X149
Bone mineral density low risk 1 site: X152
Bone mineral density low risk 2+ sites: X153
Bone mineral density high risk 2+sites: X155
Diag. rad. bone density (mineral content) measurement: X157
ICD-9 Codes
Hypertensive chronic kidney disease, malignant, with chronic kidney disease
stage i through stage iv, or unspecified: 403.00
Hypertensive chronic kidney disease, malignant, with chronic kidney disease
stage v or end stage renal disease:403.01
Hypertensive chronic kidney disease, benign, with chronic kidney disease
stage i through stage iv, or unspecified: 403.10
Hypertensive chronic kidney disease, benign, with chronic kidney disease
stage v or end stage renal disease: 403.11
Hypertensive chronic kidney disease, unspecified, with chronic kidney
disease stage i through stage iv, or unspecified: 403.9
Hypertensive heart and chronic kidney disease, malignant, without heart
failure and with chronic kidney disease stage i through stage iv, or
unspecified 404.00
Hypertensive heart and chronic kidney disease, malignant, with heart failure
and with chronic kidney disease stage i through stage iv, or unspecified:
404.01
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Hypertensive heart and chronic kidney disease, malignant, without heart
failure and with chronic kidney disease stage v or end stage renal disease:
404.02
Hypertensive heart and chronic kidney disease, malignant, with heart failure
and with chronic kidney disease stage v or end stage renal disease: 404.03
Hypertensive heart and chronic kidney disease, benign, with heart failure
and with chronic kidney disease stage i through stage iv, or unspecified:
404.11
Hypertensive heart and chronic kidney disease, benign, without heart failure
and with chronic kidney disease stage v or end stage renal disease: 404.12
Hypertensive heart and chronic kidney disease, benign, with heart failure
and chronic kidney disease stage v or end stage renal disease: 404.13
Hypertensive heart and chronic kidney disease, unspecified, without heart
failure and with chronic kidney disease stage i through stage iv, or
unspecified: 404.90
Hypertensive heart and chronic kidney disease, unspecified, with heart
failure and with chronic kidney disease stage i through stage iv, or
unspecified: 404.91
Hypertensive heart and chronic kidney disease, unspecified, without heart
failure and with chronic kidney disease stage v or end stage renal disease:
404.92
Hypertensive heart and chronic kidney disease, unspecified, with heart
failure and chronic kidney disease stage v or end stage renal disease:
404.93
Chronic kidney disease, stage i: 585.1
Chronic kidney disease, stage ii (mild): 585.2
Chronic kidney disease, stage iii (moderate): 585.3
Chronic kidney disease, stage iv (severe): 585.4
Chronic kidney disease, stage v: 585.5
End stage renal disease: 585.6
Chronic kidney disease, unspecified: 585.9
Renal failure unspecified:586
Secondary hyperparathyroidism (of renal origin):588.81
Other specified disorders resulting from impaired renal function : 588.9
Diabetes with renal manifestations, type ii or unspecified type, not stated as
uncontrolled: 250.40
Diabetes with renal manifestations, type i [juvenile type], not stated as
uncontrolled: 250.41
Diabetes with renal manifestations, type ii or unspecified type, uncontrolled:
250.42
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Dialysis (exclusion criteria)
Dialysis (reference group)
Censoring events
Non-vertebral fracture
Death
Additional censoring events
Receipt of another kidney transplant‡
Dialysis¥

CORR
CORR

Diabetes with renal manifestations, type i, uncontrolled: 250.43
ICD-10 Codes
Type 1 diabetes mellitus with incipient diabetic nephropathy adequately or
inadequately controlled with insulin, diet, oral agents: E10.2
Type 2 diabetes mellitus with incipient diabetic nephropathy adequately or
inadequately controlled with insulin, diet, oral agents: E11.2
Other specified diabetes mellitus with incipient diabetic nephropathy
adequately or inadequately controlled with insulin, diet, oral agents: E13.2
Unspecified diabetes mellitus with incipient diabetic nephropathy
adequately or inadequately controlled with insulin, diet, oral agents: E14.2
Hypertensive renal disease: I12
Hypertensive renal and heart disease: I13
Glomerular disorders in diseases classified elsewhere: N08
Chronic renal failure: N18
Unspecified renal failure: N19
OHIP DX
Hypertensive renal disease: 403
Chronic renal failure, uremia: 585
Please refer to CORR codes for dialysis above.
Please refer to CORR codes for dialysis above.
Please refer to Table D.2.

RPDB
CORR
CORR

Please refer to codes previously defined above.

Abbreviations: CCI=Canadian Classification of Health Interventions; CCP=Canadian Classification of Diagnostic, Therapeutic and Surgical Procedures; CIHIDAD=Canadian Institutes for Health Information-Discharge Abstract Database; CORR= Canadian Organ Replacement Registry; DXA= dual-energy x-ray
absorptiometry; DX, diagnostic code; ICD=International Classification of Diseases; OHIP=Ontario Health Insurance Plan; RPDB=Registered Persons Database.
‖We defined hemodialysis and peritoneal dialysis based on the modality they first received. We defined pre-emptive transplant as no evidence of hemodialysis or
peritoneal dialysis prior to transplant.
¶
Years on dialysis prior to transplant was calculated by (transplant date-dialysis start date)/365.25. Individuals who received a pre-emptive transplant were given 0
years as the time spent on dialysis.
*
All recipients with a Charlson Comorbidity Index of 0 were given a score of 2 and recipients with a score of 1 were given a score of 3; one of the variables in the CCI
is presence of end-stage renal disease which automatically gives individuals a score of 2. The Charlson comorbidity index includes the following variables: acute
myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, rehuamtic-like
diseases, digestive system ulcers, mild liver disease, diabetes (with and without complications), hemiplegia or paraplegia, renal disease, cancer (with and without
secondary), liver disease (moderate/severe), and HIV/AIDS. Source: Quan, H., V. Sundararajan, et al.. Coding algorithms for defining comorbidities in ICD-9-CM
and ICD-10 administrative data. Med Care 2005; 43: 1130-1139
‡
Defined as receipt of another transplant day 1 to 3 years after the initial transplant.
¥
Defined as chronic dialysis in the 31 days to 3 years after the initial transplant.
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Table D. 2. Database codes used to identify non-vertebral fracture events
Diagnostic codes
Fracture
Location‡
Hip

Forearm
Proximal
Humerus
Fracture Location
Hip

Forearm

ICD-9 Codes

ICD-10 Codes

Neck of femur: 8200, 8201,
8208, 8209
Trochanteric/subtrochanteric:
8202, 8203
813

Neck of femur: S720
Trochanteric: S721
Subtrochanteric: S722

812

S422

Procedural codes†
CCP Codes
Reduction: 9104, 9124
Reduction with fixation: 9054,
9114, 9134
Arthroplasty: 935x, 936x
Reduction: 9101, 9121,
9141
Reduction with fixation: 9111,
9131, 9052

S52

CCI Codes
Reduction: 1VA73,
1VC73
Fixation: 1VA74,
1VA53, 1VC74
Arthroplasty: 1VA80
Reduction: 1TV73
Fixation: 1TV74
Immobilization: 1TV03

OHIP Fee Codes
Not applicable

Reduction: F014,
F022, F023, F025,
F026, F028, F030,
F032, F033, F046
Immobilization:
F024, F027, F031,
Z203

Abbreviations: CCI, Canadian Classification of Health Interventions; CCP, Canadian Classification of Diagnostic,
Therapeutic, and Surgical Procedures; ICD-9 CA, International Classification of Disease, Ninth Revision; ICD-10-CA,
International Classification of Disease, Tenth Revision; OHIP, Ontario Health Insurance Plan
‡
Fracture diagnoses accompanied by trauma codes were included.
†
Procedural codes were required to accompany hip and forearm fractures for the diagnosis to be included as a fracture
event. These procedural codes appeared within +/- 30 days of fracture diagnosis, using the respective hospital
admission dates. We found that the proportion of diagnosis and procedural codes that had identical admission dates was
very high (Hip, Canadian Institute of Health Research (CIHI) database, 99.4%; Forearm, CIHI, 98%; Forearm, OHIP,
83%).
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Table D. 3. Database codes used to identify additional fracture events and fall events
Diagnostic codes
‡

Fracture Location
Pelvis

ICD-9 Codes
Sacrum/coccyx: 8056, 8057
Acetabulum/pubis/ilium/ischium
/unspecified: 808x

ICD-10 Codes
Sacrum/coccyx: S321, S322
Acetabulum: S324
Pubis/ilium/ischium: S323, S325
Unspecified: S327, S328

Vertebral

Thoracic: 8052, 8053
Lumbar: 8054, 8055

Thoracic: S220, S221
Lumbar: S320x

Femoral Shaft

Shaft or unspecified part, closed: 8210
Shaft or unspecified part, open: 8211

Shaft of femur: S723

Lower leg

Fracture of ankle: 824
Fracture of tibia and fibula: 823
Fracture of patella: 822
Fracture of rib(s), sternum, larynx, and
trachea:807
Fractures of bones of trunk:809

Fracture of lower leg, including ankle: S82

Fracture of clavicle: 810
S820
Fracture of scapula: 811
Accidental fall on or from escalator:E880.0
Accidental fall on or from sidewalk curb:
E880.1
Accidental fall on or from other stairs or steps:
E880.9
Accidental fall from ladder: E881.0
Accidental fall from scaffolding: E881.1
Accidental fall from or out of building or other
structure: E882
Accident from diving or jumping into water
(swimming pool): E883.0
Accidental fall into well: E883.1
Accidental fall into storm drain: E883.2
Accidental fall into other hole or other opening

Fracture of clavicle: S420
S820
Fracture of scapula: S421
Fall on same level involving ice and snow: W00
Fall on same level from slipping, tripping and stumbling: W01 W02
Fall involving ice-skates, skis, roller-skates or skateboards: W02 W03
Other fall on same level due to collision with, or pushing by, another
person:W03
Fall while being carried or supported by other persons: W04
Fall involving wheelchair: W05
Fall involving bed: W06
Fall involving chair: W07
Fall involving other furniture: W08
Fall involving playground equipment: W09
Fall on and from stairs and steps: W10
Fall on and from ladder: W11
Fall on and from scaffolding: W12

Rib/sternum/trunk

Other

Falls with Hospital
Presentation

Fracture of rib(s), sternum and thoracic spine: S22
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Fracture Location
Femoral Shaft
Fracture

in surface: E883.9
Accidental fall from playground: E884.0
Accidental fall from cliff: E884.1
Accidental fall from chair: E884.2
Accidental fall from wheelchair: E884.3
Accidental fall from bed: E884.4
Accidental fall from other furniture: E884.5
Accidental fall from commode: E884.6
Other accidental fall from one level: E884.9
Accidental fall from (nonmotorized) scooter:
E885.0
Accidental fall from roller skates: E885.1
Accidental fall from skateboard: E885.2
Accidental fall from skis: E885.3
Accidental fall from snowboard: E885.4
Accidental fall from other slipping tripping or
stumbling: E885.9
Accidental fall on same level from collision
pushing or shoving by or with other person in
sports: E886.0
Other and unspecified accidental falls on same
level from collision pushing or shoving by or
with other person: E886.9
Fracture cause unspecified: E887
Accidental fall resulting in striking against
sharp object: E888.0
Accidental fall resulting in striking against
other object::E888.1
Other accidental fall :E888.8
Unspecified accidental fall: E888.9
Procedural codes†
CCP Codes
Reduction: 9104, 9124
Reduction with fixation: 9054,
9114, 9134

Fall from, out of or through building or structure: W13
Fall from tree: W14
Fall from cliff: W15
Diving or jumping into water causing injury other than drowning or
submersion: W16
Other fall from one level to another: W17
Other fall on same level: W18
Unspecified fall: W19

CCI Codes
Reduction: 1VC73x
Fixation: 1VC74x
Immobilization: 1VC03x
Other repair: 1VC80x

OHIP Fee Codes
Reduction: F095, F096, F097
Immobilization: Z211

Abbreviations: CCI, Canadian Classification of Health Interventions; CCP, Canadian Classification of Diagnostic, Therapeutic, and Surgical Procedures; ICD-9,
International Classification of Disease , Ninth Revision;ICD-10-CA, International Classification of Disease, Tenth Revision; OHIP, Ontario Health Insurance Plan
‡
Fracture diagnoses accompanied by trauma codes were included.
†
Procedural codes were required to accompany femoral shaft fractures for the diagnosis to be included as a fracture event.
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Table D. 4. Summary of validation studies of fracture code algorithms (description of studies)
Study,
Country,
Year
Hudson et al.,
Multinational,
(2013)

Study Population

Database and
source of data

Validation
Years

Fracture Location

Validated codes

-Systematic review
of validation studies

-In-/outpatient
records
and pharmacy
data
-Group Health
Plan
-Local database
and
national register

1987-2006

Hip

ICD-9 820-821

Jean et al.,
Canada,
(2012)

-Women ≥50 years

-Quebec
provincial
database for
medical service
-Outpatient
records

2003-2006

-Hip, femur

ICD-9 820-821

-Forearm, wrist,
elbow

ICD-9 8130–8133

-Foot, ankle

ICD-9 825

-Pelvis

ICD-9 8080–
8089

- Tibia, fibula
ICD-9 823
-Vertebra, sacrum,
coccyx

ICD-9 805–806

-Shoulder, humerus
Fracture care
method
-open reduction
-closed reduction
-immobilization

ICD-9 810, 811,
812

Possible Flags
for Diagnostic
Codes
Any discharge
diagnosis

Gold
Standard

At least one
fracture claim
combined with
a
procedural
code for
fracture
treatment
OR
Visit with an
orthopedic
surgeon

Chart review

-Bone
mineral
density
-Chart review
-Self report
-Radiology
and medical
reports
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Table D.4. (continued)
Study,
Country, Year

Study
Population

Database and
source of data

Validation
Years

Fracture
Location

Validated
codes

Possible Flags
for Diagnostic
Codes

Gold Standard

Curtis et al.,
USA,
(2009)

Gen. pop. ≥18

Insurance company
(non-profit)
administrative
claims data

2003-2004

Spine

ICD 9-CM:
8052, 8054,
8058, 73313

Primary
diagnosis

Henderson et
al.,
Australia,
(2006)

Sample of
hospital
admissions from
Victoria,
Australia
18 Hospitals
from Ontario

Hospital discharge
data

2000-2001

Hip

ICD 10-AM:
S720, S721

Discharge
Diagnostic code

Hospital discharge
data

2002-2004

Femur

ICD 10-CA:
S72

Lower leg
including
ankle

ICD 10-CA:
S82

Most
responsible
Diagnostic
Code

Two reviewers
independently
looked at medical
records and
radiology reports
-Auditors with
coding experience
(majority had 10 or
more years of
experience)
Reabstractors
trained by CIHI

Hip

ICD-9: 820

Forearm

ICD-9:813

Juurlink et al.,
Canada,
(2006)

Joakimsen
et al.,
Norway,
(2001)

-Tromso
Norway
residents
-Male residents
born between
1925-1959;
female residents
(1930-1959)

Self-report and
computer linkage to
radiographic
archives from a
University Hospital
in Norway

1988-1995

Discharge
diagnostic code

Radiographs
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Table D.4. (continued)
Study,
Country,
Year
Tamblyn et
al.,
Canada,
(2000)

Study
Population

Database and
source of data

Validation
Years

Fracture Location

Validated
codes

General
elderly
population (
≥65 years)

-Quebec
outpatient
physician
Claims

1993-1994

Skull & face

ICD-9 800804

Thorax
ICD-9 807,809
Pelvis
ICD-9 8-8
Scapula/clavicle
ICD-9 810,811
Humerus
ICD-9 812
Radius/ulna
ICD-9 813
Carpal/hand
Femoral shaft

ICD-9 814817

Patella

ICD-9 821

Tibia/fibula

ICD-9 822

Ankle

ICD-9 823

Foot

ICD-9 824

Hip

ICD-9 825,826
ICD-9 820

Possible Flags
for Diagnostic
Codes
Emergency
department
diagnostic code

Gold
Standard
Trained
abstractor
performed a
chart review
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Table D.4. (continued)
Study,
Country,
Year
Ray et al.,
USA,
(1992)

Study
Population

Database and
source of data

Validation
Years

Fracture Location

Validated codes

Gen. pop. ≥65

In-/outpatient
records

1987

Rib/sternum

ICD-9:80708074

Pelvis/sacrum/coccyx
ICD-9: 8056,
8057, 8066,
8067, 808
Ankle
ICD-9: 824
Femoral Shaft
ICD-9: 821
Hand
ICD-9: 814-817
Tibia/Fibula
ICD-9: 823
Skull/face
ICD-9: 800-804
Foot
ICD-9: 825, 826
Clavicle/Scapula
ICD-9: 810,811
Patella
ICD-9: 822

Possible Flags
for Diagnostic
Codes
Diagnostic codes
unless the code
meets the
following
exclusion criteria:
- no
corresponding
procedural code
for fracture
in a clinic
- absence of
fracture discharge
code after
admission to
hospital for a
fracture
- primary
diagnosis of
arthroplasty
- follow-up
treatment of an
old fracture as
identified through
procedural codes

Gold
Standard
Medical
chart review

Abbreviations: CIHI=Canadian Institute for Health Information; ICD-9= 9th version of the International Classification for Disease; ICD 9-CM= International
Classification of Diseases, Ninth Revision, Clinical Modification ; ICD 10-AM= Australian Modification of the International Classification of Diseases,
10th revision; ICD 10-CA= 10th version of the Canadian Modified International Classification of Disease system
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Table D. 5 Accuracy of fracture database codes used in validation studies
Study,
Country,
Year
Hudson
et al.,
Multinational,
(2013)

Database

Fracture
event

Sample
Size

Hospital discharge
data

Hip

12 studies

n.r.

Jean
et al.,
Canada,
(2012)

Quebec provincial
database for
medical service

Hip, femur

41,288
1506 for
subsample

368 (24.4)

Forearm, wrist,
elbow
Foot, ankle

Prevalence
(%)

396 (26.3)

Sensitivity

Specificity

PPV

NPV

Kappa

69-97%
With the
addition of
procedural
codes 83-97
99 (97-100)
____________
95 (94-97)

n.r.

63-96%
With the
addition of
procedural
codes 86-98
83 (79-87)
_________

n.r.

n.r.

n.r.

n.r.

n.r.

90 (87-93)

236 (15.7)

92 (89-95)

78 (72-83)

Pelvis

30 (2.0)

82 (66-98)

63 (46-81)

Tibia, fibula

83 (5.5)

91 (87-96)

75 (64-83)

Vertebra,
sacrum, coccyx

25 (1.7)

50 (19-81)

76 (59-93)

238 (15.8)

93 (90- 96)

81 (76-86)

Shoulder,
humerus
Fracture care
method
Open reduction

454 (30.1)

Closed
reduction

214 (14.2)

Immobilization

191 (12.7)

96 (94-97)

98 (96-100)

84 (77-89)
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Table D.5. (continued)
Study,
Country,
Year
Curtis et al.,
USA,
(2009)

Henderson
et al.,
Australia,
(2006)
Juurlink
et al.,
Canada,
(2006)

Joakimsen
et al.,
Norway,
(2001)

Database

Fracture
event

Insurance
company (nonprofit)
administrative
claims data (USA)
A sample of
Australian
Hospital
Discharge
Data
CIHI-DAD

Spine (vertebral
compression
fracture)

Sample
Size

Prevalence
(%)

Specificity

PPV

NPV

Kappa

259

63
(24.3)

32
(22-44)

99
(96-100)

91
(72-97)

82
(77-86)

0.39
(0.27-0.51)

Hip

7,631

4579
(0.60)

95
(94-96)

856
(85-87)

91
(90-92)

92
(91-93)

0.82
(0.80-0.84)

Femur

13 803

356

95
(93 - 97)

n.r.

95
(92 -97)

n.r.

0.95
(0.94-0.97)

99
(92 - 100)
87
(76-94)

n.r.

99
(92- 100)
90
(79-96)

(2.6)
Lower leg
including ankle
Local Norwegian
Hospital
Discharge
Abstract Database

Sensitivity

Hip

68
(0.5)
21,441

54 (0.25)

100

n.r.
100

0.99
(0.96-1.00)
0.89
(0.88-0.90)
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Table D.5. (continued)
Study, Country, Year
Tamblyn
et al.,
Canada, (2000)

Database
Quebec outpatient physician
Claims

Fracture event
Skull & face

Sample Size
915

Prevalence (%)
15 (1.6)

Sensitivity
0a; 27b; 27c
___________

Thorax
_____________

47 (5.1)
___________

0a; 26b; 26c
___________

Pelvis
____________

26 (2.8)
___________

15a;54b;62c
___________

Scapula/clavicle
___________

13 (1.4)
___________

62a; 69b; 77c
___________

Humerus
____________

88 (9.6)
__________

52a; 56b; 69c
___________

Radius/ulna
___________

110 (12.0)
_________

64a; 41b; 66c
___________

Carpal/hand
___________

44 (4.8)
__________

50a; 41b; 61c
___________

Femoral shaft
____________

15 (1.6)
___________

93a; 60b; 93c
___________

Patella
___________

16 (1.7)
___________

50a; 56b; 63c
___________

Tibia/fibula
____________

18 (2.0)
__________

56a; 38b; 63c
___________

Ankle
____________

41 (4.5)
___________

54a; 61b; 73c
__________

Foot
__________

31 (3.4)
__________

61a; 42b; 68c
___________

Hip

178 (19.5)

94a; 83b; 97c

Specificity
n.r.

PPV
n.r.

NPV
n.r.

Kappa
n.r.
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Table D.5. (continued)
Study, Country, Year
Ray et al., USA, (1992)

Database
Medicaid (Parts A and B)

Fracture Event
Hip

Prevalence (%)
538 (41.0)
___________

Sensitivity
97
_________

Radius/ulna

162 (12.4)
__________

93
_________

96
____

Humerus

109 (8.3)
___________

90
_________

95
____

Ribs/sternum

107 (8.2)
_________

82
______

84
____

Pelvis

67 (5.1)
________

89
_________
75

93
____

Femoral shaft

53 (4.0)
__________

_________

87
____

Hand

43 (3.3)
__________

87
_________

86
____

47 (3.6)
__________

87
_________

79
___

40 (3.1)
___________

90
_________

95
____

Tibia/fibula
___________
Foot
____________

Sample Size
1,311

Specificity
n.r.

PPV
98
____

21 (1.6)

91

86

Clavicle/scapula
____________

___________

_________

____

Patella
___________

17 (1.3)
__________

100
_________

82
____

Ankle
____________

69 (5.3)
____________

78
_________

96
____

All

1311 (100)

91

94

NPV
n.r.

Abbreviations: CIHI-DAD, Canadian Institute for Health Information-Discharge Abstract Database; ICD-9, international classification of diseases; NPV, negative
predictive value; n.r.=not reported; PPV, positive predictive value; a-procedure code alone; b- diagnostic code alone; c- procedure or diagnostic code

Kappa
n.r.
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D.1.2 Power
Based on a recently conducted study using the CORR dataset that applied similar
inclusion/exclusion criteria to this chapter it was expected there would be over 5000
kidney transplant recipients eligible for inclusion. It was anticipated that there would be
over 1,000,000 adults who would meet the eligibility criteria for individuals with no
kidney disease and with no prior non-vertebral fracture (18). The two-sample independent
chi-square test which allows for unequal group sizes (1:3) was used to calculate power
(alpha 0.05) (19). Based on these calculations it was expected there would be >80%
power. See Table D.6 for a sensitivity analysis of power calculations and Figure D.1 for
the power formula used in the calculations. Given the large sample size statistical
significance may not equate to clinical significance. For this reason a priori clinical
significance was defined as a ≥ 50% relative increase in non-vertebral fracture in kidney
transplant recipients compared to individuals with no kidney disease and no prior nonvertebral fracture; this was chosen in consultation with transplant nephrologists and was
defined as the magnitude of effect needed to influence the clinical care of kidney
transplant recipients.
______________________________________________________________________________
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N= sample size
=proportion kidney transplant recipients who fractured
= proportion of individuals who do not have kidney disease and have not sustained a prior non-vertebral
fracture and do not have an osteoporosis diagnosis who fractured
= 0.05
̅=
+
=sample size for kidney transplant recipients
= sample size for individuals who do not have kidney disease and have not sustained a prior nonvertebral fracture and do not have an osteoporosis diagnosis.
=power to detect a statistically significant difference (this formula was solved for )

Figure D.1. Formula for power calculation
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Table D. 6. Sensitivity analysis for power calculations (Objective 3b)
Percentage of kidney
transplant recipients with
non-vertebral fracture

1%

Percentage of
individuals with no
kidney disease and
no prior nonvertebral fracture
0.6%

Power achieved*

2%

0.6%

>.999

4%

0.6%

>.999

6%

0.6%

>.999

8%

0.6%

>.999

10%

0.6%

>.999

12%

0.6%

>.999

0.806

*Based on access to 5000 kidney transplant recipients and randomly selecting 15,000 individuals who do not have
kidney disease and have not sustained a prior non-vertebral fracture and do not have an osteoporosis diagnosis.

D.1.3 Cohort Creation Additional Details: Kidney Transplant Recipients
Inclusion Criteria:
i.

Evidence of receipt of a kidney transplant between July 1st, 1994 and
December 31st, 2009. Rationale: The reason for having the accrual period end
December 31st, 2009 was to ensure that the incidence rate was useful for
sample size calculations in future clinical trials; therefore, ending the accrual
on December 31st, 2009 allowed for the three-year incidence rate of fracture
to be determined (last date of follow-up December 31st, 2012). The length of
follow-up in previously conducted systematic reviews on clinical trials
assessing the relationship between fracture and bisphosphonate use in the nontransplant population was between one and four years (20-22). Although the
mean length of follow-up in trials assessing interventions to prevent bone
disease in kidney transplant recipients was 15 months a meta-analysis
recommended that the length of follow-up was underestimated resulting in
inadequate power to determine the effects of fracture prevention treatment on
fracture rates (23).

ii.

An age of ≥ 18 years at the date of transplant. Rationale: Adult recipients
were the sole focus of Chapters 4, 5, and 6 as mechanisms underlying fracture
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risk in children with decreased kidney function are different and would be the
subject of other studies (24).
Exclusion Criteria:
i.

Individuals with an invalid Institute for Clinical Evaluative Sciences (ICES)
key number (IKN) [each individual has a unique IKN that is used allowing for
linkage with other databases], missing sex, missing date of birth, and date of
death prior to index date (date of transplant). Rationale: These were data
cleaning steps.

ii.

Non-Ontario residents. Rationale: These individuals would be more likely to
go back to their province of residence after receiving the transplant and
therefore follow-up data (e.g. death) would not be available for these
individuals using ICES data sources.

iii.

Recipient of multiple organ transplants (including multiple kidney transplants)
or combination transplants (e.g. kidney-pancreas) prior to receiving a kidney
transplant. Rationale: Recipients of multiple/combination transplants may
have different comorbidities (24, 25). The focus of chapters 4, 5, and 6 was on
first time kidney-only transplant recipients.
Figure D.2 describes the cohort selection for kidney transplant recipients.
Figures D.3, D.4, and D.5 describe the cohort selection for the reference
groups including: healthy segment of the general population with no previous
non-vertebral fracture, healthy segment of the general population with a
previous non-vertebral fracture, and non-dialysis chronic kidney disease.
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5913 Ontario kidney transplant recipients
listed in CORR from 1994-2009

13 Recipients excluded during data
cleaning (i.e., missing sex, missing
date of birth, invalid IKN, death
date ≤ index date)

1079 Recipients excluded:
7 Non-Ontario residents
255 Age <18 years at index date
(transplant date)
566 History of any transplant prior to
index date including previous kidney
transplant (look back to 1981)
251 Previous multi-organ transplant
(including kidney-pancreas)

4821 Ontario kidney transplant
recipients included in the analysis

Figure D. 2. Cohort selection for kidney transplant recipients
Abbreviations: CORR, Canadian Organ Replacement Registry; IKN, Institute for Clinical Evaluative Sciences key
number
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18,194,929
Ontario individuals in the databases from 1994-2009
who were not in the kidney transplant recipient cohort

3,464,196 Individuals excluded during
data cleaning (i.e., invalid IKN, missing
sex, missing date of birth, non-Ontario
resident, death date ≤ index date)

4,092,337 Individuals excluded:
3, 494, 309 Age <18 years at index date
137,272 History of chronic kidney
disease
8427 History of any transplant or
dialysis code
331,475 History of osteoporosis
119, 769 previous non-vertebral fracture
in the 5-years prior to index date
1085 Age ≥105 years at index date

10,638,396 Individuals eligible to be
matched to kidney transplant recipients

19,284 Ontario individuals with no
previous non-vertebral included in the
analysis after matching

Figure D. 3. Cohort selection for the healthy segment of the general population with no
previous non-vertebral fracture
Abbreviation: IKN, Institute for Clinical Evaluative Sciences key number
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18,194, 929 Ontario individuals in databases
from 1994-2009 who were not in the kidney
transplant recipient cohort

3,464,196 Individuals excluded during
data cleaning (i.e., invalid IKN,
missing sex, missing date of birth, nonOntario resident, death date ≤ index
date)

14,644,961 Individuals excluded:
3, 494, 309 Age <18 years at index
date
137,272 History of chronic kidney
disease
8427 History of any transplant or
dialysis code
11,004,945 with no non-vertebral
fracture in the 5-years prior to index
date
8 Age ≥105 years at index date

85,770 Individuals eligible to be
matched to kidney transplant recipients
4821 Ontario individuals with a
previous non-vertebral included in the
analysis after matching

Figure D. 4. Cohort selection for the healthy segment of the general population with a
previous non-vertebral fracture
Abbreviation: IKN, Institute for Clinical Evaluative Sciences key number
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481,918 Ontario individuals with
evidence of a CKD diagnostic code
from 1994-2009

3245 Individuals excluded during data
cleaning (i.e., invalid IKN, missing sex,
missing date of birth, non-Ontario
resident, death date ≤ index date)

25,740 Individuals excluded:
12,256 Age <18 years at index date
19 Age ≥105
7188 Previous dialysis code
2279 Previous transplant
3998 Selected in the kidney
transplant recipient cohort

452,924 Individuals eligible to be
matched to kidney transplant
recipients

19,284 Ontario individuals with nondialysis CKD included in the analysis
after matching

Figure D. 5. Cohort selection for non-dialysis chronic kidney disease (CKD)
Abbreviation: IKN, Institute for Clinical Evaluative Sciences key number
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D.1.4 Confounders
Age (± one year), sex, and cohort entry date (index date) (± one year) were
controlled through individual matching with the reference groups. Age and sex were both
considered potential confounders as numerous studies in both the non-transplant and
transplant population have found older age and female sex to be associated with an
increased fracture risk (26-32). Index date was also controlled for as numerous changes in
clinical practice (e.g. pharmacotherapy) and in the patient population (e.g. increase in
obesity) have occurred from 1994-2009 (33-36). In an additional analysis diabetes was
also adjusted for given that diabetes is an established risk factor for fracture (37). The
reason other confounders were not controlled for was that the rationale for this study was
to determine if kidney transplant recipients had a high risk of fracture; markers that are
helpful to determine high risk individuals (e.g. kidney transplantation is a marker of an
increased fracture risk) can be confounded (38). For example, even if recipients have a
higher risk of fracture as a result of low activity levels (potential confounder) fractures
are still more common in individuals with a kidney transplant and therefore potential
preventative actions (e.g. bisphosphonates) should be considered. Therefore, a true
statistical relationship even if it is confounded is helpful for public health as it identifies
individuals who are at a high risk and therefore need to be screened (38).
D.1.5 Cox Proportional Hazard Analysis
To ensure that the proportional hazard assumption was met it was assessed using
two different methods. First, a graphical approach (log-log survival curves) was used to
visually assess violations of the proportional hazard assumption (Figure D.6) (39). If the
log-log survival curves did not appear parallel (e.g. lines cross-over, converged or
diverged) then the Extend Cox model would be considered (39). Second, a statistical test
was used to assess the proportional hazard assumption (40); if the p-value was <0.05 then
the proportional hazard was considered violated. Specifically, the ASSESS option in
PROC PHREG (SAS) was used which plots the follow-up time against the observed
score process (41). The proportional hazards assumption was not violated in this chapter.
However, it is important to note that when the log-log survival curve for CKD and
transplantation was assessed the curves did cross-over; however, when assessing the
proportional hazards assumption, using multiple methods, the p-values were all >0.05
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(Assess method in SAS, P=0.33; time-dependent method, P=0.23; Schoenfeld residuals,
P=0.29). It is recommended that the extended Cox model should only be used if the
evidence for non-parallelism is strong (39); therefore, the Cox proportional hazard model
was used when comparing fractures in CKD and kidney transplant recipients.

Figure D. 6. Log-minus-log survival curves of the primary outcome (non-vertebral
fracture) for each reference group
a) General population with no previous non-vertebral fracture
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b) General population with a previous non-vertebral fracture

c) Non-dialysis chronic kidney disease (CKD)

Note: Although the two curves cross when assessing the proportional hazards assumption using multiple methods the pvalues were all >0.05 (ASSESS method in SAS, P=0.33; time-dependent method, P=0.23; Schoenfeld residuals,
P=0.29).
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d) Rheumatoid arthritis

D.1.6 Competing Risk of Death
To take into account the potential competing risk of death the 3-year cumulative
incidence of fracture was also calculated using the cumulative incidence function; this
function estimates the cumulative probability of fracture while taking into account the
competing risk of death (42, 43). Cumulative incidence estimates were nearly identical
regardless of the method used. A modified version of the Cox proportional hazard
analysis for cause-specific hazards proposed by Fine and Gray (1999) was used to assess
competing risks (43); no substantial difference in hazard ratio estimates were found using
the two methods; therefore, all results in chapter 4 were presented using standard Cox
proportional hazard regression.

D.2 Additional Analyses and Results: Rheumatoid Arthritis Reference Group
Originally, it was proposed to include rheumatoid arthritis as a reference group to
compare fracture rates with kidney transplant recipients allowing recipients to be
compared to another group of individuals who are often prescribed steroids (a risk factor
for fracture) (44). This reference group was not included in the main text of chapter 4.
However, the methods and results of this analysis are presented below.
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D.2.1 Rheumatoid Arthritis Cohort Selection
Databases were reviewed from July 1st, 1994-December 31st, 2009 for first
evidence of one hospitalization for rheumatoid arthritis or three OHIP diagnostic codes
for rheumatoid arthritis with at least one diagnostic code given by a rheumatologist,
orthopedic surgeon, or general internist within a two year period (sensitivity 97%, 95%
CI, 94-100%; specificity 85%, 95% CI 81-89%; positive predictive value 76%, 95% CI
70-82%; negative predictive value 98%, 95% CI 96-100%) (45). Individuals were
excluded who met any of the following criteria: <18 years at index date, prior kidney
disease, previous transplant, or selected for the kidney transplant recipient cohort. Figure
D.7 describes the cohort selection for rheumatoid arthritis.
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117, 539 Ontario individuals with
rheumatoid arthritis from 1994-2009

174 individuals excluded during data
cleaning (i.e., invalid IKN, missing sex,
missing date of birth, non-Ontario
resident, death date ≤ index date)

5961 Individuals excluded:
2524 Age <18 years at index date
371 Previous dialysis code
3025 Previous chronic kidney disease
11 Previous transplant
30 Selected in the kidney transplant
recipient cohort

111,404 Individuals eligible to be
matched to kidney transplant recipients

4821 Ontario individuals with
rheumatoid arthritis included in the
analysis after matching

Figure D. 7. Cohort selection for rheumatoid arthritis
Abbreviation: IKN, Institute for Clinical Evaluative Sciences key number
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D.2.2 Rheumatoid Arthritis Results
After matching (age [± 1 year], sex, and index date [± 1 year]) individuals with
rheumatoid arthritis to recipients there were a total of 4821 individuals with rheumatoid
arthritis (matched 1:1). Matching characteristics were similar between individuals with
rheumatoid arthritis and kidney transplant recipients (Table D.7). Individuals with
rheumatoid arthritis were followed for 14,200 person-years, 142 died (3.0%), and 30
(0.6%) sustained a non-vertebral fracture. The 3-year cumulative incidence of nonvertebral fracture was 0.6% (95% CI 0.4-0.9%) and was highest in women aged ≥ 50
years (1.6%, 95% CI 0.9-2.5%) (Table D.8). Recipients had a higher 3-year cumulative
incidence of non-vertebral fracture (1.6%, 95% CI 1.3-2.0%) compared to individuals
with rheumatoid arthritis (0.6, 95% CI 0.4-0.9%; P-value<0.001 by the log-rank test).
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Table D. 7. Baseline characteristics of kidney transplant recipients compared to
rheumatoid arthritis
Characteristic

Age, years

Kidney transplant
recipients
(n=4821)
50 (38-59)

Rheumatoid
Arthritis
(n=4,821)
50 (38-59)

Women

1781 (36.9%)

1781 (36.9%)

1994-1997

914 (18.9%)

908 (18.8%)

1998-2001

1111 (23.1%)

1130 (23.4%)

2002-2005

1182 (24.5%)

1196 (24.8%)

2006-2009

1614 (33.5%)

1587 (32.9%)

Hypertension

3572 (74.1%)

1282 (26.6%)

Diabetes

1255 (26.0%)

533 (11.1%)

Cardiovascular disease¶

2068 (42.9%)

551 (11.4%)

Prior non-vertebral
fracture‡

106 (2.2%)

55 (1.1%)

Era

Data are medians (interquartile range) or n(%).
¶
Cardiovascular disease was defined as the presence of peripheral vascular disease, congestive heart failure, or coronary
artery disease.
‡
Prior non-vertebral fracture defined as a composite of proximal humerus, forearm, hip fractures from 1991 to cohort
entry. The median number of years (interquartile range) of baseline records prior to cohort entry is as follows: kidney
transplant recipients, 11.9 years (7.5-15.6); rheumatoid arthritis 11.9 years (7.6-15.5).
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Table D. 8. 3-year cumulative incidence, incidence rate, and hazard ratios of nonvertebral fracture (proximal humerus, forearm, or hip) in kidney transplant recipients
compared to rheumatoid arthritis
Population

Kidney transplant
recipients
(n=4821)
Rheumatoid
arthritis
(n=4821)

3-year
cumulative
incidence, %
(95% CI)
1.6
(1.3-2.0)

Incidence rate
per 1000
person years
(95% CI)
5.6
(4.4-6.9)

Hazard Ratio‡
(95% CI)

Hazard Ratio⃰
(95% CI)

1.00
(reference)

1.00
(reference)

0.6
(0.4-0.9)

2.1
(1.4-3.0)

0.4
(0.3-0.6)

0.4
(0.3-0.7)

‡

Matched on age (±1 year), sex, and index date (±1 year)
⃰ Matched on age (±1 year), sex, and index date (±1 year) and adjusting for diabetes.

D.3 Additional Analyses and Results: Dialysis Reference Group
It was proposed to compare fracture rates in kidney transplant recipients to
dialysis patients on the kidney transplant waitlist. However, this reference group was not
included in the main text of chapter 4 because kidney transplant waitlist data was not able
to be accurately obtained from the ICES data holdings. Initially, kidney transplant waitlist
data contained in the CORR database was to be used in this analysis; however, upon
working with the data it was apparent the data was inaccurate with 99.9% of individuals
on the kidney transplant waitlist receiving a transplant; this is inaccurate as in 2012 there
were 115 individuals who withdrew from the waitlist and 34 individuals who died on the
waitlist (46). Moreover, approximately 44% of individuals were missing information on
whether they were active on the waitlist (eligible to receive a transplant when one
becomes available) versus inactive (for short period of time medical reasons or other
reasons prohibit an individual from receiving a transplant) (46). Only information on
patients who were on dialysis, without indication of waitlist status, could be obtained.
However, individuals on dialysis are not an adequate comparator group as many
individuals are too sick to be on the waitlist and would never qualify for transplantation.
Therefore, previous studies comparing outcomes in dialysis patients to transplant
recipients have used waitlist data in an attempt to make the health status comparable
between the two groups (47, 48). For this chapter multiple strategies were used in an
attempt to create a “mock waitlist”. For example, the Canadian Society of
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Transplantation guidelines for transplant eligibility were used in an attempt to create a
group of individuals who were likely on the waitlist based on eligibility (49). However,
the guidelines state that transplants are contraindicated under the following conditions:
active infections, non-adherence to medication, and substance abuse (49); it would be
difficult to reliably obtain information on active infections and substance abuse from
ICES databases. Moreover, there would be no way to determine medication adherence.
Additionally, some of the guidelines depend on severity of disease and information on
severity of disease is not available in ICES (49). After consultation with several
transplant nephrologists across the province it was agreed that an accurate representation
of individuals on the kidney transplant waitlist could not be reliably created. However,
given it is still of interest to assess whether kidney transplant recipients have a higher
fracture risk compared to dialysis patients this was conducted as an additional analysis
and attempts were made to control for the differences in health status between the two
groups.
D.3.1 Dialysis Cohort Selection
The CORR database was reviewed from July 1st, 1994- December 31st, 2009 for
first evidence of chronic dialysis. Individuals were excluded under the following
conditions: 1) <18 years of age at index date, 2) previous transplant, and 3) chronic
dialysis prior to the index date (to ensure incident patients). The date of cohort entry
(index date) was defined as the date of the first chronic dialysis code. In an attempt to
include healthier dialysis patients, for individuals whose index date was within a hospital
admission the index date became the date of hospital discharge and if the individual died
during hospitalization they were excluded from the cohort. Moreover, if the discharge
date was after the study accrual period (December 31, 2009) then these individuals were
excluded. Figure D.8 describes the cohort selection for dialysis patients.
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62,467
Chronic dialysis codes recorded in CORR from
1994-2009

29,418 Unique individuals recorded in
CORR with a chronic dialysis code
after restricting to the first date the code
was recorded (many individuals had
multiple codes for chronic dialysis)

56 Individuals excluded during data
cleaning (i.e., invalid IKN, missing sex,
age date of birth, non-Ontario resident,
death date>index date)

6823 Individuals excluded:
315 Age <18 years at index date
1425 History of any transplant
1544 Previous dialysis in CORR or OHIP
3498 Died in hospital
32 Discharge date from hospital after accrual
period (never left hospital)
9 Death date before transplant date
22,539 Ontario individuals on dialysis

Figure D. 8. Cohort selection for dialysis population
Abbreviations: CORR, Canadian Organ Replacement Registry; IKN, Institute for Clinical Evaluative Sciences key
number; OHIP, Ontario Health Insurance Plan
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D.3.2 Dialysis Statistical Analysis
To assess whether kidney transplant recipients had a higher rate of non-vertebral
fractures compared to dialysis patients a Cox model that allowed for time-dependent
covariates, known as the Extended Cox model was used (39). This allowed for changes in
treatment modality (dialysis patients receiving a transplant during follow-up) to be taken
into account and modeled as a time-dependent covariate (39). Specifically, if an
individual did not receive a transplant prior to being censored (censored at fracture,
death, or end of follow-up [December 31, 2012]) they remained in the dialysis group;
however, if an individual received a kidney transplant before being censored they were
placed in the transplant group and followed forward in time for a fracture event. This
method has been used in previous studies assessing changes in transplant status (50). Age
at dialysis start date (continuous variable), sex, and index date (dialysis start date) were
adjusted for in the Extended Cox model. In an additional analysis the Charlson
comorbidity index (CCI) (continuous variable) was also adjusted for in an attempt to
make the health status comparable between individuals who remained on dialysis and
individuals who received a transplant. The CCI is a score that predicts 10-year mortality
based on the presence of comorbid conditions (e.g. heart disease, dementia, liver disease,
diabetes, tumor) (51) and has been found to be an accurate tool to assess comorbidities in
kidney transplant recipients (52) and in dialysis patients (53). One of the comorbidities
included in the CCI is presence of end-stage renal disease which is assigned 2 points;
therefore, all individuals were given a minimum score of 2 (51); if individuals were
found to have a score of 0 they were given a score of 2 and if they had a score of 1 they
were given a score of 3. In an additional analysis a modified version of Cox hazard
regression for cause-specific hazards proposed by Fine and Gray (1999) was used to
account for the competing risk of death (43).
D.3.3 Dialysis Results
After the exclusion criteria was applied there were 22,539 adult Ontario
individuals who were on dialysis with 19,075 individuals who remained on dialysis
throughout the study period and 3464 individuals who received a transplant. When
comparing individuals who remained on dialysis to individuals who received a transplant,
individuals remaining on dialysis were older (median age 71 vs 48 years) and had more
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comorbidities (diabetes 54.8% vs 33.7%; coronary artery disease 52.7% vs 23.3%; prior
non-vertebral fracture 4.1% vs 1.0%) (Table D.9). Individuals on dialysis who never
received a transplant were followed for 69,264 person-years (average 3.6 years), 14,640
died (76.7%), and 1645 (8.6%) sustained a non-vertebral fracture. Individuals on dialysis
who eventually received a kidney transplant were followed for 33,606 person-years
(average 9.7 years), 788 died (22.8%), and 150 (4.3%) sustained a non-vertebral fracture.
The incidence rate of non-vertebral fracture in individuals who remained on dialysis was
23.8 fractures per 1000 person-years (95% CI % 22.6-24.9) (Table D.10). In individuals
who received a transplant the incidence rate for non-vertebral fracture was 4.6 fractures
per 1000 person-years (95% CI 3.8-5.2). Individuals who received a transplant during
follow-up had a significantly lower fracture rate compared to individuals who remained
on dialysis even after adjusting for comorbidities (HR 0.59, 95% CI 0.49-0.72) (Table
D.10). Specifically, at any given time, the fracture hazard for an individual who has not
received a transplant was approximately 1.7 times the hazard of fracture for an individual
who already received a transplant at that time. However, it is important to remember that
patients in the dialysis group could receive a transplant later on in follow up. When
accounting for the competing risk of death the fracture rate was significantly higher in
kidney transplant recipients compared to individuals who remained on dialysis after
adjusting for relevant covariates (HR 1.61, 95% C I1.33-1.93) (Table D.10). A potential
explanation for the change in direction of the hazard is that many dialysis patients died
prior to being able to observe a fracture or receive a transplant. In the non-competing risk
model, censoring for death leaves patients open to experiencing a fracture in follow up,
suggesting that all we know is that the patient did not have a facture at the time of
censoring (or death). In the Fine and Gray model, those patients who died are considered
weighted so that they are not considered “censored” (43). Moreover, without accounting
for the competing risk of death fracture risk was overestimated in dialysis patients.
Clinically, it is plausible that kidney transplant recipients may have a higher fracture risk
due to greater activity levels in recipients compared to dialysis patients (54-57). Ball et
al. found similar results with kidney transplant recipients having a higher fracture risk in
the first 630 days after transplant (adjusted relative risk 1.34, 95% CI 1.12-1.61)
compared to dialysis patients who remained on the kidney transplant waitlist; after this
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time period patients who continued with dialysis had a higher fracture risk (48).
However, this study did not state whether they accounted for the potential competing risk
of death.
Table D. 9. Baseline characteristics of dialysis patients and kidney transplant recipients†
Dialysis with no
transplant
(n=19,075)
71 (61-78)

Transplantation
(n=3,464)

Total cohort
(n=22,539)

48 (38-57)

68 (56-76)

Women

8035 (42.1%)

1232 (35.6%)

9267 (41.1%)

Era
1994-1997

1764 (9.3%)

803 (23.2%)

2567 (11.4%)

1998-2001

5085 (26.7%)

981 (28.3%)

6066 (26.9%)

2002-2005

6084 (31.9%)

892 (25.8%)

6976 (31.0%)

2006-2009

6142 (32.2%)

788 (22.7%)

6930 (30.7%)

Diabetes

10,444 (54.8%)

1167 (33.7%)

11,615 (51.5%)

Hypertension

15,911 (83.4%)

2712 (78.3%)

18,623 (82.6%)

Peripheral vascular disease

1899 (10.0%)

146 (4.2%)

2045 (9.1%)

Congestive heart failure

8485 (44.5%)

350 (10.1%)

8835 (39.2%)

Coronary artery disease

10,057 (52.7%)

806 (23.3%)

10,863 (48.2%)

783 (4.1%)

36 (1.0%)

819 (3.6%)

Race
Caucasian

13091 (72.9%)

2467 (71.2%)

16,373 (72.6%)

Black

777 (4.1%)

215 (6.2%)

994 (4.4%)

Asian

1097 (5.8%)

214 (6.2%)

1311 (5.8%)

Other‡

1818 (9.5%)

373 (10.8%)

2193 (9.7%)

Unknown

1482 (7.8%)

195 (5.6%)

1677 (7.4%)

Age, years

Fracture (hip, forearm,
or proximal humerus) from
1991 to cohort entry¥
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Cause of end-stage renal
disease
Glomerulonephritis

1994 (10.5%)

1086 (31.4%)

3080 (13.7%)

554 (2.9%)

436 (2.6%)

990 (4.4%)

Diabetes

7347 (38.5%)

874 (25.2%)

8221(36.5%)

Renal vascular disease

4441 (23.3%)

322 (9.3%)

4763 (21.1%)

Other

2467 (12.9%)

429 (12.4%)

2896 (12.9%)

Unknown/missing

2272 (11.9%)

317 (9.2%)

2589 (11.5%)

Pre-transplant dialysis
Hemodialysis

15,025 (78.8%)

2235 (64.5%)

17,260 (76.6%)

Peritoneal dialysis

4050 (21.2%)

1229 (35.5%)

5279 (23.4%)

Cystic kidney disease

Dialysis vintage

2.8 (1.4- 4.9)

Charlson Comorbidity Index

3 (2-5)

2 (2-3)

3 (2-4)

Data are median (interquartile range) or n(%)
†
Baseline characteristics were determined looking backwards in time from the dialysis start date. For example, age is
shown as age placed on dialysis for both groups.
¥
The median number of years (interquartile range) of baseline records prior to cohort entry (defined as date placed on
dialysis) is as follows: dialysis patients with no transplant, 12.3 years (9.0-15.4); transplant, 10.2 years (6.8-14.2); total
cohort, 12.0 years (8.6-15.2).
‡
Other was defined as a composite of Indian Sub-Continent, Pacific Islander, Aboriginal, Mid East/Arabian, Latin
American, Other/Multiracial.

Table D. 10. 3-year cumulative incidence, incidence rate, and hazard ratio of nonvertebral fracture (hip, forearm, or proximal humerus) in kidney transplant recipients
compared to dialysis patients

Cumulative incidence¥, %
(95% CI)

Dialysis
(n=19,075)
11.1
(10.0-12.2)

Transplantation
(n=3464)
7.3
(6.1-8.7)

23.6
4.6
Incidence rate per 1000
(22.4-24.7)
(3.8-5.2)
person years
(95% CI)
Hazard ratios not accounting for the competing risk of death
1.00
0.29
Hazard ratio
(0.24-0.35)
(95% CI)*
Hazard ratio¶
(95% CI)

1.00

0.57
(0.47-0.69)

Hazard ratio‡
(95% CI)

1.00

0.59
(0.49-0.72)

Hazard ratio

Hazard ratios accounting for the competing risk of death
1.00

1.00
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(95% CI)*

(0.85-1.18)

Hazard ratio¶
(95% CI)

1.00

1.61
(1.33-1.93)

Hazard ratio‡
(95% CI)

1.00

1.57
(1.30-1.89)

¥

Cumulative incidence was calculated using the cumulative incidence function was takes into account the competing
risk of death.
*
Hazard ratio was unadjusted.
¶
Hazard ratio was adjusted for age placed on dialysis, sex, and date placed on dialysis.
‡
Hazard ratio was adjusted for age placed on dialysis, sex, date placed on dialysis, and Charlson comorbidity index at
the date placed on dialysis.

It is important to note that these results should be interpreted with caution. As
discussed in section D.3, information on dialysis patients who were on the kidney
transplant waitlist was not able to be obtained; therefore, many individuals in the dialysis
patient group who never transplanted may have been too sick to be eligible for a
transplant, potentially impacting our findings. For example, Stehman-Breen et al., found
that dialysis patients had a higher fracture risk compared to kidney transplant recipients
(58); however, the authors noted that fracture risk in recipients may have been
underestimated as they included all dialysis patients, not just individuals on the waitlist;
therefore dialysis patients would be less healthy compared to individuals on transplant
waitlist (48).
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E.1 Detailed Methods
E.1.1 Data Sources
A description of the databases and codes used to determine risk factors for
fracture are shown in Table E.1.

Table E. 1. Database codes used to determine risk factors for fracture
Variable

ICD -9

ICD-10

OHIP

Other

Age

RPDB

Sex

RPDB

Prior Major Fracture*

Codes and validity of codes described in Appendix D

Prior Fall

Codes described in Appendix D

Race£
Diabetes not as cause of
ESRDβ

CORR

250

E10, E11,E13,
E14

DX:
250
Fee code:
K045, K046 ,K029,
K030,Q040

Donor Type

CORR

Dialysis Modality

CORR

End-stage Renal Disease
Cause∞

CORR

Length of time on dialysis
prior to transplant

CORR

Donor age/ donor sex

CORR

Abbreviations: CORR= Canadian Organ Replacement Registry; Dx, diagnostic code; ICD=International Classification
of Diseases; OHIP=Ontario Health Insurance Plan; RPDB=Registered Persons Database
*Previous major fracture defined as a composite of proximal humerus, forearm, clinical vertebral, or hip fracture
occurring from 1991 to cohort entry (date of transplant).
£
CORR validation study found agreement between CORR and the medical chart, assessed using the κ statistic, for race
was 58%; many of the differences occurred when race was recorded in CORR but race was recorded as unknown in
the medical chart. Source: Moist LM, Richards HA, Miskulin D, Lok CE, Yeates K, Garg AX, et al. A validation study
of the Canadian Organ Replacement Register. Clin J Am Soc Nephrol. 2011;6:813-818.
β
Defined diabetes as one hospital admission code for diabetes or one diagnosis code for OHIP or one OHIP fee code
for diabetes in the 5 years prior to the transplant date.
∞
CORR validation study found that the agreement, assessed using the κ statistic, between CORR and medical chart
review for the primary cause of ESRD was: glomerulonephritis (82.8, 95% CI 74.9-90.7); cystic kidney disease (89.1,
95% CI 77.0-100.0); hypertension/other vascular (66.7, 95% CI 56.5-77.0); diabetes (78.3, 95% CI 70.8-85.8); etiology
uncertain or unknown (46.6, 95% CI 35.9-57.4); other (64.2, 95% CI 48.6-79.8). Source: Moist LM, Richards HA,
Miskulin D, Lok CE, Yeates K, Garg AX, et al. A validation study of the Canadian Organ Replacement Register. Clin J
Am Soc Nephrol. 2011;6:813-818.
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E.1.2 Missing Data
Originally several additional risk factors that have been found to be associated
with fractures in the non-transplant population were going to be assessed, including: body
mass index (BMI), rheumatoid arthritis, smoking (chronic obstructive pulmonary disease
used as a proxy), and high alcohol intake (alcoholism used as a proxy). However, there
were several issues with including these variables. First, BMI had a considerable amount
of missingness (76.2% missing for height and 80.9% missing for weight). Moreover,
there were a large number of implausible values (e.g. BMI > 50 kg/m2). Additionally,
there was no date recorded for when the height and weight measurements occurred with
many measurements occurring during dialysis. Therefore, the BMI could have changed
considerably if the measurement was taken several years prior to transplant. Changes in
BMI are common in ESRD patients due to changes in nutritional status and wasting (1).
For example, one study found that approximately 16% of ESRD patients had a weight
change ≥ 5% over a three month time frame (2). Regarding smoking, rheumatoid
arthritis, and high alcohol intake there were too few individuals to assess with ≤ 5
individuals with these comorbidities experiencing a fracture event. Several transplant
specific risk factors were also originally going to be assessed but were not due to the
large amount of missingness, including: number of human leukocyte antigen mismatches
(missing 41.8%) and cold ischemic time (missing 48.7%).
As described in chapter 5 missing data for categorical variables was handled by
randomly assigning values based on the distribution of variables that were not missing
(single imputation). For the cause of ESRD, prior to randomly assigning values, we
looked for evidence of a diabetes diagnosis code or fee code in OHIP or a diagnosis code
in CIHI in the five years prior to the transplant date; if there was evidence of diabetes the
cause of ESRD was coded as diabetes. For donor age (continuous variable) the median
age was used to supplement missing values. Table E.2 demonstrates the pattern of
missingness before and after handling the missing values.
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Table E. 2. Distribution of missing data before and after handling missing data
Variable

Before
(n=2723)

After
(n=2723)

Glomerulonephritis

891 (32.7%)

990 (36.4%)

Cystic

365 (13.4%)

416 (15.3%)

525 (19.3%)

597 (21.9%)

Renal Vascular

269 (9.9%)

317 (11.6%)

Other

358 (13.2%)

403 (14.8%)

Missing/unknown

315 (11.6%)

0

1748 (64.2%)

1948 (71.5%)

Asian

184 (6.8%)

216 (7.9%)

Black

180 (6.6%)

205 (7.5%)

Other

320 (11.8%)

354 (13.0%)

Unknown

291 (10.7%)

0

Living

1133 (43.9%)

1195 (43.9%)

Deceased

1449 (56.1%)

1528 (56.1%)

21 (0.77%)

0

46 (36-54)

46 (36-54)

60 (2.2)

0

Female

1350 (49.6%)

1363 (50.1%)

Male

1349 (49.5%)

1360 (49.9%)

24 (0.88%)

0

Cause of end-stage renal disease

Diabetes

⃰

Race
Caucasian

Donor type

Missing
Donor age
Median age
Missing
Donor Sex

Missing

Data are median (interquartile range) or n(%).
⃰ Initially there were 501 recipients with diabetes as their primary cause of ESRD; however, after looking for previous
evidence of diabetes there were 525 individuals with diabetes as their primary cause of ESRD. The primary cause of
ESRD was then imputed based on the distribution of ESRD cause.

E.1.3 Proportional Hazards

To ensure that the proportional hazard assumption was met it was assessed using
multiple methods. First, a statistical test was used to assess the proportional hazard
assumption for both continuous and categorical variables; if the p-value was <0.05 then
the proportional hazard was considered violated. Specifically, the ASSESS option in
PROC PHREG (SAS) was used which plots the follow-up time against the observed
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score process (3,4). Second, for categorical variables, a graphical approach (log-log
survival curves) was also used to visually assess violations of the proportional hazard
assumption (5). If the log-log survival curves did not appear parallel (e.g. lines crossover, converged or diverged) then the Extend Cox model would be used (5). Third, for
continuous variables (e.g. age) the proportional hazard assumption was assessed using the
time-dependent variable approach which includes an interaction term comprised of the
time-independent variable and time (e.g., age*log[time]); a p-value <0.05 was considered
to violate the proportional hazard assumption (5). There were no violations of the
proportional hazards assumption.
E.1.4 Departures from Linearity
To ensure there were no departures from linearity (e.g., threshold, quadratic)
martingale residuals were assessed for each continuous risk factor (6), as implemented in
the PROC PHREG ASSESS statement (SAS) which plots the cumulative martingale
residuals against each continuous covariate; a p-value <0.05 was used as criteria for
violation of linearity (6,7). To visually assess departures from linearity a martingale
residual plot was created using the SAS command PROC PHREG which did not include
the exposure variable for which the functional form was being assessed (8,9). A lowess
line was then fit through the martingale residuals (8).
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